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The development of an effective prophylactic human immunodeficiency virus (HIV) 
vaccine is a critical global health priority. However, to-date, all efforts to design an 
HIV vaccine have been met with a paucity of success. The design of an effective HIV 
vaccine is challenging, however, the recent isolation of potent broadly neutralizing 
antibodies (bNAbs) capable of neutralization across multiple HIV strains suggests 
that a properly designed HIV immunogen could develop into an effective vaccine. 
The work presented here describes the synthesis of a series of HIV antigens for 
functional studies as well as potential immunogens. Five projects are described 
herein, probing both the role of carbohydrates in defining the epitopes of anti-HIV 
carbohydrate reactive proteins, as well as approaches to reconstitute these 
carbohydrate-based epitopes in a synthetic format. In Chapter 2, a series of 
oligomannose-virus-like particle (VLP) conjugates representing the bNAb 2G12 
epitope were synthesized and used to probe the specific binding preferences of 2G12. 
  
The synthetic glycan-protein conjugates were highly antigenic toward 2G12. Chapter 
3 describes a general method developed to chemoenzymatically synthesize 
differentially glycosylated HIV-related glycopeptides in a site-defined manner. The 
method was used to synthesize of series of glycopeptide antigens of the bNAb PG9. 
The method developed was applied in in Chapter 4 toward the synthesis of 
multivalently displayed glycopeptides on a VLP scaffold as PG9 immunogens. The 
multivalent glycopeptide display significantly enhanced the antigenicity compared to 
monomeric glycopeptides. In Chapter 5 the synthesis of an oligomannose library 
containing all intermediate oligomannose glycans Man1-9GlcNAc2 is described, 
including the associated glycan-protein conjugates. Preliminary binding studies 
against a panel of mannose-reactive lectins and anti-HIV bNAbs revealed binding 
preferences consistent with the given oligomannose display. Similarly, in Chapter 6, a 
library of highly-branched, bisected Galactose/N-acetylglucosamine terminal glycan-
protein conjugates were synthesized. The conjugates were designed to present 
potential cryptic N-glycan HIV epitopes for use in serum screening studies to identify 
novel glycan binding proteins. The work presented has yielded important information 
regarding the reconstitution of HIV glyco-epitopes using synthetic protein conjugates. 
Together, these insights should facilitate the rational design of immunogens that are 
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Chapter 1: Introduction 
1.1 Human Immunodeficiency Virus (HIV) 
   
         The Human immunodeficiency virus (HIV) remains one of the most tenacious 
infectious diseases confronting modern science. The global HIV pandemic has 
infected over 60 million and claimed the lives of over 25 million people since the 
discovery that HIV is the cause of acquired immunodeficiency syndrome (AIDS) 
over 30 years ago. As of 2014, it is estimated that there are 37 million people globally 
living with HIV infection (Figure 1.1). In addition to the staggering cost of human 
life, recent antiretroviral therapy options that keep the virus in check, also extend the 
lives of those infected, leading to enormous health care costs to care for the secondary 
infections and associated symptoms of the increasing number of people living with 
HIV.  
 
Figure 1.1. The number of individuals living with HIV infection has steadily risen 





        There are two broad epidemiological patterns that are observed in the global 
distribution of HIV-1 infection. In concentrated HIV-1 epidemics, occurring in the 
majority of countries, HIV-1 infection is detected in specific at-risk groups (i.e. sex 
workers and injection drug users). In contrast to concentrated HIV-1 epidemics, the 
epidemics in many sub-Saharan countries are generalized in that they are self-
sustaining in the population (i.e. between married couples and mother to child 
infections). 2 
       One of the major obstacles in treating HIV is its high degree of genetic 
variability. There are two known HIV types that are capable of infecting humans 
HIV-1 and HIV-2. It is widely assumed that HIV-1 arose from a cross-species (i.e. 
zoonotic) transmission of a chimpanzee virus to humans. 3-4 Similarly, HIV-2 is very 
closely related to the simian immunodeficiency virus endemic to sooty mangabeys. 5 
HIV-2 infection is highly localized, especially in comparison to globally prevalent 
HIV-1, infecting individuals in primarily West Africa and India. Additionally, for 
unknown reasons, HIV-2 is far less pathogenic than HIV-1, characterized by a slower 
progression to immune deficiency and lower transmission efficiency between 
individuals.  6 The limited range and slower progression of HIV-2 has driven research 
efforts for focus primarily on HIV-1. HIV-1 is characterized by three distinct groups, 
marked by distinct genomes, labelled M, N, and O, where group M is the most 
common. Group M is further divided into 9 distinct subtypes called clades (A-D, F-H, 
J, and K). The genomes between the clades generally differ by 15-20%. 7 The 





dominated by one or more clade. Increasingly, recombinant strains are also being 
detected. 
         
1.2          HIV-1 Infectivity 
 
           Transmission of HIV, irrespective of the route of infection, is predicated on 
two variables, the infectiousness of the “index case,” or the person transmitting the 
virus, and the idiosyncratic susceptibility of the naïve host. 8 There is a direct 
correlation between viral burden in the blood and infectiousness. It has been generally 
observed that the infectiousness of the index case is greatest in the acute stages (first 
3 months after the transmission event), as the immune system is still naïve and can 
offer no resistance, and in late stage infections, due to the effects of attrition on the 
immune system such that the infected host can no longer attempt to clear the virus. 9 
Late stage infections are also a co-indication of low CD4 counts, which similarly 
indicates high viral burden in the host. In contrast to the relative constancy of the 
factors of infectiousness, there is little uniformity in human susceptibility to HIV-1 
infection. The factors impacting HIV-1 susceptibility are diverse and in large part, 
poorly understood. Resistance to infection appears to reflect a combination of genetic 
factors, innate resistance, and potentially even acquired resistance. The best 
characterized example of the impact of genetic factors in conferring resistance to 
infection is the deletion mutation of the gene that encodes the C-C chemokine 
receptor type 5 (CCR5). CCR5 is a co-receptor critical for cell entry in the early 





receptors (see section 1.3). 10 People that are homozygous for the CCR5 deletion 
display a profound resistance to HIV-1 infection, presumably due to the inability of 
HIV to enter the target host cells and initiate the infection cycle. Subsequently the 
converse is also true: higher expression of CCR5 co-receptors have been associated 
with higher susceptibility to HIV infection. 11 Individuals homozygous for the 
CXCR4 deletion display a similar resistance to HIV infection. 12  Other mutations 
conferring resistance to HIV-1 have been reported, however, the extent of protection 
is lower and the reasons for resistance are largely unclear. 13  
1.3 HIV Structure and Genome 
           Like all viruses, the structure of HIV is quite simple. HIV-1 relies on the host 
cell for many of its structural requirements, leading to a limited number of requisite 
transcribed biological structures. HIV is a single stranded RNA, enveloped lentivirus. 
Composed of a small number of proteins, the two copies of single stranded RNA are 
the entire viral genome. The genome only encodes three major polypeptide gene 
products, Gag, which provides the structural requirements for HIV (i.e. viral matrix, 
capsid, and the nucleocapsid). 14  Pol contains the information to express viral 
enzymes (including protease, reverse transcriptase and integrase). 15 The final gene 
product, Env, forms the viral spike, a transmembrane protein that decorates the outer 
surface of the virus and is incorporated into the lipid bilayer envelop during viral 






Scheme 1.1 Cross section of HIV. The main surface antigen and target of vaccine 
design on HIV-1 is gp120 (gp120 structure adapted with permission from the 
publisher). 16  
 
            The viral spike of HIV, the major antigenic determinant of the virus, is 
composed of a heterodimer of trimers, a membrane-spanning portion, gp41, and 
surface protein gp120. The initial Env protein begins as a single pro-protein gp160, 
and the mature viral spike forms upon furin cleavage. Trimeric gp120 mediates viral 






Scheme 1.2 HIV Life Cycle 
 
          Cluster of differentiation 4 (CD4) is the main receptor for HIV. HIV-1 tropism 
is further defined by two co-receptors C-C cytokine receptor 5 (CCR5) or CXC 
chemokine receptor 4 (CXCR4). 18-20 CD4 is expressed on a number of 
immunological cells including T lymphocytes, dendritic cells, and macrophages. 21 
All three types of cells subsequently contribute to propagating the HIV-1 infection. 
Cell entry by the virus is mediated by the interaction of the gp120 subunits binding to 





observed during binding. 22 The membrane spanning protein, gp41 initiates fusion of 
the viral and host cell membranes, releasing the viral capsid into the host cell 
cytoplasm. 23 Within the cytoplasm, the viral reverse transcriptase (RT) produces 
double stranded DNA from the viral RNA template. After import of the viral DNA 
into the host cell nucleus, the viral integrase splices the viral DNA into the host-
genome creating a provirus. 23 Upon incorporation of the viral DNA into the host cell 
genome, the host cell’s translational machinery is exploited to produce viral proteins, 
enabling the formation of new virions. 24 The newly packaged virions bud from the 
cell surface, gaining the final envelop, and undergo maturation leading to fully 
functional viruses. 24 Depending on the host conditions, the HIV-1 can persist in 
memory T cells as a provirus for extended periods, avoiding eradication by anti-
retroviral therapy. 25-26 It has been demonstrated that proviral reservoirs are 
preferentially derived from quiescent T cells, rather than active T cells undergoing 
clonal expansion. 27 
1.4 HIV Transmission and Pathogenesis 
         HIV-1 transmission occurs primarily via intravenous exposure and via entry 
through the vaginal or rectal mucosa. The mucosa acts as a barrier stymying HIV-1 
access to host cells susceptible to infection. HIV penetrates the mucosal layer by 
several means, including endocytosis, transcytosis, and migration through epithelial 
junctures. 28 The initial HIV-1 infection is usually established by a single founder 
virus; this creates an immunological bottleneck, and a successful vaccine would 
primarily be required to induce an immune response capable of eliminating the initial 





infection follows a series of phases with defined characteristics. During the eclipse 
phase of the HIV infection (the first 8-12 days following exposure), there is no 
detectable viral RNA present in the plasma. 31 However, immediately following this 
ostensibly quiescent phase, there is an exponential increase in viral levels, termed the 
acute phase, with the viral load peak between 21-28 days. The acute phase is 
characterized by a pronounced adaptive immune response. 31 CD8+ T cells are 
activated, the humoral immune response ramps up and seroconversion of antibodies 
occurs. There is also a measurable loss of CD4+ T cells during the acute phase. 30 The 
activation of the immune response leads to influenza-like symptoms that assist the 
virus in spreading to the lymph nodes, rich in CXCR4+/CCR5+/CD4+ T lymphocytes. 
32 After the virus reaches the lymph nodes, a significant loss of T lymphocytes is 
observed. At the close of the acute phase, viral levels decline until a viral set point is 
reached corresponding to the pressure from the rising adaptive immune response. As 
the infection reaches this final stage, the virus is difficult to detect and only very 
slowly targets CD4+ T lymphocytes, which nearly return to pre-infection levels. 
During the final stage of infection, HIV-1 continually evades immune surveillance by 
developing escape variants. The gradual attrition of CD4+ T lymphocytes eventually 
weakens the immune system, leaving the host vulnerable to opportunistic infections, 






Scheme 1.3 Innate and Adaptive immune responses to HIV-1 infection. 
 
1.5 Host Immune Response to HIV Infection 
          Innate resistance in HIV-1 infection has been a considerable challenge to 
characterize. The degree of resistance to infection during the initial exposure is 
thought to reflect both the native host microbial flora and the immunologic mucosal 
defenses. There are two major cellular contributors to the HIV-1 innate immune 
response, dendritic cells (DCs) and natural killer cells (NK). During the initial 
transmission event, HIV-1 must pass through the mucosa and breach the robust 
epithelial wall to contact the target host cells (CD4+ T cells). 33 The mucosal barrier is 
rich with dendritic cells that capture HIV-1. DCs express pattern recognition 





upregulation of chemokine production, inducing inflammation and recruiting 
activated HIV-1 target cells, which leads to local amplification of the infection. 34 
DCs also act as antigen presenting cells, which accelerate the adaptive immune 
response to HIV-1 infection. In rare individuals that are functionally non-infected due 
to immune control over viral production (i.e. exposed uninfected individuals, long-
term non-progressors, and elite-controllers), DCs have decreased pro-inflammatory 
cytokine production, and increased antigen-presenting properties. 35 These anomalous 
features in so-called ‘elite-controllers’ are thought to contribute to the slow or absent 
progression of the HIV-1 infection. Natural killer cells are also found in the sites of 
HIV-1 infection and have been found, in conjunction with DCs, to be a critical 
checkpoint in shaping the adaptive immune response. 36 The interactions between 
NKs and DCs is multidimensional. There is a so-called cross-talk between NKs and 
DCs with the ratio of NKs/DCs determining the nature of the cross-talk. 36 At high 
NKs concentration, NKs kill immature DCs, concentrating the DC response to just 
maturated DCs, therefore only mature DCs fully present HIV-1 antigens to licensed T 
cells, leading to a directed immune response to HIV-1, rather than one that is diluted 
by immature DCs. 37 Conversely, at low NK concentrations, DCs activate NKs, 
priming them to kill HIV-1 infected CD4+ T cells. 37 In this way, even with a weak T 
cell response, the infection can be controlled early and confined to the site of the 
transmission event. In the case of an HIV-1 progressor, the cross-talk between NKs 
and DCs is thought to be lost, resulting in an amplification of inflammation and 
progression of the infection at the site due to high levels of immature DCs (not 





could lead to ineffective T cell responses, given the failure of NKs to kill immature 
DCs due to inappropriate NK/DC cross-talk. 38 Other smaller contributions by the 
innate immune system have also been implicated in long-term HIV-1 control, 
however, the sources of viral suppression are largely unclear.  
           In addition to the innate response, the adaptive immune system plays a critical 
role in HIV infection. During an effective immune response to a viral infection, both 
neutralizing (NAbs) and non-neutralizing Abs (non-NAbs) are simultaneously 
stimulated. In the context of HIV, a NAb is defined as an Ab that binds specifically to 
a critical feature of HIV-1 Env, preventing viral transmission to its cellular CD4 
receptor. A non-NAb is defined as an Ab that binds specifically to non-critical sites of 
HIV-1 proteins, which is unable to prevent viral binding to CD4. 39 These two classes 
of Abs work synergistically to contribute to antiviral immunity by four major 
pathways. First, the NAbs neutralize free virus particle, preventing cellular uptake. 
Second, both classes of Abs stimulate the complement system leading to 
complement-mediated lysis of both free virus particles and infected host cells. 39 
Third, both classes of Abs are critical for opsinization-mediated phagocytosis by both 
macrophages and other cells. Finally, both NAbs and non-NAbs trigger viral 
destruction via Ab-dependent cellular cytotoxicity (ADCC). 39 HIV-1 is able to 
escape complement-mediated destruction facilitated by NAbs/non-NAbs, by 
harnessing an immunotolerance mechanism, the incorporation of a host derived 
membrane-bound hCD59 receptor during viral budding, which regulates complement 





        Beyond activation of critical Ab-facilitated antiviral immunity, non-NAbs are 
unable to prevent viral entry into target cells. However, it has been repeatedly 
anomalously observed that the major titers of anti-HIV Abs raised upon viral 
challenge are non-NAbs. 40 This paradoxical observation obfuscates typical anti-viral 
immune rationale, given the obvious superiority of NAbs, which can activate 
extraneous anti-viral pathways while simultaneously blocking viral entry into target 
cells. The key to this unusual observation lies in the heterogeneity of the Env protein 
on the surface of HIV capsid. Successful viral entry into a target cell requires intact 
trimeric gp120. However, it has been well established that gp120 monomers can be 
shed from the HIV capsid, resulting in a heterogeneous presentation to the immune 
system. 40 It was initial thought that only gp120 monomer was sufficiently labile to 
dissociate, leaving trimeric gp41 stumps with varying degrees of gp120 association. 
The presumed stability of the gp41 trimer was based on the strength of the association 
in the pre-fusion state, however, it has been shown that the stability of gp41 trimer 
association decreases in the post-cleavage state. 41 Studies have shown that upon 
gp120 monomer shedding, the gp41 stalks are able to dissociate and move freely 
through the membrane as trimers, dimers, or monomers, with or without an associated 
gp120 monomer (Figure 1.2). The observed heterogeneity present on the viral 
envelop has important implications in the development of the humoral immune 
response. The heterogeneity gives rise to the observed non-NAbs (raised against 
“junk” Env proteins) as well as the NAbs (raised against intact trimeric Env protein). 
This observation also explains the source of non-NAbs inability to prevent viral 





(trimer-associated face) which is normally occluded in the trimeric context. These 
highly antigenic non-neutralizing epitopes are accessible only on monomeric and 
dimeric forms of gp120, which are non-functional and cannot facilitate host-cell 
entry. Conversely, NAbs target the solvent exposed neutralizing face of gp120 and, 
depending on the quaternary preferences (requirements) of a given epitope, are 
largely focused on intact Env proteins (i.e. trimeric gp120). Moreover, the dense 
glycan shield (discussed at length in section 1.8) on the neutralizing face (solvent 
exposed) of gp120 obscures access to the conserved peptide epitopes on the gp120 
surface. The limited access to peptide epitopes focuses the neutralizing humoral 
response against largely carbohydrate-based epitopes. During B-cell priming, there is 
a selection process in which the viral particle is viewed as a single target. Affinity 
selection of germ-line B-cells mandates the amplification of higher-affinity clones in 
preference to those of lower affinity. As a corollary, the development of Ab responses 
toward each of the antigens on the viral capsid surface is contingent on their relative 
accessibility to Ab binding. Therefore, the high accessibility of the non-functional 
“junk” forms of Env may explain the ostensible immunodominance. 42 Finally, the 
initial NAb response is strain-specific, and the neutralizing epitopes are subsequently 
lost upon the emergence of viral escape variants. 
1.6 Current therapeutic options (HAART Therapy): Advantages and Limitations 
        Within a few years of the discovery of the virus, the first antiretroviral drug 
against HIV-1, azidothymidine, was approved for therapeutic use. 43 The high rate of 
HIV-1 mutation to overcome anti-retroviral therapy has led to the rapid development 





has necessitated the coincidental development of a large number of inhibitors. The 
inhibitors can be divided into six basic classes, categorized according to their 
mechanism of action, nucleoside-analog reverse transcriptase (RT) inhibitors, non-
nucleoside RT inhibitors, integrase inhibitors, protease inhibitors, fusion inhibitors, 
and entry inhibitors. 44 HIV is characterized by an error prone reverse transcriptase, 
leading to a high rate of mutation and the selection of drug-resistant escape mutants. 
45-46 The selection of escape mutants (referred to as quasi-species) quickly overcomes 
single therapeutic treatment, and has therefore been replaced by the use of a cocktail 
of at least three inhibitors, called highly active antiretroviral therapy (HAART). 47 
HAART therapy has revolutionized HIV treatment, making a previously fatal disease 
treatable. In certain cases, HAART therapy has increased the life-expectancy to near 
normal levels. 48 
             Unfortunately, despite the successes of HAART therapy, it is far from a cure 
and there are a number of significant limitations. There are a high number of side-
effects associated with HAART therapy that, when combined with the complex daily 
treatment regimens, often lead to patient compliance issues. Discontinuing HAART 
therapy results in an almost immediate relapse to initial viral load levels, as HAART 
therapy is unable to eradicate latent viral reservoirs. 49 Additionally, there are a 
number of chronic health problems associated with long-term HAART therapy. A 
major pathology associated with long-term HAART therapy is chronic liver disease. 
Indeed, end-stage liver disease is a major cause of death in patients receiving long-
term HAART therapy. 49 While HAART-related toxicities are identified as the main 





been shown to contribute to the pathogenesis of liver fibrosis via activation by gp120 
of the Toll-like Receptor 4 (TLR4).49 TLR4 is thought to form a co-cluster receptor 
with CCR5, expanding the repertoire of cellular proteins propagating the gp120 
signals. TLR4 activation with CCR5 co-clustering by gp120 signals a cascade event 
leading to proinflammatory and profibrogenic signals. The ability of HIV to maintain 
persistent immune activation and the associated accelerated liver fibrosis progression 
even with the intervention of HAART remains a major obstacle to effective HAART 
therapy. 50 
1.7 Structure and Function of HIV-1 Env Protein 
 
          One of the most effective evasive defenses of HIV-1 is the host-derived lipid 
envelope that assembled virions obtain during viral budding from the host cell’s 
plasma membrane. During the budding process, various glycolipids can be 
incorporated into the viral lipid bilayer, and, as they are host-derived, the ability of B 
cells to respond to these antigens is severely limited due to antigen self-tolerance 
mechanisms. 51-52 In addition to masking the virions, some of the host-derived 
glycolipids can facilitate viral infection. For example, sialylated viral envelope 
glycolipids (gangliosides) have been shown to interact with cellular lectin receptors, 
sialic acid-recognizing Ig superfamily lectins-1 (Siglec-1), on DCs, potentially 
enhancing the infection. 53-54 An interesting exception to the largely protective role of 
host-derived glycans in HIV immune evasion, is the observation that during 
transmission, HIV-1 primary virions can carry non-self ABO blood group antigens 
from the infected individual. 55-56 Therefore, viruses from A or B donors show 





recipients blood group. 55 56 Despite this minor exception, the host-derived glycans 
(both glycolipids and glycoproteins) are an extremely effective shield that protects 
HIV.  
        Beyond the host-derived glycolipids, the major antigenic determinant on the 
surface of HIV is the viral spike, composed of the glycoproteins gp41/gp120. Both 
components of the metastable viral spike in its pre-fusion state are involved in CD4 
receptor binding. Upon CD4 binding, the pre-fusion state undergoes a dramatic 
conformational change that instigates fusion of the viral and host cell membranes. 
Gp120 has a highly variable surface composed of five variable loops (V1-V5) 
dispersed among five constant regions. 19, 57-61 While gp41, responsible for fusion 
mediation, is far more conserved and simple. Gp41 is composed of only four 
components, an ectodomain, which interacts with gp120, a membrane proximal 
external region (MPER), the transmembrane domain, and a cytoplasmic tail. 62 The 
conformationally dynamic nature of Env, together with the high level of N-
glycosylation (carbohydrates comprise ~50% of the total weight gp120, making it one 
of the most highly glycosylated proteins to date) has made elucidating the structure of 
Env a challenge. 59 Nevertheless, Peter Kwong’s group reported the first X-ray crystal 
structure of CD4-complexed monomeric gp120 nearly 20 years ago. 57 Subsequently, 
a number of studies using both X-ray crystallography and cryo-electron microscopy 
(cryo EM) have generated a number of structures of gp120, both free and receptor 
bound, and monomeric and trimeric. 58 59-61, 63-69 The structural studies have yielded 
unprecedented access to the fine-details of gp120 structure and have helped facilitate 





trimeric gp120 structure has been the development of recombinant trimer mimics 
(BG505 SOSIP.664), with mutations introduced that stabilize the structure while 
maintaining the native conformation and antigenic properties. 70-71  
      The structural studies of monomeric gp120 have revealed a common fold 
consisting of an N-terminal inner domain and a C-terminal outer domain. 59 The inner 
and outer domains are connected by a bridging sheet, composed of four-strands 
forming an anti-parallel β-sheet. 59 A number of significant structural changes occur 
to the viral spike, induced by CD4 receptor binding, a process characterized by a 
large unfavorable change in entropy. 72-73 Receptor binding results in the formation 
and stabilization of the co-receptor binding site within the viral spike, triggering the 
insertion of the hydrophobic gp41 N-terminal fusion peptide into the target cells lipid 
membrane. Rearrangement of two gp41 α-helix proteins into a hairpin-like domain 
within each of the three gp41 subunits creates a six-helical bundle, driving membrane 
fusion. 62 
1.8 Env Glycan Shield 
 
        Env glycosylation plays a dual role in the viral life cycle. The glycan structures 
can contribute to disease transmission by interacting with host cell receptors (i.e. 
lectins on DC-SIGN shuttle the virus to CD4+ T lymphocyte rich lymph nodes). The 
glycan structures also act as a shield to hide the highly antigenic protein surface from 
immune surveillance. The profound ability of HIV to withstand the host humoral 
immune system, despite the presence of high-titer anti-HIV antibodies, is largely 
attributed to an evolving glycan shield, together with the high-rate of mutation, 





glycosylation, with an average of 93 N-linked glycans on certain trimer strains, makes 
a formidable immunological defense. 74 Indeed, studies have shown that only 19% of 
the gp120 protein surface is solvent-accessible, with only 3% accessible to the Fab 
domain of an IgG Ab, the rest of the surface is occluded by glycans. 69 Each N-glycan 
is encoded by a characteristic tripeptide sequence Asn-X-Ser/Thr (where X can be 
any amino acid except proline), referred to as the N-glycan sequon. 75  
Scheme 1.4 N-glycan processing. Glycan maturation pathway. 
 
HIV glycosylation is derived from host glycosylation machinery, facilitated by en 
bloc transfer of a dolicol-linked Glc3Man9GlcNAc2 precursor glycan onto nascent 





lumen of the endoplasmic reticulum (ER) (Scheme 1.4). During the calnexin 
(CXN)/calreticulin (CRT) folding cycle, the Glc3Man9GlcNAc2 precursor is trimmed 
down to Man9GlcNAc2. 
76 Glycan processing within the ER by α-mannosidase 
ordinarily yields Man5GlcNAc2; however, the high spatial density of glycans on 
gp120 results in stymied glycan processing, yielding a mix of Man5-9GlcNAc2 
glycans (Scheme 1.4). For non-congested N-glycosylation sites, further glycan 
processing occurs in the Golgi via trimming by glycosidases and modifications by 
glycosyltransferases, resulting in a mixed display of various forms of oligomannose 
glycans, as well as highly processed complex and hybrid-type glycans. 77 Because the 
N-linked glycosylation on Env is host-derived, the glycan shield is largely privileged 
from Ab recognition through immune tolerance mechanisms. For example, Ab cross-
reactivity of viral N-glycans with host N-glycans (self-recognition) would lead to 
anergy or apoptosis of the glycan reactive B cell. 78 Although host-glycans are 
immunologically silent, Abs are capable of recognizing non-self glycosylation (i.e. 
blood-group antigens). 79 HIV gp120 glycosylation is heterogeneous and depends on 
the strain, stage of HIV infection, the type of cell producing the virus, and the 
oligomeric form (i.e. monomer versus trimer). 80 Moreover, there are several unusual 
feature to gp120 glycosylation that enhance the antigenicity and support the notion 
that the glycan shield is a viable target for vaccine design. HIV glycosylation is 
generally divided into three distinct regions. First, in the regions of gp120 that are 
close to the trimeric interface (the interprotomer region), the steric inaccessibility of 
glycans to glycosidase enzymes at the trimer interface results in an enrichment of 





(TAMP)). The second region is related and referred to as the intrinsic high-mannose 
patch (IMP). The spatial distribution of potential N-glycosylation (PNG) sites within 
the IMP is very close, resulting in dense glycosylation, and steric hindrance to glycan 
processing, yielding mostly unprocessed oligomannose glycans. This site is centered 
around the N332, N334, N392, and N295 PNG sites. 81 82 The remaining portions of 
gp120, outside of the protomer interface and regions of dense glycosylation, have 
been shown to bear more highly processed complex or hybrid-type glycans. The 
preponderance of oligomannose glycans on gp120 show a lower structural variation 
when compared to host-cell glycoproteins. Moreover, the oligomannose glycans tend 
to form clusters on the Env surface that are immunologically distinctive from host 
glycosylation. Broadly speaking, the display of the host-derived glycans in a viral 
protein context can yield a modicum of differentiation and serve as the basis for 
targeting the Env glycan shield. 83 84  
1.9 HIV Glycan Role in Immune Escape 
            The Env glycan shield is dynamic and it is constantly evolving in different 
strains to avoid recognition by newly produced NAbs. 85 The degree of PNGS 
plasticity for trimeric spike is limited by the unique glycan structural feature, 
particularly the IMP, TAMP, and the non-glycosylated CD4-binding site. These 
features of the Env architecture, including the relative number of PNGSs, are 
surprisingly maintained in spite of years of viral evolution. Indeed studies have 
indicated that in certain strains up to 60% of N-linked glycans are highly conserved. 
86 Oligomannose-type glycans are the most highly conserved PNGSs, suggesting an 





escape mutants display non-random mutations in the PNGS, conserving both the 
spatial distribution, and the specific identity of the glycan, suggesting conservation 
within the glycan shield and further supporting the notion of targeting the glycan 
shield for antigen design. 85 The N332 PNGS, the so-called ‘super-site of 
vulnerability,’ bearing almost exclusively a Man9GlcNAc2 glycan, is known to be 
vulnerable to migration. Studies following the pathogenesis of a single infection have 
shown that the virus responds to immunological recognition of this site by shifting the 
position from N332 to N334. After two years of infection, the virus was shown to 
have escaped immune recognition again simply by migrating the N334 position back 
to N332. 87 The persistence of HIV to maintain a spatially consistent glycan shield is 
highly significant and suggests a more fundamental structural role of the glycan 
shield beyond immune evasion. 
1.10 Non-carbohydrate-mediated HIV immune evasion  
           Beyond the ability of HIV to evade immune surveillance by decorating the 
functional Env in a dense carbohydrate shield, HIV has been shown to exhibit the 
ability to induce gp120-mediated immunosuppressive responses from dendritic cells. 
88 The immunosuppressive ability is predicated on gp120 mannose moieties via IL-10 
expression.89 The exact mechanism of IL-10 upregulation by gp120 mannose 
moieties has not been elucidated. 90 IL-10 is a pleiotropic cytokine and suppresses 
immune activation by downregulating the expression of pro-inflammatory cytokines. 
88 This discovery indicates that the glycan shield of HIV promotes pathogenesis, not 
only by preventing recognition by the immune system, but also by actively 





Elite controllers (EC) are thought to limit HIV infection in part due to the high 
antibody-dependent cell-mediated cytotoxicity (ADCC) activity that characterizes EC 
individuals. ADCC is therefore expected to be an integral feature in controlling HIV 
infection. It has been recently reported that HIV has developed a mechanism to 
suppress ADCC-mediated immune clearance via the intervention of the accessory 
viral protein Nef. Nef is thought to downregulate CD4, affecting the conformation of 
Env. The epitope required for ADCC-mediated recognition is only exposed in the 
CD4-bound conformation, therefore in the unbound conformation, the site is 
unavailable, and HIV is able to evade recognition by NK cells. 91  
           Subsequent to gp160 cleavage, the heterodimer of homodimers is held intact 
by non-covalent forces. Consequently, the gp120-gp41 complex can dissociate to 
varying extents yielding a mixture of functional (i.e. trimeric) and non-functional Env 







Figure 1.2 A) After furin cleavage of gp160, the Env complex exists as a 
hetergeneous mixture of functional and non-functional proteins within the HIV 
milieu. B) Non-neutralizing and strain-specific Abs do not lead to a sustained 
inhibitory response. The conserved epitopes of bNAbs ensure neutralization capacity 






highly antigenic epitopes on the protomer-associated face that is occluded in 
functional trimers. The non-neutralizing epitopes raise a strong non-neutralizing 
immune response, however, as the non-trimeric Env protein cannot mediate cell 
entry, the response is unable to impede HIV pathogenesis. Similarly, the Env protein 
displays a limited number of strain-specific neutralizing epitopes capable of eliciting 
strain-specific NAbs (Scheme 1.5B). However, as the epitope is strain-specific, the 
neutralizing capacity is lost upon the emergence of the first escape variants that arise 
in response to the mounting immune pressure. The ability of broadly neutralizing Abs 
(bNAbs) to recognize conserved epitopes on Env across strains make them attractive 
targets for vaccine design (Scheme 1.5B). 
1.11 The Env glycan shield as an immunological target: bNAbs 
            Glycosylation play a critical dual role in viral pathogenesis. Exposed glycans 
on the viral surface often interact with host cell receptors and mediate disease 
transmission. The densely displayed, dynamic, bulky glycans also prevent access by 
the host immune system to the variable antigenic viral protein surface. The glycan 
shield of HIV is incredibly effective at mediating the multi-step relationship between 
host and virus during the first stages of infection, as well as masking the virus after 
the infection has been established. HIV also uses mutations in the glycan shield to 
create viral escape variants that continually evade host immune surveillance. Despite 
the sophisticated application of the glycan shield by HIV to facilitate viral 
pathogenesis, the discovery of broadly neutralizing Abs (bNAbs) that largely 
incorporate the glycan shield as a critical component of their neutralizing epitope 





system is capable of discriminating between host glycans and host-derived viral 
glycans as the HIV glycan shield has several unusual features that deviate from host-
glycosylation patterns. First, the spacing between glycans on gp120 is unusually close 
in comparison to glycan spacing on mammalian proteins, placing a conformational 
constraint on the glycans, increasing the rigid presentation. 92 This rigid presentation 
is bolstered by a network of intermolecular hydrogen bonds, which stabilizes the 
glycans structures, partially locking them in a non-self conformation, forming the 
basis for immunological discrimination. 65  
 
 
Figure 1.3 In the context of quaternary structure, gp120 glycosylation exhibits lower 
glycan processing and therefore less complex-type glycan than recombinant 
monomeric gp120. 
 
Second, the unusually high degree of glycosylation that is characteristic of HIV Env 





processed oligomannose-type glycans (Scheme 1.6-right). The underprocessed 
oligomannose glycans are primarily concentrated in sterically constrained regions, 
including regions with the highest numbers of PNGSs (i.e. IMP), and the interface 
between gp120 protomers (i.e. TAMP). 93 The under-processed glycans display lower 
structural variation compared to host cellular glycosylation, a distinction that is 
recognized by the innate immune system through mannose-binding lectins (MBLs). 
94-95 Unfortunately, HIV takes advantage of the recognition by dendritic cells (i.e. 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
[DC-SIGN]) via MBLs, which shuttle the virus from the site of infection (usually 
mucosal tissue) to CD+ T cell-rich lymphoid tissue, thereby propagating the infection. 
94, 96 The regional delineation of oligomannose glycans results in clustered 
arrangements of oligomannose glycans in congested regions, as well as clustered 
arrangements of highly processed complex-type glycans to regions that are more 
accessible to host glycosylation machinery, typically the region near the gp120-gp41 
interface. 16 The predominance of oligomannose glycans on trimeric Env is limited to 
a quaternary context. Recombinant gp120, expressed in a variety of cells, results in a 
significantly different glycosylation profile with considerably higher quantities of 
complex-type glycans (Scheme 1.6-left), although oligomannose glycans are still the 
dominate species. 93 
        Given the paucity of antigenic features on the surface of the HIV, Env is the 
most promising feature of HIV for targeted antigen design. Traditional vaccination 
attempts using monomeric gp120 have been largely unsuccessful. Four approaches to 





different priming/booster strategies. 97 98 99 100 In all cases, the primary humoral 
immune response was largely limited to non-neutralizing Abs with no discernable 
protection against HIV. The only vaccine trial that has achieved a modicum of 
success, the RV144 trial in Thailand, was found to provide ~30% protection from 
HIV infection. 100 The source of the protection is attributed to a high titer of weakly 
neutralizing V2-directed Abs. As discussed in section 1.5, the expose trimer 
associated face of gp120 is highly antigenic and humoral responses raised against this 
non-neutralizing epitope dominate (Scheme 1.5A). 101  The first NAbs elicited target 
strain-specific epitopes and are unable to subsequent escape variants (Scheme 1.5B). 
102-103 In contrast, several classes of anti-gp120 antibodies targeting diverse strains 
with strong, neutralizing capacity have been recently described. These so-called 
broadly neutralizing Abs (bNAbs) target conserved regions accessible on the gp120 
trimer, providing clues regarding HIV’s vulnerability to neutralization (Scheme 
1.5B). Moreover, an adequate understanding of the bNAb epitope can facilitate 
synthetic antigen/vaccine design targeting a conserved, neutralizing epitope. A 
common feature among the vast majority of anti-gp120 bNAbs is the incorporation of 
the HIV-1 N-glycan shield as a critical component of the individual epitopes. 104 
bNAbs that target self-glycans as an epitope component initially gave rise to concerns 
that many of these bNAbs were self-reactive. Such self-reactivity would render them 
poor targets for vaccine design as self-reactivity would likely lead to their elimination 
from the B cell pool, making them extremely difficult to induce. 105 However, 
subsequent studies have revealed that the induction of bNAbs during HIV-1 infection 





humoral responses within two years of infection, with some bNAb responses arising 
within a year of infection. 106-108 Given the relatively slow development of these 
bNAbs, the patients that develop such NAbs are not protected by them, rather the 
viral load and strain-diversity is too high by the time the mature bNAbs appear. 109 
The slow rate of development of bNAbs is likely due to their development at the edge 
of immune tolerance mechanisms, and their reliance on unusual structural features to 
allow strong antigen binding.  
         There is a characteristic interdependence between HIV-1 changes and bNAb 
sequence variation due to parallel evolution pathways. 110-111 This interdependence 
has far reaching consequences for the affinity maturation ceiling within the germinal 
center (GC). Normally, the GC reaction is limited due to the Ab affinity ceiling. 112-113 
However, the increased pressure on the immune system due to the diversity and swift 
development of HIV-1 escape variants that can escape immune surveillance via 
mutation and selection, results in a continually evolving antigen that produces a 
persistent co-evolving immune response. The persistence of the immune response 
raises the affinity maturation ceiling, resulting in unusual exotic bNAb structures that 
can only arise during chronic infection. 114-115  
          The majority of bNAbs are poly-reactive and display a modicum of 
promiscuity that allows them to accommodate a variety of HIV strains. The 
endogenous promiscuity of bNAbs expands the level of sequence variation tolerated 
from glycan shifts in the PNGSs that often characterize viral escape variants. 
Provided the glycan shift is spatially conserved, the bNAb can often accommodate 





of bNAbs to neutralize not only the founder virus, but the subsequent escape variants 
as well, make bNAbs an ideal immunological template for vaccine design. Indeed, 
numerous studies have shown the ability of passive immunization with bNAbs to 
provide complete protection from viral challenge with SHIV (chimeric simian/human 
immunodeficiency virus) in non-human primates. 117-121 The ability of these bNAbs to 
provide protection in passive circulation justifies the efforts to develop a rationally 
designed vaccine to elicit such bNAbs. 
          To date, there have been ~100 bNAbs isolated and characterized. 122 The 
described bNAbs generally target defined, conserved regions of vulnerability on the 
HIV-1 Env glycoprotein, including the IMP, the CD4 binding site, the membrane-
proximal external region (MPER) of gp41, glycopeptide epitopes on the V1/V2 and 
V3 variable loops, and the bridging region at the gp120-gp41 interface (Scheme 1.4). 
123-124 These bNAbs primarily incorporate N-linked glycans as a component of their 
neutralizing epitopes, proving that the dense HIV-1 glycan shield contains 
immunological vulnerabilities that can be used as a basis for discrimination by the 
host humoral immune response. Carbohydrate-reactive bNAbs primarily target either 
the N332 glycan (and the associated V3 loop), the N160 glycan (and the associated 
V1/V2 loop), or the glycans associated with the gp120-gp41 interface. 125 The first 
carbohydrate reactive bNAb described, 2G12, recognizes an exclusively carbohydrate 
epitope composed of a cluster of oligomannose glycans within the IMP, including 
N295, N332, N339, and N392. 84, 126-127 2G12 achieves remarkably high-binding to a 
carbohydrate epitope through an unusual domain-exchanged structure affording high 





carbohydrate-reactive bNAbs have not shared the unusual domain-exchange structure 
characteristic of 2G12, but in all cases have a typical Y-type Ab structure, with 
integrated epitopes consisting of both protein and glycan components. 129  Compared 
to 2G12, newer classes of carbohydrate-reactive bNAbs have exhibited higher 
breadths and potencies. For example, while 2G12 has been shown to neutralize 32% 
of viral strains with a median IC50 of 2.38 μg/mL, it has been demonstrated that 
PGT128 can neutralize 72% of HIV-1 strains with a median IC50 of 0.02 μg/mL. 
92, 
130-131 There are two major classes of bNAbs that target an integrated epitope, the 
PGT-series and the PG-series. Members of the PGT-series target several regions of 
the glycan shield, including the gp120-gp41 interface (PGT151), targeting complex-
type glycans on gp41 and a protein epitope on gp120, 132 and the glycan at N160 on 
the V1/V2 loop (PGT145) (Scheme 1.7). 131 Other members of the PGT-series target 
the V3 loop, and specifically incorporate a high-mannose glycan at N332 as a 
component of the epitope (Scheme 1.7). The supersite of vulnerability N332, 
although incorporated in multiple bNAb epitopes (2G12, PGT series) has been shown 
to be non-critical as many of these bNAbs display a modicum of promiscuity 
allowing them to bind to other glycans in the absence of N332 and thereby recover 
the epitope. 116 The other major family, the PG-series, targets the V1/V2 loop at the 








Figure 1.4 bNAb epitopes are scattered across the silent face of gp120, and almost 
exclusively incorporate N-glycans as an epitope component (gp120 structure adapted 
with permission from the publisher). 16  
 
            There are five major structural characteristics that define the majority of 
bNAbs that deviate from more traditional IgG Abs, including extended heavy chain 
third complementarity-determining regions (CDRH3), unusual post-translational 
modifications (i.e. tyrosine sulfation), domain-exchange (2G12 only), auto-/poly-





epitope consisting of N-glycans and the underlying protein sequence, long, extended 
CDRH3 regions are common, usually containing charged sequences within the 
CDRH3. For example, while the average length of a typical human B cell CDRH3 is 
14 residues, 134 PG9 and PG16 both contain 30 residues, while PGT145 contains 33 
residues. 135-137 The extended CDRH3 facilitates penetration through the dense glycan 
shield that extends ~20 Å from the protein surface allowing contact with the 
otherwise occluded protein surface. The long CDRH3 in certain cases even provides 
sufficient length to accommodate secondary structure within the loop, allowing this 
feature of the paratope to “fit” the epitope more closely. An example of this is the 
“hammerhead” shape of the PG9/PG16 CDRH3, permitting penetration of the glycan 
shield and extensive contact with glycan and protein targets. The high incidence of 
unusual PTMs often works in conjunction with other characteristic structural features 
to enhance binding affinity. For example, tyrosine sulfation has been reported on the 
CDRH3 of certain bNAbs, and is known to interact with cationic residues within the 
protein component of the epitope. 133, 135, 138 A subset of bNAbs have the remarkable 
characteristic of polyreactivity, in which a single Ab can recognize more than one 
antigen. 139-140 Many of these bNAbs recognize two specific binding sites on the Env 
surface, a high-affinity anti-HIV-1 binding site and a low-affinity self-antigen (i.e. 
host-derived N-glycan) that is present on the Env surface. The polyreactivity of these 
bNAbs most likely mediates this bivalent heteroligation, overcoming the low affinity 
of the second binding site and increasing the apparent affinity of the bNAb to HIV-1. 
Polyreactivity, normally deselected from typical B cell lines, plays a critical role in 





specific memory B cells that are polyreactive in HIV-1 infected individuals. Indeed, 
75% of memory B cells in HIV-1 positive individuals are polyreactive, compared to 
just 5% of the B cells in non-infected individuals. 140 The exotic and unusual nature of 
bNAbs necessitates extensive rounds of mutations within the GC, requiring extensive 
somatic hypermutations (SHM) during affinity maturation. 141-143 While non-HIV-1 
Abs typically undergo 5-15% changes in the heavy chain during affinity maturation, 
some bNAbs accumulate up to 36% of changes. 141 The majority of SHMs are limited 
to the CDR regions, however, certain HIV-1 targeting bNAbs have also undergone 
SHMs within the conserved framework region (FWR) of the Ab as well. 144  
1.12 HIV-1 Vaccine Design 
        There have been a number of attempts to vaccinate against HIV infection, 
largely following four major vaccination strategies, protein subunit vaccines, 
recombinant andenovirus vectors, canarypox vector prime, followed by a protein 
subunit boost, and a DNA prime followed by a recombinant andenovirus vector 
boost. 145 Early attempts using recombinant gp120 mixed with the adjuvant alum 
(AIDSVAX), elicited only non-neutralizing Abs, and no protection was observed. 97-
98 Two vaccine attempts, the Step trial and the Phambili trial, investigated three types 
of recombinant, attenuated adenovirus vectors expressing three HIV-1 related 
proteins (i.e. Gag, Pol, and Nef). Both studies observed a stimulated CD8+ T cell 
response to the viral vectors, however, the vaccination yielded no protective benefits, 
and the trials were cut short due to concerns that HIV-1 infection risk was actually 
enhanced post-vaccination. 99, 146-148 The reasons for the enhanced susceptibility to 





to-date was the RV144 trial in Thailand (so-called ‘Thai trial’), which incorporated a 
canarypox viral vector that expressed gp120, Gag, and Pol. The recombinant viral 
vector was used as the prime, which was followed by two sequential booster 
injections of the previously reported AIDSVAX preparation. 100 Significantly, the 
combined vaccination strategy provided a small but noteworthy protective effect, 
with 30% fewer infections among vaccinated patients. 100 The source of the protective 
effect is somewhat unclear, but it is thought to be due in part to the elicitation of V2-
directed NAbs. Most recently, a combined DNA/viral vector vaccination strategy has 
been applied, incorporating a DNA prime, composed of plasmids encoding HIV-
related proteins from several strains, and an adenovirus vector boost. 149 This trial 
(referred to as the HVTN 505 trial) resulted in no observable protective effects, and 
was also cut short due to concerns over increased risk of infection among the 
vaccinated. 149     
            A recent alternative vaccination approach is the design of recombinant trimer 
mimics. The design of a stable, soluble gp140 trimer eschews the challenges 
associated with vaccination with gp120 monomer by occlusion of the 
immunodominant non-neutralizing epitopes, solely focusing presentation of the 
neutralizing epitopes as immunological targets. A number of Env constructs have 
been reported, however, the structures correspond to uncleaved trimers (i.e. gp160), 
which are not representative of the native trimeric gp120 conformation. 64  Recently, 
a new recombinant trimeric gp140 Env protein has been developed that incorporates 
subtle modifications that generate a stable and soluble trimer mimic. These ‘SOSIP’ 





(removal of the MPER and transmembrane domain) gp41 and gp120 (SOS) as well as 
a point mutation (isoleucine to proline-IP). 70 The development of these SOSIP 
trimers has led to a number of strain-specific variants, many of which have 
demonstrated native-like structural properties and antigenicity. 71, 150 Immunization 
studies using these soluble, native-like Env SOSIP trimers have successfully elicited 
Abs against autologous tier 2 virus, 151 however it was later demonstrated in a mouse 
study that there is an immunodominant non-neutralizing epitope near the trimer base 
that limits the utility of these gp140 constructs as immunogens. 152  
         Despite the extensive progress that has been made by the development of 
soluble, native-like trimers, there is a significant possibility that a heavily 
glycosylated recombinant protein will not be sufficiently immunogenic to induce the 
type of strong, sustained Ab response that will be required by an effective vaccine. 
An optimized vaccine will likely require repetitive presentation of the antigen, 
perhaps through particulate presentation, to initiate a sustained immune response. 
Particulate presentation of epitopes improves Ab responses through a variety of 
mechanisms. First, repeated presentation of the epitope allows the immunogen to 
cross-link B cell receptors, improving B cell activation.153-154 Second, circulating 
IgMs are capable of binding to repetitively displayed antigens via high-avidity 
interactions, simultaneously activating the complement system and lowering the 
threshold necessary for B cell receptor activation. 153 Third, the affinity of naïve B 
cell receptors for bNAb epitopes is likely to be low; a repetitive array of low-affinity 
epitopes increases avidity, raising the likelihood that the right B cell will be activated. 





frequently induce Abs against additional epitopes compared to antigen alone, 
increasing the neutralization breadth. 156-159 Fourth, host self-antigens usually don’t 
contain highly repetitive antigenic structures and recurring epitopes are regarded as 
non-self antigens by B cells. 160 The use of repetitive self-derived epitopes may also 
rescue autoreactive B cell progenitors that would otherwise be deleted during Ab 
development expanding the potential repertoire of germline B cells available. In such 
a case, the autoreactive B cell progenitors would be tuned to recognize self-antigens 
only in the context of highly repetitive epitopes. 160 Finally, studies have suggested 
that highly repetitive and recurring epitopes are capable of inducing long-lived Abs. 
154, 157 This is particularly relevant for strategies that are alternatives to Env based 
vaccines, as both monomeric and trimeric gp120 based vaccines usually induce short-
lived Ab responses. 100, 151, 161 
1.13 Challenges of Carbohydrate-based Vaccine Design 
 
        Protein-protein and protein-carbohydrate interactions are both mediated by a 
high degree of hydrogen bonding, hydrophobic interactions, van der Waals forces, 
and electrostatic interactions. Similarly, Ab binding to both carbohydrates and 
proteins results in a favorable enthalpy contribution to the free energy of the 
interaction. 162 However, for carbohydrates, the favorable enthalpy contribution is 
significantly offset due to an entropic penalty incurred during binding. The entropic 
penalty arises from the disruption of the solvation shell and subsequent solvent 
rearrangement upon binding, together with the loss of oligosaccharide conformational 
flexibility upon complex formation. 163 164 The entropic penalty incurred during 





oligosaccharide epitope. The low-affinity binding interactions necessitate the reliance 
of glycan-protein interactions on avidity effects enabled through multivalent 
interactions. 
         In contrast to protein/peptide antigens, purely carbohydrate antigens are 
thymus-independent type 2 (TI-2) antigens and therefore activate B cell responses in 
the absence of T cell assistance. 165 166 B cell receptor cross-linking through binding 
repetitive motifs (i.e. repetitive carbohydrate antigens) activates antigen specific B 
cells independent of CD4+ helper T cells. 167 The failure to recruit the full 
complement of the immune response necessitates several limitations in the efficacy of 
the response. First, largely low-affinity IgM antibodies are produced by the B cells 
upon stimulation by purely carbohydrate antigens. 168 These low affinity IgM 
antibodies lack both affinity maturation and isotype switching, severely hampering 
the specificity achieved by these Abs for the particular antigen. 169 The generalized 
immune response lacks the necessary features to distinguish the antigens, resulting in 
a short-lived, weak immune response. Finally, Ab responses cannot even be induced 
in newborns and children up to 2 years old when vaccinated with a purely 
carbohydrate antigen. 170 In contrast, proteins typically generate a CD4+ helper T cell-
dependent response, resulting in the generation of high affinity, class-switched Abs. 
171 172  In order to overcome the short-lived immune response typical of the vast 
majority of carbohydrate antigens, and generate long-lived antibody-mediated 
protection, exogenous CD4+ helper T cell epitopes are typically required in the 
vaccine design, usually in the form of a carrier protein. 171 173 An additional challenge 





endemic to glycoproteins, such heterogeneity can dilute the efficacy of glycan 
specific Ab responses. Therefore, the multivalent display of defined carbohydrate 
epitopes on a protein carrier is necessary for successful carbohydrate-based vaccines. 
 
1.14 Antibody-guided approach to vaccine design 
             The most promising strategy towards a rationally designed HIV-1 
immunogen is the so-called ‘reverse vaccine engineering’ strategy, also known as the 
‘antibody-guided’ strategy. The reverse vaccine engineering strategy uses known 
bNAbs to define neutralizing epitopes that can be used as targets to induce a similarly 
potent and broad B cell response. 174 175 The antibody-guided approach has been 
applied to design several minimal, putative, carbohydrate-based mimics of bNAb 
epitopes. The epitope of 2G12 for example, has been the target of intensive effort. 
2G12 recognizes a cluster of α1,2-linked mannose within the IMP, many groups have 
designed chemically synthesized multivalent oligomannose antigens on a variety of 
scaffolds, including proteins, peptides, dendrimers, carbohydrates, DNA, steroid, and 
gold nanoparticles. While no construct to date has been capable of stimulating HIV 
neutralizing activity post-vaccination, many of these constructs have reported 
excellent antigenicity results, indicating a close similarity to the native epitope. A 
number of glycopeptide-based mimics of the PG9/PG16 epitope have also been 
reported, exhibiting excellent antigenicity.    
1.15 Long-term Vaccination Strategies 
         There is much speculation regarding the ability of the immune system to 





suggests that the target bNAbs may need to be elicited via stepwise vaccination using 
multiple immunogens. Initial strategies were centered around targeting the inferred 
germ-line (iGL) precursors of the target bNAbs. However, it has been consistently 
demonstrated that iGL precursors have little to no affinity for HIV-1 Env antigens 
and totally lack neutralizing activity. 176-178 This observation suggests that activation 
of specific germline bNAb-expressing B cells will require specific antigens that are 
designed to target an epitope that is considerably different from the mature target 
epitope (i.e. a germline prime). The stochastically dynamic model of the immune 
response to a rapidly evolving viral target makes rational design of a vaccination 
strategy extremely difficult. One proposed method that has been supported by in vivo 
and in silico studies is the combination of different antigen variants containing the 
same neutralizing epitope (Scheme 1.5A). The major benefit of this method is the 
induction of cross-reactive Abs that are focused on the same shared epitope. 179 180-181 
The initial antigen primes the B cell responses to the desired epitope, while the other 
epitope scaffold conjugates, displaying the same epitope as the prime, selectively 
stimulate memory B cells that are specific for the shared antigenic determinant. This 
strategy narrows the response to the antigenic determinant alone, regardless of the 
epitope scaffold.  Another design, proposed by Hayes et al., referred to as the B cell 
lineage immunogen design, targets the unmutated common ancestors (UCAs) of the 
target bNAb. 182 124 183 An immunogen that can stimulate the precursor bNAbs may 
lead the immune system to elicit the target bNAb (see Scheme 1.5B). A major 
challenge associated with this strategy is the observed lack of binding between bNAb 





requires the design of sequential serial immunogens with decreasing epitope 
modifications that can target the germline bNAbs, the mature bNAb, as well all 
intermediate species. 186 This method has been tested in the past with limited success. 
187 188 Recently, this strategy has been applied to generate VRC01-like bNAbs, 189 as 
well as the V3-loop-directed PGT121. 190-191 Both studies relied on a reductionist 
sequential immunization strategy in which immunogens were strategically mutated to 
remove selected sites, generating a panel of potential vaccine primes that were tested 









Scheme 1.5 A) Sequential immunization strategy: same neutralizing epitope 
presented on different scaffolds may promote affinity maturation of cross-reactive 
antibodies that focus on the shared epitope. B) B-cell lineage immunogen design. 
 
        The concentration of the antigen(s) at the time vaccination is another major 
determinant in the efficacy of a vaccine candidate. The dose of the antigen needs 
to be sufficiently high, but not too high. If an Ag dose is too low, B cells within 
the GC are not likely to be selected, and the GC will collapse without the 
production of Abs. 192 If the Ag dose is too high the B cell selection is very rapid, 
however, due to the lack of competition between B cells, the GC is overwhelmed 
by low-affinity clones, rather than the highly specific clones that are desirable. 192 
1.16 Conclusion 
         The significant global health impact of the HIV-1 pandemic necessitates the 
development of a means to eradicate the virus. A prophylactic vaccine capable of 
inducing even modest titers of NAbs could be sufficient to provide circulating 
protection from HIV infection. Despite the tremendous advances in our 
understanding of HIV-1 structure and function, the development of an effective 
protective HIV-1 vaccine continues to present a significant challenge. The series 
of failed vaccination studies do not define the current prognosis. The discovery of 
bNAbs that are potent at concentrations achievable by vaccination regimens, 
provides a basis for optimism that a properly designed immunogen(s) combined 
with a proper vaccine regimen could lead to a functional vaccine. The exotic 





hypermutations, and are, most likely, a result of the length of time required for 
bNAb development, rather than a strict requirement for substantial mutations. 
Recent reports highlighting efforts to ‘walk’ B cell development from distant 
germline bNAb precursors to bNAb-like phenotypes via sequential immunization 
demonstrate that a direct path to eliciting bNAbs is possible without long-term 
mutations. A successful vaccine will likely need to overcome the self-tolerance 
mechanisms to host-derived glycans in the glycan shield via non-self presentation 
of the epitopes. One of the most promising methods to overcome self-tolerance 
mechanisms, without disrupting the careful immunological balance, is the 
repetitive presentation of the epitopes on antigenic scaffolds. The repetitive 
presentation of host-derived antigens is viewed as foreign by the immune system, 
thus potentially overcoming the ability of HIV to hide from immune recognition. 
One of the most pressing needs for the development of an effective anti-HIV 
vaccine is the design of antigens that present the native-like epitope outside of the 
context of the greater gp120 structure to focus the development of a neutralizing 
response against neutralizing epitopes only. Such a strategy will avoid dilution of 
the immune response by co-presentation of non-neutralizing epitopes. The focus 
of the work presented here is the development of synthetic antigens intended to 
mimic the epitopes of host-generated anti-gp120 proteins. The construction of 
these complex biomolecules relies extensively on the tools of chemical biology. 
          The work presented here seeks to address several of these pressing needs in 
HIV research, including optimized immunogen design and a means to identify 





vaccine design. In chapter 2, I developed a series of immunogens targeting 2G12-
like bNAbs that will probe the exact glycan preference of 2G12 towards 
developing an optimized 2G12 vaccine. In chapter three, I describe the 
development of a general chemoenzymatic method to facilitate site-selective 
addition of two unique N-glycans on a polypeptide. The method was used to 
construct a series of differentially glycosylated glycopeptides that serve as 
minimal putative mimics of the V1/V2 loop of HIV. In chapter 4, the method 
developed in chapter 3 was applied to design and construct a series of 
glycopeptide-VLP protein conjugates that present the bNAb PG9 epitope in a 
multivalent format, thereby enhancing the antigenicity. The second half of my 
dissertation describes the synthesis of two novel N-glycan libraries that can be 
applied to serum screening of HIV+ serum. In chapter 5, the construction of a 
chemoenzymatically derived oligomannose N-glycan library is presented. The 
individual oligomannose glycans were conjugated to a protein carrier and tested 
against a panel of mannose-reactive proteins in a microarray format. Finally, in 
chapter 7, the design and synthesis of a naturally-derived N-glycan library 
containing highly branched, bisected tri-/tetra-/penta-antennary glycans is 
described. The presentation of these unusual Gal/GlcNAc terminal glycans on a 
carrier protein can be used to probe HIV+ serum for proteins that recognize 
clustered, highly branched N-glycans that may be present on the HIV virion itself, 
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Chapter 2: 2G12-Epitope Vaccine Design: Synthesis of 
Triazole-Linked Oligomannose-Bacteriophage (Qβ) Conjugates 
to Probe the Specific Contribution of the Chitobiose Core on 




       Despite over thirty years of intensive HIV research, an effective prophylactic 
vaccine, widely considered the best hope to combat the global HIV-1 pandemic, 
continues to evade all design efforts. To date no vaccine that induces a sustained 
neutralizing antibody (NAb) response across multiple HIV-1 strains has been 
effectively designed. 1-4 The sole target for vaccine design, the unstable heterodimeric 
trimer consisting of the homotrimeric glycoproteins gp120 and gp41 composing the 
viral envelop spike (Env)—required for viral infectivity, is extremely effective at 
masking conserved regions of the immunological target. The viral spike is a very 
dynamic structure with conserved epitopes recessed, transiently exposed, or else 
occluded by both an extremely dense glycan shield and immunodominant loops that 
are characterized by a high level of sequence variability. 5-8 These formidable 
defenses contribute to the difficulties in the elicitation of neutralizing Abs to the 
masked, conserved epitopes located on the Env protein. Traditional vaccine 
approaches incorporating recombinantly expressed monomeric gp120 have been 
consistently unsuccessful, despite extensive efforts 9 10-12 in part due to the formidable 





vaccine design arose from the observation that certain HIV-infected individuals 
remained asymptomatic in the absence of treatment. Subsequent investigations 
revealed that certain individuals produce rare and unusual Abs that effectively 
neutralize a broad range of HIV-1 isolates. 13 These broadly neutralizing Abs 
(bNAbs) achieve this remarkable ability by targeting conserved epitopes within the 
glycan shield itself. The discovery of these bNAbs suggests that a cross-reactive NAb 
response against HIV-1 is possible. Therefore, the very defenses that HIV employs 
for immune evasion (i.e. the glycan shield) form the basis for immunological 
neutralization. The discovery of monoclonal bNAbs provides exciting tools for 
facilitating informed vaccine design, as elucidation of their neutralizing epitopes 
adumbrates conserved elements within the immunological “armor” of Env protein 
that can be exploited to generate a more effective vaccine that targets neutralizing 
HIV-1 epitopes.  
        Within the past five years there has been an explosion in the number of bNAbs 
discovered and characterized. 14-21 22 The vast majority of the described bNAbs 
incorporate components of the gp120 glycan shield as a critical feature of their 
neutralizing epitope. An interesting corollary to this observation is that, though highly 
variable, the pattern and spatial distribution of glycosylation on gp120 is highly 






Figure 2.1 Structural differences between 2G12 and typical IgG Abs. 
  
The prototypical carbohydrate-reactive anti-HIV-1 bNAb is 2G12. 2G12 was the 
second bNAb to be described 26 and the first to target HIV glycans. 26 2G12 targets 
the gp120 “glycan shield” binding to a cluster of oligomannose glycans located 
within the intrinsic high-mannose patch, specifically, N-linked glycans on N295, 






Figure 2.2 Model of 2G12 glycan recognition of gp120. 14 
 
         Based on the model of 2G12 co-crystallized with Man9GlcNAc2 and overlaid on 
gp120 (Figure 2.2), three separate oligomannose moieties (shown in red) interact with 
2G12. Two Man9GlcNAc2 glycans interact with the two primary combining sites, and 
a third interacts with the newly created combining site at the VH/VH’ interface formed 
by domain-exchange (see Figure 2.2).  Additional oligomannose glycans within the 
cluster are also critical for maintaining the epitope conformation. 27 28 
              The “glycan shield” of HIV is composed of host-derived glycans and it is 
therefore difficult to overcome the immunotolerance mechanisms to target these 
glycans. The presentation of the oligomannose glycans within the 2G12 epitope as a 





epitope. Clustering of oligomannose glycans on mammalian glycoproteins is 
extremely rare, and therefore viewed as “non-self” by the human immune system. 
The ability of 2G12 to bind with neutralizing capacity to a solely carbohydrate 
epitope is thought to be a result of the extremely unusual domain-exchanged 
architecture of the 2G12 Fab (see Figure 2.1). 14 30 The variable heavy chain subunit 
(VH) of each antibody arm is exchanged with the VL domain on the opposite branch 
creating a compact multivalent binding surface, providing a means to bind the solely 
carbohydrate epitope with high affinity, an affinity that is unachievable by a typical 
Y-shaped Ab. Indeed, mutagenesis studies that eliminate the domain-exchanged 
structure, abrogates 2G12 binding to gp120. 31 32 The large antigen recognition 
surface is capable of high avidity interactions with multiple tightly packed mannose 
residues. For several years, 2G12 was the only known carbohydrate-reactive bNAb, 
in addition, the relatively straight-forward nature of the 2G12 epitope (i.e. 2-4 tightly 
clustered oligomannose glycans) has made reconstitution of the epitope an attractive 
target. Initial attempts at 2G12 antigen design centered around constructing densely 
clustered oligomannose glycans. The strategies can be loosely grouped into two 
categories: immunogens which incorporated natural oligomannose glycans containing 





Figure 2.3 Selected multivalent high-mannose glycan cluster antigens. A) 
Tetravalent Man9GlcNAc2 on a galactoside scaffold conjugated to KLH. 
33 34 35 B) 
Divalent cyclic peptide conjugated to OMPC. 36-37C) Recombinant yeast proteins 
bearing Man8GlcNAc2 glycans. 
38-39 40 41 D) Man4-conjugated to BSA carrier. 
42 43 E) 
Man9 dendrimers on a CRM-197 carrier. 
44 45 F) Heterogeneous multivalent display 
of Man9 and Man8 on a Qβ phage particle. 
46 
 
             The Wang group was the first to report a synthetic 2G12 antigen 35 
constructed from a cluster of Man9GlcNAc2 glycans on a galactoside scaffold (Figure 
2.3A). 2G12 exhibited markedly higher affinity for the tetra-valent cluster versus the 
individual Man9GlcNAc2 subunits. This initial design was modified by utilizing a 
rigid cholic acid scaffold with tri-valent display of Man9GlcNAc2. 





scaffold reduces the entropic penalty that is incurred upon 2G12 binding to a 
dynamic, heavily solvated epitope. The cholic acid cluster again demonstrated higher 
affinity for 2G12. Both studies highlighted the importance of glycan clustering in 
2G12 binding. In an alternative design, Danishefsky and co-workers utilized a 
functionalized cyclized peptide as a scaffold to construct oligomannose glycan 
clusters to further characterize the 2G12 epitope (Figure 2.3B). 36 The cyclic peptide 
scaffolds displayed up to three Man9GlcNAc2 glycans and again showed enhanced 
recognition by 2G12 as compared to individual Man9GlcNAc2 glycans. The 
limitations of antigenicity toward host-derived “self-glycans” were considered in the 
design of oligomannose glycan clusters that incorporated synthetic non-self sugars 
within the cluster. A design by Wang and co-workers utilized a similar cyclic peptide 
scaffold strategy to that reported by Danishefsky, however, the glycan clusters 
attached to one face of the cyclic peptide were composed of non-natural fluorinated 
Man4 glycans that mimic the D1 arm of Man9 while remaining non-self due to the 
fluorination. 47 The other face of the cyclic peptide was used to attach two T-helper 
peptides. Surface plasmon resonance indicated the enhanced affinity of these glycan 
clusters over individual glycan subunits.  
          Despite the clear enhancement in 2G12 affinity of multivalent glycan display 
exhibited by the reported clusters. The highest affinity of the synthetic glycan clusters 
(μM level) was still far lower than the affinity of 2G12 for gp120 (low nM level), its 
native epitope. It was speculated that the level of multivalent display was still too low 
to properly mimic the 2G12 epitope on gp120. In order to reach the required 





dendrimeric skeleton scaffold to attach multiple copies of synthetic Man4 or Man9 
glycans. The dendrimers were found to bind 2G12 with extremely high affinity, 
comparable with gp120 itself. 44 The promise of the strategy instigated the 
development of glycodendrimers as candidate vaccines using diverse carriers, 
including polyamidoamine (PAMAM) 45 and gold nanoparticles allowing measurable 
changes in the density of loading (Figure 2.3E). 48 An elegant approach reported by 
Krauss and co-workers, used a directed evolution approach using a DNA scaffold 
with random insertions of alkyne-modified base-pairs followed by click-chemistry 
with synthetic Man9 glycan. 
49 The DNA-scaffold glycoconjugates were screened 
using a 2G12-affinity column, and the most promising candidates were sequenced 
and multiplied by PCR selection with modified aptamers (SELMA). 50 A second 
generation of the directed evolution SELMA approach uses RNA-DNA duplex. The 
associated peptide was translated and tagged with oligomannose glycans via click 
chemistry yielding a peptide screened to bind to 2G12. 51-52 Despite excellent 
antigenicity results, no immunization data has been reported. 
        The antigenicity studies focusing on the design of multivalent oligomannose 
display indicated that clustered synthetic oligomannose antigens are capable of 
binding 2G12 with neutralizing affinity. However, given the poor immunogenicity of 
carbohydrates antigens, an effective carbohydrate-based immunogen usually requires 
conjugation of the antigen to a T-cell helper epitope (i.e. a carrier protein). Such a 
conjugate is more effective at triggering the T cell-dependent immune response 
capable of eliciting IgG Abs that is usually required for a successful vaccine 





results were reformulated with a carrier protein and tested as possible HIV 
immunogens for raising anti-mannose Abs with a shared epitope with 2G12. The 
galactoside-based tetravalent Man9GlcNAc2 cluster reported by Wang and co-workers 
was conjugated to a key-hole limpet hemocyanin (KLH) carrier protein via maleimide 
linkages (Figure 2.3A). 34 Rabbits were immunized with the glycoconjugates and 
analysis of the antisera revealed moderate anti-carbohydrate Abs that were weakly 
cross-reactive with gp120. Unfortunately, the Abs raised were unable to neutralize 
HIV. Similarly, Danishefsky and co-workers conjugated their previously described 
Man9GlcNAc2 clusters on a cyclic peptide scaffold to the protein outer membrane 
protein complex (OMPC) isolated from Neisseria meningitis (Figure 2.3B). 37 
Analysis of the antisera from the associated immunogenicity study, obtained from 
both guinea pigs and rhesus macaques, indicated that the glycoconjugate was capable 
of eliciting high-titers of anti-carbohydrate Abs. The Abs were weakly cross-reactive 
with recombinant gp160, but were unable to neutralize viral isolates. In a more recent 
study, Angrawal-Gamse and co-workers expressed a library of recombinant yeast 
proteins produced in the presence of kinfunisine, which blocked the glycan 
processing pathway resulting in proteins bearing Man8GlcNAc2 glycans alone. 
(Figure 2.3C). Screening of the expressed proteins (via a 2G12 affinity column) 
isolated a single candidate that was recognized by 2G12 with high affinity. The 
candidate was sequenced and cloned (via PCR). Immunization with the yeast-derived 
glycoproteins elicited carbohydrate-reactive Abs that were cross-reactive with gp120 





only virions expressing exclusively high-mannose glycans were vulnerable to 
neutralization. 
       
 
Figure 2.4. Immunogens incorporating natural Man9GlcNAc2 glycans elicit gp120-
cross-reactive Abs. Abs raised by immunogens that use synthetic (mannose-only) 
glycans are not cross-reactive with gp120. 
 
        A number of immunogens incorporating synthetic (mannose-only) oligomannose 
glycans have been reported, also largely constructed from previously described 
antigenicity studies. The dendrimer-based oligomannose clusters bearing either Man4 
or Man9 glycans were conjugated to a non-toxic mutant protein derived from 





on a bovine serum albumin (BSA) scaffold was tested as an immunogen (Figure 
2.3D). 42 In both studies, while capable of raising anti-mannose Abs, the antisera 
derived from either of these glycoconjugates was unable to recognize high-mannose 
glycans in the context of gp120, indicating that the immune response was directed 
against a different mannose-only epitope on the immunogens. Several groups have 
explored virus-like particles (VLPs) as carrier proteins for glycoconjugate vaccines. 
Finn, Burton, and co-workers tested a side-by-side comparison of two VLPs (Cowpea 
Mosaic Virus [CPMV] and bacteriophage Qβ) by construction of glycoconjugate 
immunogens using click-chemistry to attach synthetic Man4, Man8, and/or Man9 
glycans (Figure 2.3F). The Qβ scaffold was found to be superior, displaying multiple 
copies of high-mannose glycans in a highly organized presentation. 46 The researchers 
incorporated alkyne groups in a two-step process (i.e. during protein expression and 
acylation of the exposed surface lysine groups) allowing two-step glycosylation, 
providing greater control in investigating the effects of varying the number, identity, 
and geometry of oligomannose display. The strategy allowed for manipulation of 
individual parameters to fine-tune the glycan presentation. The Qβ conjugates 
carrying Man4 and Man9 glycans were found to bind 2G12 with high affinity, and a 
heterogeneous mixed conjugate containing Man8 and Man9 showed the highest 2G12 
recognition. Despite the promising antigenicity results, the antisera from the 
associated immunogenicity studies yielded high-titers of anti-Man4 and anti-Man9 
IgG Abs, however, none of the Abs isolated from the antisera could cross-react with 
gp120. In addition, the antisera displayed no HIV neutralization activity. In a similar 





Man4 to a Qβ scaffold. The use of methylated Man4 glycans provided a non-self sugar 
mimic, intended to have enhanced antigenicity and overcome immune tolerance 
mechanisms. 53 The associated immunogenicity studies produced antisera that was 
not cross-reactive with gp120. Moreover, the antisera totally lacked HIV 
neutralization activity. Interestingly, glycan microarray analysis of the antisera 
indicated a higher antigenicity toward 2G12 when compared to unmodified Man4, 
supporting the notion that non-self sugar mimics are capable of improving 
immunogenicity. A similar rationale was utilized by Pantophlet and co-workers, who 
incorporated a bacterial lipooligosaccharide as a non-self oligomannose analog. The 
study utilized heat-killed bacteria displaying the lipooligosaccharide as an 
immunogen. Interestingly, the antisera obtained from the immunization studies was 
found to interact moderately with monomeric gp120, however, the antisera was 
unable to neutralize HIV virions. 54 
         In spite of enormous effort, to date, no effective 2G12-targeted vaccine has 
proven successful. However, the results of these studies have yielded interesting and 
important observations. Without exception, glycoconjugates containing natural, full-
length, chitobiose core containing oligomannose N-glycans (i.e. Man9GlcNAc2) have 
been capable of raising Abs that are moderately cross-reactive with HIV-1 gp120 
(Figure 2.4). The inability of glycoconjugates containing synthetic mannose-only 
oligomannose glycans to elicit Abs capable of cross-reactivity with gp120 may be 
due, in part, to the lack of a chitobiose core. Importantly, these synthetic mannose 
glycoconjugates are capable of eliciting carbohydrate-reactive Abs, however, this 





are not able, thus far, to mimic the orientation of the glycans on gp120. Taken 
together, the observations suggest that the chitobiose core may contribute to 
modulating the orientation of the oligomannose glycans. The orientation of the 
glycans appears to be critical for enhancing the antigenicity and especially the 
immunogenicity of the glycoconjugates, and may be required for a faithful 
reconstitution of the 2G12 epitope in a glycoconjugate context. In order to determine 
the specific role of the chitobiose core in defining the immunogenicity of a given 
glycoconjugate, it is necessary to compare two conjugates side-by-side (i.e.one 
containing the chitobiose core and the other lacking the chitobiose core). The 
subsequent differences in the immunogenicity of the antisera will directly indicate the 
specific requirement of the core GlcNAc. Herein we designed several 
glycoconjugates using a Qβ scaffold that display oligomannose clusters intended to 
represent the principal epitope of 2G12. The oligomannose clusters each incorporate 
an alternative glycan presentation intended to yield information regarding the specific 
glycan preferences of 2G12, including a side-by-side comparison of high-mannose 
Man9 glycans with and without the chitobiose core. Utilizing different glycan 
presentations on the glycoconjugates provided a means to fine-tune the presentation 
of oligomannose glycans to maximize the binding affinity to 2G12.  
        The well-characterized icosahedral viral particle bacteriophage Qβ capsid was 
chosen as the platform for presentation. Qβ self-assembles into a virus-like particle 
engulfing random cellular RNA upon recombinant expression in Escherichia coli. Qβ 
is pathogenic to E. coli, and presents no risk of infectivity in mammalian cells. Qβ 





excellent polyvalent scaffold for the display of various macromolecules. 55 56-59 60 Qβ 
capsid particles self-assemble from 180 small (14 kDa) subunits. The assembly from 
multiple small subunits results in a VLP with a smooth capsid surface, and regular, 
geometrically displayed reactive amines (lysine residues and the N-termini of the Qβ 
subunit) on the surface of the capsid. 61 The reactive surface amines that act as the 
attachment sites for the oligomannose glycans are spaced at distances roughly 
correspondent with those required for 2G12 recognition. 56, 60  
          Several glycoconjugates displaying Man9GlcNAc2, Man9, Man5-9GlcNAc2, and 
Man5GlcNAc2 on a Qβ scaffold were synthesized, allowing us to probe the specific 
glycan preferences of 2G12, as well as the specific impact of the chitobiose core on 
glycan orientation. The linkers and method of conjugation to the protein are shared 
among the glycoconjugates, and therefore any differences in 2G12 affinity can be 
attributed to differences in the glycan preference of 2G12. The immunogenicity 
studies are ongoing, and will be informative as to the specific role of the chitobiose 
core on defining the 2G12 epitope. 
 
2.2 Results and Discussion 
 
         In the design of these novel oligomannose glycan clusters, we were seeking to 
probe several aspects regarding the specific glycan preferences of 2G12. The major 
question that we are seeking to answer, namely, what is the specific contribution of 
the chitobiose core in defining the immunogenicity of oligomannose clusters, 
informed the initial design of the project. This specific question was addressed by a 





chitobiose core, and one lacking the chitobiose core. The subsequent questions were 
related to optimizing glycan presentation to mimic the native epitope with the highest 
possible fidelity. Specifically, sufficient latitude must be extended to the 
heterogeneity of gp120 glycosylation. Given recent reports, 23, 62-64 65 the traditional 
picture of the 2G12 epitope consisting of 2-3 homogeneous Man9GlcNAc2 glycans is 
clearly an artifice and doesn’t accurately represent the complicated pattern of 
glycosylation on gp120. It is probable that the actual 2G12 epitope on native gp120 
consists of a heterogeneous mixture of oligomannose glycans at varying stages of 
glycan processing, likely consisting of a mixture of Man5-9GlcNAc2 glycans. We 
therefore chose to incorporate a mixed building block that consists of a heterogeneous 
mixture of Man5-9GlcNAc2 glycans within the ensemble of oligomannose building 
blocks. The mixed oligomannose glycan presentation by this building block will 
hopefully mirror the actual native epitope. The final building block chosen to 
complete the ensemble consists of Man5GlcNAc2. 2G12 has been shown in previous 
studies to be unable to recognize Man5GlcNAc2 
35  presumably due to the lack of 
distal α1, 2-Man-Man linkages that ostensibly make up the 2G12 epitope. Supporting 
this was the finding that treating gp120 with α1, 2-mannosidase abrogates 2G12 
binding to g120. 28 We speculated that the incorporation of a Man5GlcNAc2 building 
block will yield interesting results regarding the linkage specificity of the Abs raised 
by the immunogen. Specifically, it will indicate whether the Abs raised by the 
immunogens are mannose-reactive only, or share a similar linkage preference to 





          The synthesis of the alkyne tagged sugar building blocks containing the 
chitobiose core was achieved via a top-down method utilizing naturally derived 
Man9GlcNAc2Asn as the common starting material. All subsequent final compounds 
were derived by a chemoenzymatic synthetic strategy.  
 
Scheme 2.1 Top-down chemoenzymatic synthesis of alkyne-tagged chitobiose-core 
containing oligomannose glycan building blocks. 
 
          The precursor of the chitobiose core containing N-linked oligomannose glycans 
bearing an alkyne group 1 (Man9GlcNAc2Asn) was isolated from soybean agglutinin 
(SBA) by a modified method recently reported by our group. 35, 66-67 Compound 3 
(Man9GlcNAc2) was prepared by acylating the amino-terminus of asparagine of 1 
using a large excess of 4-pentynoic acid succinimidyl ester (2).  The other two 
chitobiose-containing alkyne-sugar precursors were prepared by enzymatic digestion 





digestion by α1, 2-mannosidase. While all α1, 2-mannose linkages in compound 5 
(Man5) were hydrolyzed by the enzyme, 4 (Man5-9) was digested in a controlled 
manner, affording access to a mixture of high-mannose glycans particularly enriched 
with Man7GlcNAc2 (see Appendix Figure A.2.1). Compound 1 (Man9Asn) served as 
the common starting material for both types of precursor oligomannose building 
blocks, with and without the chitobiose core. 
 
Scheme 2.2  Top-down chemoenzymatic synthesis of an alkyne-tagged oligomannose 
building block lacking the chitobiose core. 
 
          The second class of alkyne-sugar building block lacking the chitobiose core (9) 
was prepared by digestion of 1 with Endo A (WT) yielding the reducing sugar 6. A 
reductive amination strategy was employed which both installed a reactive amine 





acyclic glycan which served functionally as a linker (Scheme 2.6). An amine group 
was added at the reducing terminus using a modified benzylamination strategy similar 
to that reported previously by Y.C. Lee et al. 68 We chose to use a masked, benzyl-
protected amine, given the reported superiority of the method over the direct 
installation of an amine to prevent the formation of dimers. Initially, we tested the 
reported reducing conditions (i.e. BH3-Pyridine), however, we discovered the 
formation of a side-product corresponding to dehydration of the target compound, 
leading us to test alternative, more mild reducing strategies. We found an optimized 
condition incorporating sodium cyanoborohydride (NaCNBH3) in DMSO to be a 
more effective method, as the mild reducing agent eschewed the formation of the 
dehydration product. The conditions used are identical to those used for the well-
established 2-aminobenzamide (2-AB)/2-aminobenzoic acid (2-AA) method for 






Figure 2.5 1H-NMR comparison of Man9GlcNAc (6) and Man9(Acyclic-GlcNAc)-





~5.15 ppm, indicating acyclic structure. Anomeric proton signals for protons 3’ and 2 
from 7 are hidden under the HOD peak. 
4.6The open-ring form of the reducing GlcNAc was confirmed by 1H-NMR. The 
anomeric proton signal from the terminal GlcNAc was clearly lost upon the 
acyclization/reduction of Man9GlcNAc (Figure 2.5). In comparison to the starting 
material, which had a doublet corresponding to the anomeric GlcNAc proton at 5.1 
ppm, the benzyl-tagged Man9 with an acyclic GlcNAc lost the signal at 5.1 ppm 
(Figure 2.5). In addition, two-dimensional NMR spectra, Heteronuclear single 
quantum coherence spectroscopy-distortionless enhancement by polarization transfer 
(1H-13C-HSQC-DEPT) and proton-proton correlation spectroscopy (1H-1H-COSY) 
was used to analyze the samples. Through HSQC-DEPT, the other two anomeric 
proton signals of two Man residues, obscured by the water peak in the 1H-NMR, were 
clearly observed and assigned for 7 (see appendix for 2D-NMR data).  The result was 
further confirmed using high-resolution mass spectrometry (MALDI-FTICR). 
Subsequent to the reductive amination reaction with benzylamine, the benzyl group 
was removed using palladium-catalyzed hydrogenation. De-N-benzylation by low-
pressure hydrogenation proved ineffective, as the N-benzyl group was obdurate to 
removal. Complete unmasking of the amine group required the use of a catalytic 
hydrogenator apparatus under high pressure (35 psi) hydrogen atmosphere. The 
unmasked amine-bearing oligomannose sugar, lacking the chitobiose core (8) was 
tagged with an alkyne group by direct acylation with 2 in a single step, yielding the 





         Subsequent to the synthesis of the oligomannose building blocks, careful 
consideration was given to the type of carrier protein scaffold that would be most 
appropriate for the given application. Multivalent display of oligomannose clusters is 
requisite for the proper reconstitution of the 2G12 epitope, and the chosen scaffold 
needed to accomodate dense loading of oligomannose glycans while incorporating 
proper spacing. The scaffold needed to display oligomannose glycans in a rigid 
manner so that the binding interaction between 2G12 and the immunogen is not 
stymied by the flexibility of the antigenic glycans. The spacing between the antigenic 
oligomannose glycans in the 2G12 epitope have been reported as 5.8 Å (N295-N332), 
20.3 Å (N332-N392), and 23.6 Å (N295-N392). The presentation of the 
oligomannose glycans on the synthetic immunogen should, at least roughly, 
approximate these distances. Bacteriophage Qβ has spacing of the solvent-exposed 
surface reactive amine groups that roughly approximate the spacing estimated 
between the oligomannose glycans on gp120. 







       High density display of oligomannose glycans on Qβ capsid surface by chemical 
conjugation requires a conjugation reaction that is sufficiently efficient to overcome 
the unfavored steric constraints intrinsic to the attachment of bulky, dynamic glycan 
structures within a small surface area. Click-chemistry has been used for a similar 
purpose by our group and others 47, 73-75 46 and is an attractive strategy given its high 
efficiency and bioorthogonality. In order to install an orthogonal reaction partner for 
the alkyne-tagged building blocks, the surface amino groups of Qβ (10) were acylated 
using a large excess of succinimidyl 5-azidovalerate ester 11 (Scheme 2.7). Following 
purification to remove the excess linker from the particle, the alkyne-tagged 
oligomannose glycans were attached to Qβ with the copper-catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction. The use of the CuAAC click reaction provided a 
means to couple these stable, orthogonal reaction partners at low concentrations to 
reproducibly yield high loading conjugates. The click-chemistry conditions used to 
construct the glycoconjugates were similar to those recently reported by Huang and 
co-workers. 74 The copper source was pre-complexed with the ligand tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) reported previously (14). 76 In 
addition, propargyl alcohol (13) was also used as a reaction partner yielding 19, 
displaying “naked” triazole linkage which will indicate the immunogenicity of the 
linker itself. The resulting constructs 15-19 were characterized by size-exclusion 
chromatography (SEC), polyacrylamide gel electrophoresis (SDS-PAGE), and 







Figure 2.6 MALDI-TOF analysis of oligomannose-Qβ conjugates. 
 
The number of triazole-tethered oligomannose glycans on each subunit of the VLP 





oligomannose glycans per subunit, approximately 450 oligomannose glycans attached 
to each Qβ particle (Figure 2.6). 
Interaction of Qβ glycoconjugates with 2G12  
         The ability of the neoglycoconjugates to interact with 2G12, was first estimated 
using a conventional enzyme-linked immunosorbent assay (ELISA), in which serially 
diluted 2G12 was incubated with antigens directly coated onto wells. The binding 
assay provided a means by which the affinity of 2G12 for the capsid conjugates could 









Figure 2.7 Affinity of 2G12 for oligomannose-Qβ conjugates versus gp120. A) 
Conventional ELISA. B) Competitive ELISA. 
 
As expected, compounds 15 and 16, both bearing Man9 glycans, showed similar 
affinity for 2G12. Unexpectedly, compound 17, bearing a heterogeneous mixture of 
Man5-9 exhibited the highest affinity for 2G12, a nearly 2-fold increase compared to 
the conjugate bearing Man9. Neither compound 18, nor the azide-tagged Qβ particle 
(12) displayed significant affinity for 2G12. Despite following the expected trends, 
the conventional ELISA results were disappointing, as the response from the highest 
2G12 dilution in the series was still ~2-fold lower than gp120 response at the 
midpoint concentration (Figure 2.7A). Previous reports for similar compounds 77 have 
suggested that the highly glycosylated nature of the glycoconjugates can stymie their 





displaying larger glycans. Therefore, a conventional ELISA format potentially 
underestimates the affinity of 2G12 for the described Qβ-glycoconjugates. To address 
the possibility, the synthetic glycoconjugates were examined for their capacity for 
competitive inhibition of 2G12 binding to gp120. In the new competitive ELISA 
format, monomeric gp120(BAL) was immobilized to the plate, and a fixed 
concentration of 2G12 was added to each well, containing a serial dilution of the 
glycoconjugate antigens. The competitive ELISA data followed the same trends as 
conventional ELISA, however it revealed much higher binding potencies between the 
Qβ glycoconjugates and 2G12, with IC50 values for compounds 15-17 of 641 nM, 
653 nM, and 605 nM respectively. The observed superior binding of 17 to 2G12 is in 
agreement with prior reports where a mixed display of Man9/Man8 yielded the 
strongest antigen, even compared to a similarly loaded Man9 analog.
46 A possible 
explanation is that the mixed display of heterogeneous glycans is a more faithful 
representation of the native 2G12 epitope on gp120. That compounds 15 and 16 
exhibited nearly identical affinity toward 2G12 was not surprising, as both conjugates 
bore similar loading and linker lengths with the overall effect of a similar 
oligomannose presentation. The conjugates with the highest affinity were still ~50-
fold less potent than gp120 at 2G12 inhibition. As expected, the non-glycosylated Qβ 
particle 19 and compound 18 both lacked detectable 2G12 inhibition (see Figure 
2.7B). As discussed above, 2G12 targets an epitope consisting of Man-α1, 2-Man 
glycans, so it is expected that Man5GlcNAc2 , which lacks α1,2-Man linkages, would 










Figure 2.8 Inhibition of 2G12 binding to gp120BAL by monovalent mannose display. 
A) D-mannose inhibition of 2G12-gp120 binding. B) Man9GlcNAc2-Asn inhibition of 
2G12-gp120 binding. 
 
 The significance of multivalent glycan display was reiterated by competitive ELISA 
using both monosaccharide D-mannose and Man9GlcNAc2Asn (monomeric display) 
(Figure 2.8). The IC50 values were in the high μM range for monosaccharide 
mannose. While the display of three mannose arms increased the potency, the IC50 
for Man9GlcNAc2 was in the μM range. When the oligomannose glycans are arranged 
in a multivalent display, the potency dramatically increases. Immunization studies are 
currently underway by our collaborator (Dr. Denong Wang, Stanford University). The 
results will be informative regarding the specific role of the chitobiose core in 
defining oligomannose-VLP conjugate immunogenicity. 
2.3 Conclusion 
 
          The numerous strategies that have been reported to design a synthetic 2G12 
epitope have met with limited success, presumably due to the inability to reconstitute 
the fine-details of the epitope in a synthetic format. The overall lack of success 
suggests that there is still much to learn about what is required to elicit 2G12-like Abs 
that target Manα1, 2-Man-linked glycans in the context of gp120. A particular 
challenge is targeting specific mannose reactive Abs that recognize a specific 
oligomannose cluster motif on HIV, without cross-reactivity with “self” 





obstacles by virtue of their well-defined chemistry, rigid structures, and atomic level 
understanding of the surface composition providing unprecedented access to 
previously inaccessible design aspects. These features afford access to tailored 
antigens at a level heretofore impossible. The ability to manipulate the fine details of 
antigen presentation is crucial for targeting carbohydrate antigens, which are typically 
poorly immunogenic. The VLP scaffold affords greater flexibility for tuning the fine-
details to create an immunogenic epitope even from host-derived carbohydrate 
antigens. The ongoing immunogenicity studies will be informative as to the specific 
role contributed by manipulations to the oligomannose display. In particular, the 
results will indicate the specific role of the chitobiose core in defining the 
immunogenicity of the carbohydrate antigens. Moreover, despite the well-known 
observation that strong antigenicity doesn’t necessarily translate into strong 
immunogenicity, the enhanced 2G12 affinity of the mixed oligomannose display in 
compound 17, may be indicative of an improvement in the glycan display, making the 
synthetic epitopes closer in shape and orientation to the actual 2G12 epitope on 
gp120.   
2.4 Experimental Section 
 
General Procedures. ESI-MS spectra were obtained using a ThermoFisher Q 
Exactive LC/MS orbitrap mass spectrometer. MALDI-TOF analysis was performed 
using a Bruker UltrafleXtreme (UTX) mass spectrometer with TOF/TOF detection. 
MALDI-FTICR analysis was performed using a Bruker SolariX ESI/MALDI-12T 





Carter (UMB). 1D/2D-NMR was performed using a Bruker AVIII-600MHz NMR. 
Catalytic hydrogenation was performed using a Catalytic Hydrogenation Apparatus 
(Parr Instruments, Moline, IL) under 35 psi hydrogen pressure. α1,2-Mannosidase 
was expressed from E. coli by Dr. Kevin Li as previously reported. 78 2G12 and 
monomeric gp120BAL were both obtained from the National Institutes of Health 
(NIH) through the AIDS Reagent Program. Bacteriophage Qβ was produced in E. coli 
by Dr. Qiang Yang according to a previously published procedure. 79 Purification of 
the particles was achieved by size-exclusion chromatography using Sepharose CL-4B 
column. Only the center elution band was taken to ensure high purity material. The 
yield of the recovered WT Qβ was 65%, with 95% purity, according to SDS-PAGE 
analysis. The particles were >95% intact, according to analytical size-exclusion fast 
protein liquid chromatography (FPLC) using a Superose-6 column.  
Modification of VLP Surface Chemistry 
QβWT (10) in 1X PBS (pH 7.4) was added to compound 11 (13 mM, 5 equivalents 
with respect to the Qβ asymmetric subunit, 1.25 eq. per reactive amine) in DMSO 
such that the final DMSO concentration was 20%. The final protein concentration 
was 2 mg/mL. The solution was shaken overnight at room temperature on a rotisserie 
shaker. The excess NHS-azide and DMSO were removed by repeated centrifugal 
filtration using Millipore 10 KDa MWCO filters against PBS buffer. Total protein 
concentration was determined by Quick Start Bradford Reagent (BioRad), using 
bovine serum albumin as the standard for the concentration curve, with a recovery of 
70%. Average loading of surface azido groups was estimated by MALDI-TOF 





General CuAAC Reaction Conditions 
        Synthesis of oligomannose-Qβ conjugates (15-19) was achieved using the 
CuAAC click reaction, with conditions similar to those reported by M.G. Finn and 
co-workers. 73 All solvents were degassed before use. In general, the following 
reagents were combined in the following order, 14 μL 500 mM phosphate buffer, pH 
7.0 (final 80 mM), 50 μg 12 (from 7 mg/mL stock), alkyne-tagged oligomannose 
glycans (3-5, 9, 13) [10 eq./subunit, approximately 2.5 eq./reactive azide]. Pre-mixed 
Cu-THPTA solution (CuSO4, 50 mM in water [3.4 eq.] + THPTA ligand (14) 50 mM 
in water, 5-fold excess compared to Cu), aminoguanidine (100 mM in water, 100 eq. 
compared to 12), and sodium ascorbate (100 mM in water, 100 eq. compared to 12). 
After the addition of sodium ascorbate, the reaction tube was flushed with argon and 
sealed. The mixture was shaken at 37°C overnight. The reaction was quenched by the 
addition of 500 mM EDTA (10 mM final). Purification of the glycopeptide-Qβ 
conjugates was performed by centrifugal filtration against PBS.  
Mass Spectrometry of derivitized Qβ particles 
20 μg antigen was mixed with a solution of 8 M urea (30 μL) containing 1M 
dithiothreitol (DTT) (5 μL). The mixture was incubated at 37°C for 1 h. 50 μL 0.5 M 
iodoacetamide (IAA) was added and the solution was incubated for an additional 1 h 
at 37°C. The excess IAA was reacted with 1 M DTT (10 μL), and incubated at 37°C 
for 10 min. The mixture was lyophilized and dissolved in 10 μL water containing 
0.2% trifluoroacetic acid (TFA) and purified using C4 ZipTips (EMD Millipore) 
according to the manufacturer’s instructions. The purified antigen (1 μL) was mixed 





Enzyme-linked immunosorbant assay (ELISA) 
Conventional ELISA Each well of a high binding Ultra Cruz 96-well assay plate 
(Santa Cruz Biotech.) was first coated with 100 μL PBS containing either gp120BAL 
or the oligomannose-Qβ antigens (250 ng). The plates were incubated overnight at 
4°C. The plate was then washed three times with PBS/0.05% Tween-20 (PBS-T), 
followed by the addition of 100 μL 3% (w/v%) BSA in PBS to each well. The plate 
was incubated at RT for 1 h. The plate was again washed with PBS-T (3x). Next, 
2G12 was diluted in blocking buffer (PBS/0.05% Tween-20/1% (w/v %) BSA [PBS-
BT]) to a maximum concentration of 200 nM, followed by a 1.5-fold dilution series. 
For each 2G12 antibody dilution, a total of 100 μL was added to the appropriate 
wells. The plate was incubated with 2G12 for 2 h at RT and then washed with PBS-T 
(3x). Next, a 1:1000 dilution of alkaline phosphatase (AP)-conjugated goat anti-
human IgG antibody (Jackson ImmunoResearch Laboratory) was made in PBS-BT, 
with 100 μL of this diluted secondary antibody added to each well. The plates were 
incubated with the secondary antibody for 1 h at RT then washed with PBS-T (3x). 
Finally, the wells were developed with 50 μL p-nitrophenyl phosphate liquid 
substrate system (Sigma) for 5 min at RT before quenching the reaction with 30 μL of 
3 M NaOH. The optical density was then measured at a wavelength of 405 nm. 
Competitive ELISA General assay conditions, procedures, and buffers solutions 
were as described above, except as follows. All ELISA wells were coated with 
gp120BAL (250 ng) overnight, washed and blocked. Serial dilutions of the 
oligomannose antigens in 50 μL PBS-BT were added to each well in a 2-fold dilution 





was added to each well (50 μL/well). The competition ELISA was incubated at RT 
for 2 h, followed by another series of washes and probed with secondary Ab (alkaline 
phosphatase (AP)-conjugated goat anti-human IgG antibody) for an additional 1 h. 
After a final series of washes, the plate was developed as above.  0.0001025 
Synthesis of chitobiose-core containing alkyne-linked building blocks 
 
Scheme 2.4 Synthesis of pent-4-ynoic acid 1-oxysuccinimidyl ester (2) 
4-Pentynoic acid succinimidyl ester (2). Compound 2 was prepared according to a 
previously reported procedure. 80 Briefly, 4-pentynoic acid (400 mg, 4.0 mmol) and 
N-hydroxysuccinimide (470 mg, 4.0 mmol) were dissolved in THF (14 mL) at -10°C. 
N, N’-dicyclohexylcarbodiimide (DCC) (842 mg, 4.0 mmol) was added and the 
mixture was stirred at -10°C for 2 h. The reaction was stirred at -10°C → 0°C 
overnight. The DCU that formed during the reaction was removed by filtration over a 
celite pad and the solvent was evaporated under reduced pressure. The residue was 
dissolved in cold (-20°C) ethyl acetate (10 mL), filtered again, washed with saturated 
NaHCO3 (10 mL x 3) and brine (10 mL). The organic layer was dried over Na2SO4, 
filtered, and the solvent removed under vacuum, affording 2 as a white solid (687 mg, 
88%). 1H-NMR (CDCl3, 400 mHz): δ 2.90 (t, J = 7.5, 2H), 2.86 (s, 4H), 2.63 (td, J = 
7.2 Hz, 2H), 2.08 (t, J = 2.6, 1H). 13C-NMR (CDCl3, 125 mHz): δ 169.43, 167.49, 







Scheme 2.5 Synthesis of succinimidyl-4-azidobutyrate (3).  
Methyl 4-azidobutyrate (S-1). Compound S-1 was prepared according to a 
previously reported procedure. 81 Briefly, to a solution of methyl 4-bromobutyrate 
(3.0 g, 16.7 mmol) in DMF (4 mL) was added sodium azide (2.2 g, 33.4 mmol). The 
mixture as vigorously stirred at 80°C overnight. The reaction mixture was diluted 
with ethyl acetate (50 mL) and washed with saturated NaHCO3 (20 mL x 3), water 
(20 mL x 3), and brine. The organic layer was dried over anhydrous Na2SO4, filtered, 
and the solvent was removed under vacuum, yielding S-1 as a pale yellow liquid 
(1.53 g, 64%). 1H-NMR (CDCl3, 400 mHz): δ 3.68 (s, 3H), 3.35 (t, J = 6.92 Hz, 3H), 
2.41 (t, J = 7.4 Hz, 2H), 1.89 (m, 2H). 13C-NMR (CDCl3, 125 mHz): δ 173.51, 52.09, 
50.98, 31.26, 24.60. 
5-Azidovaleric acid (S-2). Compound S-2 was prepared according to a previously 





MeOH (15 mL), S-1 (1.5 g, 10.48 mmol) was added. The suspension was vigorously 
stirred overnight at RT. The solvent was removed under vacuum and the remaining 
residue was diluted in ethyl acetate (50 mL) and washed with 1.0 M HCl (20 mL x 3), 
water (20 mL x 3), and brine (20 mL). The organic layer was dried over anhydrous 
Na2SO4 and evaporated to dryness under vacuum, yielding S-2 as a pale yellow liquid 
(1.05 g, 77%). 1H-NMR (CDCl3, 400 mHz): δ 11.12 (s, 1H), 3.39 (t, J = 6.64 Hz, 
3H), 2.49 (t, J = 7.2 Hz, 2H), 1.93 (m, 2H). 13C-NMR (CDCl3, 125 mHz): δ 179.67, 
50.86, 31.35, 24.33. 
Succinimidyl 5-Azidovalerate (11). Compound 11 was prepared according to a 
previously reported procedure. 81 Briefly, to a mixture of S-2 (800 mg, 6.2 mmol) and 
N-hydroxysuccinimide (785 mg, 6.8 mmol) in CH2Cl2 (40 mL), 1-(3-
dimethylaminopropyl)-3 ethylcarbodiimide hydrochloride (EDC-HCl) (1.31 g, 6.8 
mmol) was added. The mixture was stirred at RT overnight. Water (40 mL) was 
added, and the organic layer was washed with water (40 mL x 3) and brine (40 mL). 
The organic layer was dried over Na2SO4 and evaporated under vacuum, affording 11 
as a white solid (1.15 g, 82%). 1H-NMR (CDCl3, 400 mHz): δ 3.45 (t, J = 6.96, 2H), 
2.84 (s, 4H), 2.73 (t, J = 7.8 Hz, 2H), 2.01 (m, 2H). 13C-NMR (CDCl3, 125 mHz): δ 
169.46, 168.35, 50.37, 28.49, 25.98, 24.52. 
Synthesis of Man9GlcNAc2-Asn-NH2 (1) The precursor Man9GlcNAc2-Asn-NH2 (1) 
was obtained by enzymatic digestion of soybean agglutinin from soybean flour, 
followed by chromatographic purification using a method reported previously by our 
group and others. 66 35 HRMS (MALDI-FTICR) m/z [M + Na]+ Calcd for 





Synthesis of Man9GlcNAc2-Asn-Alkyne (3) To a solution of 1 (20 mg, 10.02 μmol) 
in 1X PBS (0.2 mL, pH 7.4), was added Alkyne-OSu (20 mg, 102.5 μmol) in DMF 
(0.2 mL). The reaction mixture was vigorously shaken at RT overnight. The solvent 
was removed under vacuum and the residue was dissolved in 0.1 M acetic acid and 
applied to a Sephadex G-10 size exclusion column and purified. The elution was 
monitored by the phenol-sulfuric acid test and carbohydrate-positive fractions were 
pooled and concentrated (to ~1 mL) under vacuum. The semi-pure glycans were 
applied to a C18 solid-phase extraction column (8.5 x 2 cm) and washed with water 
(3 CVs). The alkyne-tagged glycans were eluted with 5:1 water:MeOH. The pooled 
eluted glycans were lyophilized yielding 3 as a white powder (15.4 mg, 74%). HRMS 
(MALDI-FTICR) m/z [M + Na]+ Calcd for C79H129N4O59Na: 2099.70363; found: 
2099.70483. 
Synthesis of Man5-9GlcNAc2-Asn-Alkyne (4). To a solution of 3 (10 mg, 4.82 μmol, 
final 2 mM solution) in citrate buffer (50 mM, pH 5.6) containing 5 mM CaCl2, was 
added α1,2-mannosidase (final 2 ng/μL). The enzymatic digestion was incubated at 
RT for 30 min while monitoring reaction progress using HPAEC-PAD. When 
Man7GlcNAc2-Asn-Alkyne was the major component, the reaction was quenched by 
the addition of 0.1 M acetic acid, and the reaction mixture was applied to a G-10 size-
exclusion column and eluted with 0.1 M acetic acid. The carbohydrate positive 
fractions were pooled and lyophilized, yielding 4 as a white powder (7.8 mg, 92%). 
MALDI-TOF m/z [M + Na] Man9 Calcd for C79H128N4O59Na: 2099.70363, found: 
2099.601. Man8 Calcd for C73H118N4O54Na: 1937.65081, found: 1937.629. Man7 





C61H98N4O44Na: 1613.54516, found: 1613.532. Man5 Calcd for C55H88N4O39Na: 
1451.49234, found: 1451.471.  
Synthesis of Man5GlcNAc2-Asn-Alkyne (5). To a solution of 3 (10 mg, 4.82 μmol, 
final 2 mM) in citrate buffer (50 mM, pH 5.6) containing 5 mM CaCl2, was added 
α1,2-mannosidase (final 1 μg/μL). The enzymatic digestion was incubated at 37°C 
overnight. The reaction was monitored by HPAEC-PAD, and quenched with 0.1 M 
acetic acid upon complete hydrolysis of the α1,2-Man-Man linkages. The reaction 
mixture was applied to a G-10 size-exclusion column and eluted with 0.1 M acetic 
acid. The carbohydrate positive fractions were pooled and lyophilized, yielding 5 as a 
white powder (6.5 mg, 94%). HR-MS (MALDI-FTICR) m/z [M + Na]+ Calcd for 
C55H88N4O39Na: 1451.49234; found: 1451.49284.  
Synthesis of Man9GlcNAc (6). 
Compound 1 (20 mg, 10.02 μmol) was treated with Arthrobactor endo-β-N-
acetylglucosaminidase (EndoA (WT)) in acetate buffer (50 mM, pH 6.6) at 37°C 
overnight. Subsequent Sephadex G-10 size-exclusion chromatography and C18 SPE 
yielded pure Man9GlcNAc as a white powder (15.9 mg, 95%).  HRMS (MALDI-
FTICR) m/z [M + Na]+ Calcd for C62H105NO58Na: 1702.55512, found: 1702.55472. 
1H-NMR (400 mHz, D2O; HOD, δ 4.70): δ 5.28 (s, 1H, H-1, Man), 5.21 (s, 1H, H-1, 
Man), 5.18 (s, 1H, H-1, Man), 5.10 (d, J = 3.6, 1H, H-1, GlcNAc), 5.02 (s, 1H, H-1, 
Man), 4.92-4.90 (m, 3H, Man x 3), 4.73 (s, 1H, H-1, Man), 4.64 (s, 1H, H-1, Man), 
4.11-3.42 (m, 63H, H-2, 3, 4, 5, 6 of Man and GlcNAc), 1.91 (s, 3H, GlcNAc). 
Synthesis of Man9-Benzylamine (7). A solution of benzylamine (64 mg, 0.601 





portion to a solution of 6 (20 mg, 11.91 μmol) in anhydrous DMSO (1.08 mL). The 
mixture was heated to 55°C in a water bath for 30 min, and NaCNBH3 (40 mg, 0.640 
mmol) was added in one portion. The reaction was heated at 55°C for 1 h, with 
LC/MS monitoring. At the completion of the reaction, the mixture was diluted with 
0.1 M acetic acid and applied to a Sephadex G-10 column, eluted by 0.1 M acetic 
acid. Carbohydrate positive fractions were applied to a C18 SPE cartridge and eluted 
first with water, followed by 5:1 water/MeOH. The purified product was obtained as 
a white powder (17.7 mg, 84%). (using a modified method from that reported by Lee 
and co-workers. 68 HRMS (MALDI-FTICR) m/z [M + Na]+ Calcd for 
C69H115N2O50Na: 1793.63370; found: 1793.63315. 
1H-NMR (400 mHz, D2O; HOD, δ 
4.71): δ 7.35-7.25 (m, 5H, Benzyl), 5.32 (s, 1H, H-1, Man), 5.26 (s, 1H, H-1, Man), 
5.25 (s, 1H, H-1, Man), 5.07 (s, 1H, H-1, Man), 4.99-4.96 (m, 3H, Man x 3), 4.74 (s, 
1H, H-1, Man), 4.65 (s, 1H, H-1, Man), 4.10-3.47 (m, 67H, H-2, 3, 4, 5, 6 of Man and 
acyclic GlcNAc), 1.92 (s, 3H, acyclic GlcNAc), 1.79 (s, 2H, -NH-CH2-Benzyl). 
Synthesis of Man9-NH2 (8). To a solution containing 7 (10 mg, 5.7 μmol) in 50% 
MeOH (10 mL) was added a catalytic amount of 10% Pd/C. The benzyl group was 
removed under hydrogen atmosphere (35 psi) using a catalytic hydrogenation 
apparatus at RT for 2 h. The reaction mixture was filtered and the solvent removed 
under vacuum. The resulting residue was dissolved in water and lyophilized. The 
resulting white powder (9.6 mg, quant.) and used without further purification. HRMS 






Synthesis of Man9-Alkyne (9). To a solution of 8 (8 mg, 4.8 μmol) in 1X PBS (0.1 
mL, pH 7.4), was added 2 (8 mg, 41 μmol) in DMF (0.1 mL). The reaction mixture 
was vigorously shaken at RT overnight. The solvent was removed under vacuum and 
the residue was dissolved in 0.1 M acetic acid and applied to a Sephadex G-10 size-
exclusion column and purified. The elution was monitored by the phenol-sulfuric acid 
test and carbohydrate-positive fractions were pooled and concentrated (to ~1 mL) 
under vacuum. The semi-pure glycans were applied to a C18 solid-phase extraction 
column (8.5 x 2 cm) and washed with water (3 CVs). The alkyne-tagged glycans were 
eluted with 5:1 water/MeOH. The pooled, eluted glycans were lyophilized yielding 9 
as a white powder (7.3 mg, 85%). HRMS (MALDI-FTICR) m/z [M + Na]+ Calcd for 
C67H112N2O51Na: 1783.61297; found: 1783.61258.  
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Chapter 3: Site-Selective Chemoenzymatic Glycosylation of an 
HIV-1 Polypeptide Antigen with Two Distinct N-Glycans via an 
Orthogonal Protecting Group Strategy 
 
This chapter was originally published as: Toonstra, C.; Amin, M.N.; Wang, L.-X. 
Site-Selective Chemoenzymatic Glycosylation of an HIV-1 Polypeptide Antigen with 
Two Distinct N-Glycans via an Orthogonal Protecting Group Strategy. J. Org. Chem. 




           Glycosylation can profoundly affect a protein’s structure, stability, 
intracellular trafficking, and biological functions. 1-4 In the case of the human 
immunodeficiency virus type 1 (HIV-1), the heavy N-linked glycosylation of the 
outer envelope glycoprotein gp120 represents a major defensive mechanism for the 
virus to evade host immune attack. The N-glycans assembled by the host’s synthetic 
machinery are viewed as “self” and are weakly immunogenic. 5,6 Nevertheless, the 
recent discovery of a new class of broadly neutralizing antibodies (bNAbs) that 
recognize both conserved N-glycans and a segment of peptide in the variable (V1V2 
and V3) regions of gp120 as an integrated epitope strongly suggest that the defensive 
glycan shield of the virus and, in particular, the unique HIV-1 glycopeptide antigens, 
can serve as important targets for HIV-1 vaccine design. 7-11  PG9 is a broadly 
neutralizing antibody (bNAb) isolated from HIV-1 infected patients that can 
neutralize HIV-1 primary strains with significant breadth and potency. Mutational, 
biochemical and structural studies suggest that PG9 recognizes a strand of peptide 
and two conserved N-glycans in the V1V2 domain. 12,13 The PGT series neutralizing 





recognition mode involving unique N-glycans and a protein segment centered at the 
V3 region as targets. 14-16 These discoveries have stimulated great interest in the 
chemical and chemoenzymatic synthesis of the putative HIV-1 glycopeptide epitopes, 
aiming at fine characterization and reconstitution of the precise neutralizing epitopes 
for HIV vaccine design. 17-19 
      Major progress has been made in recent years in the total chemical synthesis of 
large glycopeptides and even homogeneous glycoproteins. 18,20,21 Nevertheless, each 
complex glycopeptide target could present a special challenge that may require 
significant optimization of the synthetic strategies in terms of the coupling efficiency 
for critical ligation steps and the compatibility of protecting group manipulations. On 
the other hand, the chemoenzymatic approach that exploits the endoglycosynthase-
catalyzed transglycosylation for transfer of large oligosaccharide en bloc to a 
GlcNAc-peptide or protein using a glycan oxazoline as donor substrate is emerging as 
a promising method for expeditious synthesis of complex glycopeptides and for 
glycosylation remodeling of glycoproteins as well. 22-30 This method is highly 
convergent and permits independent manipulations of the glycan and polypeptide 
portions. We have recently applied this chemoenzymatic method for the synthesis of 
a series of complex HIV-1 V1V2 glycopeptides that enabled the characterization of 
the glycan specificity of the bNAb PG9. 17 However, construction of complex 
glycopeptides carrying two or more different N-glycans by this method remains a 
difficult task, as the endoenzymes are unable to distinguish between the GlcNAc 
acceptors at different sites in a polypeptide. As a result, a careful HPLC separation of 





different N-glycans at the pre-determined sites, 17 which was tedious and would be 
difficult to generalize for other peptides. 
       To address this fundamental problem, we describe in this paper an orthogonal 
protecting group strategy for construction of glycopeptides carrying two distinct N-
glycans. We reasoned that introduction of two orthogonally protected GlcNAc-Asn 
building blocks during automated solid-phase peptide synthesis (SPPS) would allow 
selective deprotection of the GlcNAc primers at different stages, such that different 
N-glycans could be sequentially installed in a polypeptide by glycosynthase-catalyzed 
transglycosylation. We found that a GlcNAc-Asn building block, temporarily 
protected by O-diethylisopropylsilyl (DEIPS) groups, was particularly efficient. The 
protecting group strategy was stable during synthesis but could be readily deprotected 
simultaneously during acidic global deprotection and retrieval of the peptide from the 
resin to introduce a free GlcNAc-Asn primer. We demonstrate that the combined use 
of the DEIPS-protected and O-acetylated GlcNAc-Asn building blocks, coupled with 
the enzymatic sequential glycosylation, enables a highly efficient and quick synthesis 
of an array of HIV-1 V1V2 glycopeptides carrying distinct N-glycans.  
 
3.2 Results and Discussion 
 
         Synthesis of orthogonally protected GlcNAc-Asn building blocks. We 
envisioned that a GlcNAc-Asn building block carrying an acid-sensitive protecting 
group such a silyl group could be combined with the common O-acetyl protected 





could be simultaneously removed during the global peptide deprotection to provide the 
free GlcNAc acceptor for the attachment of the first N-glycan via enzymatic 
transglycosylation. The O-acetyl protected GlcNAc could be unmasked to allow a 
second glycosylation with a different N-glycan. To test the feasibility of this approach, 
we first synthesized the GlcNAc-Asn building blocks in which the GlcNAc moiety was 
protected with three different types of silyl groups that are supposed to possess variable 
acidic sensitivity (Scheme 3.1).  The -glycosyl azide (3) was prepared by treatment of 
the -glycosyl chloride (1) 31 with sodium azide under a phase-transfer catalysis 
conditions, followed by de-O-acetylation with a catalytic amount of MeONa in MeOH. 
Protection of the free hydroxy groups in 3 with three types of silyl groups was achieved 
by treatment of 3 with tert-butyldimethylsilyl triflate (TBDMSOTf), 
diethylisopropylsilyl triflate (DEIPSOTf), or triethylsilyl triflate (TESOTf), 
respectively, giving the corresponding silyl protected glycosyl azide derivatives (4a-c) 
in quantitative yield. It should be noted that, given the highly hindered nature of the 
protecting groups, we found that using the highly active silyl triflate was essential for 
high-yield conversions, as the use of the less active silyl chloride derivatives resulted 
in incomplete reactions on the secondary hydroxy groups. 32 Conversion of the 
anomeric azide group of 4a-c into a primary amine was accomplished via palladium-
catalyzed reduction under a hydrogen atmosphere to give the corresponding -glycosyl 
amine, which was coupled in situ with Fmoc-Asp-OAll using HATU/DIPEA as the 
coupling reagent to afford the silyl-protected derivatives (5a-c) in moderate to excellent 
yields. We observed that the TES-protected derivative (5c) was much less stable than 





during the coupling reactions (a by-product that missed one TES group was isolated in 
33% yield). De-O-allylation at the C-terminal carboxyl groups of 5a-c was achieved 
under the catalysis of Pd(PPh3)4/PhSiH3 to give the glycosylamino acid building blocks 
(6a-c) in 96%, 95%, and 90% isolated yields, respectively. It should be noted that silica 
gel purification, while successful for 6a and 6b, proved to be too acidic for the TES 
protected building block (6c). Thus, 6c was purified by LH-20 size-exclusion 
chromatography using 2:1 DCM/MeOH as the eluent. All glycosylamino acid building 
blocks and intermediates were characterized by NMR and MS analysis.  We observed 
that the J1,2 coupling constants (~5 Hz) of the anomeric protons of the silyl-protected 
-glycosyl azides (4a-c) were significantly smaller than a typical J1,2 coupling constant 
(usually > 9 Hz) found in the acetylated -glycosyl azide (2). This data suggests that 
the bulky silyl ether protecting groups may induce a conformational change in the sugar 
ring structures from a typical 4C1 chair conformation to a twisted half-chair or a skew-
boat conformation. This observation is consistent with previously reported results for 
similar silylated glycopyranoside derivatives. 33 On the other hand, the O-acetyl 
protected building block (8) was synthesized by direct coupling of the glycosyl azide 
(2) and an aspartic acid derivative (Fmoc-Asp-OtBu) with triethyl phosphine to give 7, 








Scheme 3.1 Synthesis of GlcNAc-Asn building blocks carrying silyl (acid-labile) and 
acetyl (base-labile) protecting groups. Reaction conditions: i. NaN3, water/CH2Cl2, 
Bu4NHSO4, RT; 95%; ii. 1) cat. MeONa, MeOH; 2) Dowex H
+, RT, quantative in 
two steps; iii. Silyl triflate, 2,6-lutidine, 40°C, quant.; iv. 1) Pd/C, H2, MeOH, RT; 
and 2) Fmoc-Asp-OAll, HATU, DIPEA, DMF, RT, 74% (5a), 73% (5b), and 38% 
(5c); v. Pd[P(Ph)3]4, PhSiH3, CH2Cl2, RT, 94% (6a), 95% (6b), and 93% (6c); vi. 
Fmoc-Asp-OtBu, P(Et)3, CH2Cl2, -78°C to RT, 81%; vii. 96% formic acid, RT, 
100%. 
         Use of the GlcNAc-Asn building blocks for glycopeptide synthesis.  The 
usefulness of the orthogonally protected GlcNAc-Asn building blocks (6 and 8) for 





by the synthesis of several HIV-1 V1V2 glycopeptide antigens that were proposed as 
the neutralizing epitope for the bNAb PG9. 13,17 We have recently designed and 
synthesized an array of cyclic 24-mer V1V2 glycopeptides bearing different glycan 
structures at the N160 and N173 glycosylation sites. 17 The synthesis, coupled with 
antibody binding studies, has enabled the characterization of the fine glycan 
specificity of antibody PG9 in antigen recognition. That is, a Man5GlcNAc2 glycan at 
the N160 site and a sialylated complex type N-glycan at the N173 glycosylation site 
(for the ZM109 strain) coupled with a segment of V1V2 peptide, constitutes the 
minimal epitope of PG9. However, the previous chemoenzymatic synthesis of these 
glycopeptide epitopes had to rely on tedious separation of the mono-glycosylated 
intermediates in order to introduce two distinct N-glycans. 17 Here we sought to add 
the acid-labile silyl-protected GlcNAc-Asn building block at N160 site first and then 
the base-labile acetylated GlcNAc-Asn building block at the N173 site to achieve 
sequential glycosylations with distinct N-glycans at the two sites. Thus, automated 
solid-phase peptide synthesis (SPPS) incorporating the two distinctly protected 
GlcNAc-Asn building blocks led to the assembling of the resin-bound fully protected 
peptide (9a-c) (Scheme 3.2).  
A biotin-tag was introduced at the N-terminus to facilitate detection and 
immobilization for binding studies. The sensitivity of the silyl protecting groups 
during global peptide deprotection was first examined with cocktail R 
(TFA/thioanisole/EDT/anisole, 90/5/3/2, v/v), a common cocktail reagent for global 
deprotection and retrieval of the polypeptide from the resin. Aliquots were taken at 





the TBDMS protected glycopeptide-resin (9a) with cocktail R with an extended 
reaction time (up to 4 h) led to only partial de-silylation to give a glycopeptide 
product with only one of the three TBDMS group being removed (assessed by LC-
MS analysis), which was assumed to be glycopeptide 10 with the deprotection at the 
6-position. In contrast, deprotection of the DEIPS- and TES-protected glycopeptide-
resin, 9b and 9c, respectively, was readily achieved using cocktail R or even the 
milder cocktail K (TFA/phenol/H2O/thioanisole/EDT, 82.5/5/5/5/2.5, v/v) within 2h 
to obtain the desired glycopeptide intermediate (11), in which a free GlcNAc was 
installed at the N160 site while the O-acetyl protected GlcNAc at the N173 site was 
still intact. The resistance of the O-TBDMS groups in 9a to acid-catalyzed 
deprotection was unexpected, as previous reports have shown that the TBDMS 
groups on a corresponding disaccharide moiety could be efficiently removed by a 
similar acid treatment during peptide deprotection. 32,33 To verify whether the 
phenomenon was special for the peptide context, we treated the TBDMS-protected 
GlcNAc-Asn building block (6a) with cocktail R and found that the O-TBDMS 
groups could be completely removed within 1 h. This result suggests that the 
resistance of the O-TBDMS groups in the glycopeptide-resin (9a) to acid-catalyzed 
deprotection is likely specific for the polypeptide context. The reason is not clear. 
Interestingly, complete de-silylation of 10 was readily achieved by its treatment with 
TBAF in pyridine/AcOH to give 11 in excellent yield. Taken together, the 
experimental data suggest that the DEIPS protecting group, which is much more 
stable than the TES group during building block synthesis and can be readily 





introducing a free GlcNAc-Asn building block in SPPS. Finally, cyclization of the 
linear glycopeptide (11) was achieved by treatment with 20% aqueous DMSO to give 
the cyclic glycopeptide (12), where a free GlcNAc was located at N160 and a 







Scheme 3.2 Synthesis of GlcNAc-peptide precursor using the orthogonally protected 
GlcNAc-Asn building blocks. Reaction conditions: i. Cocktail R, 4h, 39% (total 
isolated yield, only one TBDMS removed); ii.  Cocktail R, 2h, 41% (total isolated 
yield, complete removal of all three silyl ether groups), or Cocktail K, 38% (total 
isolated yield, complete removal of all three silyl ether groups); iii. Bu4NF, 
pyridine/AcOH; iv. phosphate buffer (pH, 7.2), 20% DMSO, 94%. 
 
       Convergent synthesis of HIV-1 V1V2 glycopeptide epitopes of antibody PG9.                                  
With the key intermediate (12) at hand, we first tested the transfer of a Man5GlcNAc 
glycan to the GlcNAc moiety at N160 using mutant endoglycosidase D (N332Q) 
from Streptococcus pnuemoniae. 34 Unexpectedly, incubation of 12 with 
Man5GlcNAc oxazoline (13) proceeded very inefficiently to give only trace amounts 
of the transglycosylation product (14) (Scheme 3.3). This observation was surprising 
as the N322Q mutant of Endo-D was previously found to be highly efficient to 
transfer Man5GlcNAc oxazoline (13) to a similar cyclic glycopeptide carrying two 
free GlcNAc moieties to give a doubly glycosylated peptide. 17 In contrast, we found 
that glycosynthase mutants of Endo-M from Mucor hiemalis, 35,36 such as the N175Q 
mutant, were efficient to catalyze the transfer of a Man5GlcNAc glycan to the free 









Scheme 3.3 Convergert chemoenzymatic installation of two distinct N-glycans in the 
V1V2 cyclic peptide. Reaction conditions: i. EndoD-N322Q, donor/acceptor = 8:1, 
Tris buffer (80 mM, pH 7.2), RT, <5%; ii, EndoM-N175Q,  donor/acceptor = 8:1, 
Tris buffer (80 mM, pH 7.2), RT, 85%; iii. 2.5 % aq. hydrazine, RT; iv. EndoM-
N175Q, donor/acceptor = 4:1, Tris buffer (80 mM, pH 7.2), RT, 92%;  v. EndoM-
N175Q,  donor/acceptor = 4:1, Tris buffer (80 mM, pH 7.2), RT, 95%; vi. EndoM-
N175Q, donor/acceptor = 4:1, Tris buffer (80 mM, pH 7.2), RT, 91%. 
         In order to test if a proximal acetylated GlcNAc moiety caused the low yield in 
enzymatic transglycosylation with the Endo D mutant (N322Q), we synthesized the 
corresponding linear peptide (A 3.1, see appendix) by reduction of 12 with DTT 
followed by alkylation with iodoacetamide (Scheme A 3.1, Figure A 3.1, appendix). 
Interestingly, we found that both EndoD-N322Q and EndoM-N175Q mutants were 





3.1) to give the corresponding glycopeptide (A 3.2) (Scheme A 3.1 and Figure A 3.2, 
appendix). This result suggests that the O-acetylated GlcNAc moiety present in the 
cyclic peptide (12) may provide steric hindrance and/or an unfavorable hydrophobic 
interaction with the Endo D mutant, leading to a much reduced catalytic activity, 
while the Endo M mutant seems more flexible for the presence of the 
bulky/hydrophobic Ac3GlcNAc-Asn moiety proximal to the free GlcNAc acceptor in 
enzymatic transglycosylation. 
        After the installation of the first N-glycan (Man5GlcNAc2) at the N160 site, the 
O-acetyl protecting groups on the GlcNAc moiety at the N173 site were then 
removed by treatment with 2.5% aqueous hydrazine to give glycopeptide 15, in which 
the free GlcNAc moiety at the N173 site is now ready for introduction of a different 
N-glycan. Installation of a sialylated complex type N-glycan at the N173 site was 
achieved by EndoM-N175Q catalyzed transglycosylation of 15 with sialylated glycan 
oxazoline 16 to obtain glycopeptide 17. Transglycosylation of 15 with glycan 
oxazoline 18, which lacks the sialic acids, gave the corresponding asialylated 
glycopeptide (19). Moreover, enzymatic transglycosylation with a high mannose type 
N-glycan oxazoline, the Man9GlcNAc-oxazoline (20), gave the glycopeptide (21). 
Thus, this convergent approach permits a quick construction of various glycopeptides 
from a common precursor. In all the cases, the enzymatic reaction went smoothly and 
a quantitative conversion was achieved by using an excess of glycan oxazolines, 
which could be recovered as free N-glycans during HPLC purification and could be 





transglycosylation products were purified by HPLC, and the purity and identity were 
confirmed by ESI-MS analysis (Figure 3.1). 
 
Figure 3.1 ESI-MS Characterization of doubly glycosylated glycopeptides. a) 
Compound 15, b) Compound 17, c) Compound 19, d) Compound 21. 
SPR analysis of the interactions between antibody PG9 and the synthetic 
glycopeptides. The binding of the synthetic glycopeptides with antibody PG9 was 
probed by surface plasmon resonance (SPR) analysis through immobilization of the 
biotinalyted glycopeptides on a streptavidin chip. The results are summarized in 
Figure 3.2. The data indicate that the glycopeptide 17, which carries a Man5GlcNAc2 
glycan at the N160 and a sialylated N-glycan at N173 site, has the highest affinity 
among all the synthetic V1V2 glycopeptides, with an apparent KD of 67 nM. 
Removal of the sialic acid residues in 17 resulted in more than 39-fold decrease of the 





M) for the asialylated glycopeptide (19). Interestingly, installation of a full-size, 
non-sialylated high-mannose glycan at the secondary glycosylation site, as 
demonstrated by glycopeptide 21, resulted in drastic decrease of the affinity for PG9 
(KD = 996 nM), suggesting that a bulky N-glycan at the secondary site may conflict 
the interaction of the antibody with the neutralizing epitope. These results are 
consistent with the previously reported affinity data where the PG9 antibody Fab 
fragment was used for the binding analysis, 17 and the more recent crystal structural 
analysis of PG9 and PG16 in complex with sialylated V1V2 domain. 39 The 
experimental data indicated that sialylation of the secondary N-glycan is essential for 










































































































Figure 3.2 SPR analysis of PG9 IgG recognition of synthetic V1V2 glycopeptides. 
Biotinylated glycopeptides were immobilized on streptavidin-coated chips and whole-
IgG PG9 was flowed through as the analyte. a) Compound 15 (N160 = M5 / N173 = 
GN) b) Compound 17 (N160 = M5 / N173 = SCT) c) Compound 19 (N160 = M5 / 
N173 = CT) d) Compound 21 (N160 = M5 / N173 = M9). 
3.3 Conclusion 
 
         A facile chemoenzymatic strategy that permits sequential enzymatic 
glycosylations to introduce distinct N-glycans into a polypeptide is described. This 
method exploits two orthogonally protected GlcNAc-Asn building blocks in SPPS. 
Among several acid-sensitive silyl protecting groups tested, the diethylisopropylsilyl 
(DEIPS) protecting group was found to be the most efficient, which is stable during 
building block synthesis but can be easily removed during the global peptide 
deprotection step, while the O-acetyl protecting groups can be selectively removed at 
a later stage. The usefulness of this method was exemplified by the efficient synthesis 
of the HIV-1 V1V2 glycopeptide neutralizing epitopes carrying two distinct N-
glycans. The uniqueness of this synthetic strategy is its high convergence and 
efficiency. This method should be equably applicable for convergent synthesis of 
other complex glycopeptides carrying multiple distinct N-glycans. 
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General Methods and Materials 
Endo DN322Q and Endo MN175Q mutants were produced by the reported procedures 
34,35.  1H and 13C NMR spectra were collected on either a 500 MHz or 400 MHz NMR 
spectrometer. The chemical shifts (δ) were assigned in parts per million (ppm) 
rounded to the nearest 0.01 for 1H NMR and 0.1 for 13C NMR. Complete proton 
assignment was determined by two-dimensional correlational experiments (COSY 
(1H-1H)). The 13C NMR was measured at 100 MHz. Analytical and preparative 
reverse-phase HPLC (RP-HPLC) purifications were carried out using an HPLC 
system equipped with a UV detector, using a C18 column at either a flow rate of 0.5 
mL/min (analytical) or 4 mL/min (preparative) using MeCN containing 0.1% TFA at 
40 °C. Glycopeptides were detected at two wavelengths (214 and 280 nm). Mass 
spectrometry data for peptides was collected using either a single quadrupole mass 
spectrometer or a LTQ- LC/MS tandem quadrupole mass spectrometer. High-
resolution (HR) mass spectra were collected with an electrospray ionization time-of-
flight instrument (ESI-TOF) equipped with an ESI source and a time-of-flight (TOF) 
detector. Glycopeptides were analyzed using an analytical C18 column at a flow rate 
of 0.4 mL/min at 50°C using MeCN containing 0.1% formic acid at a gradient of 5-
95%B in 10 min. Peptide synthesis was performed using a microwave-assisted 
peptide synthesizer. Surface plasmon resonance (SPR) analysis was performed at 25 
°C. Biotinylated glycopeptides were immobilized using a streptavidin-bound sensor 
chips in a solution of 0.1 M HEPES, 0.15 M NaCl, 0.5% v/v surfactant P20, pH 7.4. 





was achieved (low-loading). PG9 was injected over four cells at two-fold increasing 
concentrations at a flow rate of 50 μL/min for 3 min. Dissociation was allowed to 
occur over a period of 5 min. The chip was regenerated by injection of 3 M MgCl2 at 
a flow rate of 50 μL/min for 3 min followed by injection of the running buffer for 5 
min. Data was collected at a rate of 10 Hz. SPR evaluation software was used to 
generate the data, applying a 1:1 Langmuir binding model.  
 
  2-Acetamido-3, 4, 6-tri-O-acetyl-1, 2-deoxy--D-glucopyranosyl azide (2). A 
solution of 1 31 (50 g, 137 mmol) in DCM (50 mL) was mixed with a solution of 
sodium azide (25 g, 391 mmol) and tetrabutylammonium hydrogen sulfate (133 g, 
391 mmol) in saturated sodium bicarbonate (50 mL). The biphasic mixture was 
stirred vigorously for 2 h. Upon completion of the reaction as indicated by TLC, the 
organic layer was separated, dried with Na2SO4, and filtered. The filtrate was 
concentrated and the residues was crystallized from ethanol/hexane to give 2 31 (50 g, 
quant. yield) as a white crystal.1H NMR (500 MHz, CDCl3): δ 1.99, 2.03, 2.04, 2.10 
(s each, 3H each, 3 × OAc and NHAc), 3.84 (m, 1H, H-5), 3.95 (m, 1H, H-2), 4.16-
4.29 (m, 2H, H-6), 4.85 (d, 1H, J = 9.2 Hz, H-1), 5.10 (t, 1H, J = 7.9 Hz, H-3), 5.12 (t, 
1H, J = 8.2 Hz, H-4), 6.22 (d, 1H, J = 9.0 Hz, NH). 13C NMR (100 MHz, CDCl3): δ 
171.0, 170.9, 170.8, 169.5, 88.6, 74.1, 72.4, 68.4, 62.1, 54.3, 23.4, 20.9, 20.8, 20.8. 
MS (ESI) m/z [M + H]+ Calcd for C14H2N4O8: 372.13; Found 373.23. The 
1H and 13C 






2-Acetamido-1, 2-deoxy--D-glucopyranosyl azide (3). A solution of 2 (10 g, 27 
mmol) in MeOH (20 ml) containing a catalytic amount of MeONa (79 mg, 2.7 mmol) 
was stirred at 25 ºC for 2 h. Then Dowex (H+ form) was added, and the mixture was 
filtered. The filtrate was concentrated to dryness to afford 3 (6.65 g, quant. yield) as a 
white solid. The product was used for the next step without further purification. 1H 
NMR (500 MHz, CDCl3): δ 1.99 (s, 3H, -NHAc), 3.30-3.36 (m, 3H, H-5, H-6), 3.45 (t, 
J = 8.5 Hz, 1H, H-3), 3.65-3.72 (m, 2H, H-2, H-4), 3.89 (d, J = 12.3 Hz, 1H, H-1), 4.50 
(d, J = 9.3 Hz, 1H, -NHAc), 4.84 (s, 3H, 3 × OH). 13C NMR (100 MHz, CDCl3): δ 23.0, 
56.9, 62.8, 71.9, 75.9, 80.5, 90.3, 173.9.  MS (ESI) m/z [M + H]+ Calcd for C8H14N4O5: 
246.10; Found 246.52. The 1H and 13C NMR data are consistent with the previously 
reported data 40. 
 
2-Acetamido-3, 4, 6-tri-O-tert-butyldimethylsilyl-1, 2-deoxy--D-glucopyranosyl 
azide (4a). To a solution of 3 (1 g, 41 mmol) in 2, 6-lutidine (4 mL) at 0 °C was 
added tert-butyldimethylsilyl trifluoromethanesulfonate (1.8 g, 7.4 mmol). The 
solution was stirred for 1 h on ice, then heated to 40ºC and stirred overnight. The 
solvent was removed and the product was purified on silica (1:1 hexane: ethyl 
acetate), yielding 4a (2.4 g, quant.) as a white solid. 1H NMR (500 MHz, CDCl3): δ 
0.03-0.12 (m, 18H, 6 Si-CH3), 0.87-0.91 (m, 27H, 3 t-Bu), 1.93 (s, 3H, NHAc), 3.68 
(m, 1H, H-3), 3.75-3.84 (m, 2H, H-6a,b), 3.93 (m, 1H, H-4), 3.98 (m, 1H, H-2), 4.20 
(t, J = 9.4 Hz , 1H, H-5), 5.04 (d, J = 5.0 Hz, 1H, H-1), 6.67 (d, J = 9.2 Hz, 1H, -





63.3, 68.6, 70.8, 80.1, 87.5, 168.9. HRMS (ESI-TOF) m/z [M + Na]+ Calcd for 
C26H56N4O5Si3Na: 611.3456; Found 611.3447. 
 
2-Acetamido-3, 4, 6-tri-O-diethylisopropylsilyl-1, 2-deoxy--D-glucopyranosyl 
azide (4b). To a solution of 3 (1 g, 41 mmol) in 2, 6-lutidine (4 mL) at 0 °C was added 
diethyl(isopropyl)silyltrifluoromethanesulfonate (2.1 g, 7.4 mmol). The solution was 
stirred for 1 h on ice, then heated to 40ºC and stirred overnight. The solvent was 
removed and the product purified on silica (1:1 hexane: ethyl acetate), yielding 4b (2.6 
g, quant.) as a white solid. 1H NMR (500 MHz, CDCl3): δ 0.621-0.720 (m, 15H, Si-
CH2, Si-CH) , 0.976-1.056 (m, 36H, 4 Si-CH3), 1.964 (s, 3H, NHAc), 3.801 (m, 1H, 
H-3), 3.835-3.923 (m, 2H, H-6), 4.036 (m, 1H, H-4), 4.052 (m, 1H, H-2), 4.289 (t, J = 
9.35 Hz, 1H, H-5), 5.09 (d, J = 5.0 Hz, 1H, H-1), 6.77 (d, J = 9.35 Hz, 1H, -NHAc).13C 
NMR (100 MHz, CDCl3): δ 3.1, 3.2, 3.4, 3.4, 3.5, 4.5, 6.7, 6.9, 6.9, 6.9, 7.0, 12.6, 12.63, 
12.7, 13.3, 17.0, 17.2, 17.2, 17.3, 17.3, 23.3, 50.5, 63.1, 68.5, 70.6, 80.1, 87.4, 168.7. 
HRMS (ESI-TOF) m/z [M + Na]+ calcd for C29H62N4O5Si3Na: 653.3926; Found 
653.3927. 
 
2-Acetamido-3, 4, 6-tri-O-triethylsilyl-1, 2-deoxy--D-glucopyranosyl azide (4c). 
To a solution of 3 (1 g, 41 mmol) in 2, 6-lutidine (4 mL) at 0°C was added 
triethysilyltrifluoromethanesulfonate (1.9 g, 7.4 mmol). The solution was stirred for 1 
h on ice, then heated to 40ºC and stirred overnight. The solvent was removed and the 
product purified on silica (1:1 hexane: ethyl acetate), yielding 4c as a white solid (2.4 





1.00 (m, 27H, 9 Si-CH2CH3), 1.96 (s, 3H, NHAc), 3.74 (t, J = 6.4 Hz, 1H, H-3), 3.79-
3.81 (m, 2H, H-6), 3.92 (m, 1H, H-4), 3.94 (m, 1H, H-2), 4.16 (t, J = 10.8 Hz, 1H, H-
5), 5.02 (d, J = 5.1 Hz, 1H, H-1), 6.59 (d, J = 9.2 Hz, 1H, -NHAc). 13C NMR (100 
MHz, CDCl3): δ 4.6, 4.8, 4.8, 6.9, 6.9, 6.9, 23.6, 51.5, 62.8, 68.9, 71.4, 80.2, 87.6, 





(5a). To a solution of 4a (1 g, 1.7 mmol) in MeOH (40 mL) was added palladium on 
carbon (8.5 mg). The flask was evacuated and flushed with hydrogen three times, and 
the mixture was stirred under hydrogen for 1 h at RT, until the reaction was complete 
as indicated by TLC. The sample was filtered through celite. The filtrate was 
concentrated and the resulting clear oil was used immediately in the next step without 
further purification. The clear oil was dissolved in DMF (25 mL) and Fmoc-Asp-
OAll (0.752 g, 1.9 mmol) was added. Diisopropylethylamine (0.66 g, 5.1mmol) in 
DMF (1 M) was added with vigorous stirring under argon. HATU (1.94 g, 5.1mmol) 
in DMF (0.5 M) was added dropwise. The reaction was stirred for 1 h at RT, until the 
reaction was complete as indicated by TLC. The reaction was diluted with EtOAc, 
and washed with aq. NaHCO3. The aqueous layer was extracted with EtOAc (3x). 
The organic extracts were combined, dried over Na2SO4, filtered. The filtrate was 
concentrated. The product was purified by flash silica gel chromatography (20-50% 





CDCl3): δ  0.04-0.16 (m, 18H, 6 Si-CH3), 0.88-0.95 (t, J = 8.2 Hz, 27H, 9 t-Bu), 2.04-
2.06 (s, 3H, -NHAc),  2.75-3.02 (dd, 2H, Asn-β-CH2), 3.84-3.87 (m, 2H, H-6), 3.88-
3.90 (m, 1H, H-5), 3.95-3.98 (m, 1H, H-2), 4.24-4.47 (m, 5H, H-3, H-4, Fmoc-CH, 
Fmoc-CH2), 4.63-4.64 (m, 1H, α-CH-Asn), 4.65-4.69 (d, J = 4.8 Hz, 2H, O-CH2-
CH=CH2), 5.19-5.22 (d, J = 10.5 Hz, 1H, OCH2-CH=CHcisHtrans), 5.33 (d, J = 17.2 
Hz, 1H, OCH2-CH=CHcisHtrans), 5.55 (d, J = 7.75 Hz, 1H, H-1), 5.87-5.94 (m, 1H, 
OCH2-CH=CH2), 6.04 (d, J = 8.5 Hz, 1H, Asn-α-NH), 6.82 (d, J = 7.6 Hz, 1H, NH-
Asn), 7.19 (d, J = 8.7 Hz, 1H, -NHAc), 7.30-7.76 (m, 8H, Fmoc-Ar). 13C NMR (100 
MHz, CDCl3): δ 171.5, 170.9, 170.0, 156.4, 144.1, 141.5, 131.9, 127.9, 127.4, 125.5, 
120.1, 118.6, 81.7, 72.7, 71.0, 68.2, 67.4, 66.5, 61.5, 51.5, 50.7, 47.3, 38.1, 25.9, 23.8, 




(9-fluorenylmethyloxycarbonyl)-L-asparagine-allyl ester (5b). To a solution of 4b 
(1 g, 1.6 mmol) in MeOH (40 mL), and palladium on carbon (8 mg) was added. The 
flask was evacuated and flushed with hydrogen three times, and stirred under 
hydrogen for 1 h at RT, until the reaction was complete by TLC. The sample was 
filtered through celite. The filtrate was concentrated and the resulting clear oil was 
used immediately in the next step without further purification. The clear oil was 
dissolved in DMF (25 mL) and Fmoc-Asp-OAll (0.709 g, 1.8 mmol) was added. 
Diisopropylethylamine (0.62 g, 4.8 mmol) in DMF (1 M) was added with vigorous 





dropwise. The reaction was stirred for 1 h at RT until the reaction was complete by 
TLC. After completion, the reaction was diluted with EtOAc, and washed with 50% 
NaHCO3 (aq.). The aqueous layer was extracted with EtOAc 3x. The organic extracts 
were combined, dried over Na2SO4, filtered, and evaporated in vacuo. The compound 
was purified by flash silica gel chromatography (20-50% EtOAc in hexane), yielding 
5b (1.15 g, 73%) as a white solid. 1H-NMR (500 MHz, CDCl3): δ 0.63-0.73 (m, 15H, 
Si-CH2, Si-CH), 0.98-1.06 (m, 36H, Si-CH3), 2.06 (s, 3H, -NHAc), 2.77-3.03 (dd, 
2H, Asn-β-CH2), 3.86-3.89 (m, 1H, H-5), 3.93-3.98 (m, 2H, H-6), 4.0-4.03 (m, 1H, 
H-2), 4.25-4.41 (m, 5H, H-3, H-4, Fmoc-CH, Fmoc-CH2), 4.63-4.64 (m, 1H, α-CH-
Asn), 4.67-4.70 (d, J = 5.4 Hz, 2H, O-CH2-CH=CH2), 5.23 (d, J = 10.5 Hz, 1H, 
OCH2-CH=CHcisHtrans), 5.34 (d, J = 17.2 Hz, 1H, OCH2-CH=CHcisHtrans), 5.56 (d, J = 
8.0 Hz, 1H, H-1), 5.92 (m, 1H, OCH2-CH=CH2), 6.09 (d, J = 8.6 Hz, 1H, Asn-α-NH), 
6.84 (d, J = 8.0 Hz, 1H, 1-NH), 7.27-7.78 (m, 9H, Fmoc-Ar, -NHAc).13C NMR (100 
MHz, CDCl3): δ  171.5, 170.9, 169.9, 156.4, 144.1, 144.1, 141.5, 131.9, 131.9, 127.8, 
127.3, 125.5, 125.4, 120.1, 118.6, 118.5, 81.9, 72.0, 70.9, 68.2, 67.5, 66.5, 61.5, 51.7, 
50.8, 47.3, 38.1, 23.7, 21.2, 17.6, 17.5, 17.4, 17.4, 12.8, 12.8, 12.8, 7.2, 7.2, 7.2, 7.1, 
7.1, 3.6, 3.6, 3.6, 3.5. HRMS (ESI-TOF) m/z [M + H]+ Calcd for C51H84N3O10Si3: 
982.5465; Found 982.5466. 
 
Nω-(2-Acetamido-3,4,6-tri-O-triethylsilyl-2-deoxy-β-D-glucopyranosyl-Nα-(9-
fluorenylmethyloxycarbonyl)-L-asparagine-allyl ester (5c). Compound 4c (1 g, 
1.7mmol) was dissolved in methanol (42 mL), and palladium on carbon (8.5 mg) was 





under hydrogen for 1 h at RT, until the reaction was complete by TLC. The sample 
was filtered through celite. The filtrate was concentrated and the resulting clear oil 
was used immediately in the next step without further purification. The clear oil was 
dissolved in DMF (25 mL) and Fmoc-Asp-OAll (0.752 g, 1.9 mmol) was added. 
Diisopropylethylamine (0.66 g, 5.1 mmol) in DMF (1 M) was added with vigorous 
stirring under argon. HATU (1.94 g, 5.1 mmol) in DMF (0.5 M) was added slowly, 
dropwise. The reaction was stirred for 1 h at RT, until the reaction was complete by 
TLC. After completion, the reaction was diluted with EtOAc, and washed with 50% 
NaHCO3 (aq.). The aqueous layer was extracted with EtOAc. The organic extracts 
were combined, dried over Na2SO4, filtered, and evaporated in vacuo. The compound 
was purified by flash silica gel chromatography (20-50% EtOAc in hexane), yielding 
5c (0.61 g, 38%) as a white solid. 1H NMR (500 MHz, CDCl3): δ  0.88-1.03 (m, 18H, 
-Si-CH2-CH3), 0.53-0.71 (m, 27H, -Si-CH2-CH3), 2.02-2.05 (s, 3H, -NHAc), 2.76-
3.03 (dd, 2H, Asn-β-CH2), 3.81-3.98 (m, 3H, H-2, 5, 6), 4.22-4.43 (m, 5H, H-3, 4, 
Fmoc-CH, Fmoc-CH2), 4.62-4.66 (m, 1H, α-CH-Asn), 4.68 (d, J = 5.4 Hz, 1H, 
OCH2-CH=CH2), 5.21 (d, J = 10.5 Hz, 1H, OCH2-CH=CHcisHtrans), 5.32 (d, J = 17.2 
Hz, 1H, OCH2-CH=CHcisHtrans), 5.58 (d, J = 7.95 Hz, 1H, H-1), 5.87-5.94 (m, 1H, 
OCH2-CH=CH2), 6.07 (d, J = 8.65 Hz, 1H, NH-Asn), 6.86 (d, J = 7.95 Hz, 1H, 1-
NH), 7.29 (d, J = 8.05 Hz, 1H, -NHAc), 7.27-7.77 (m, 8H, Fmoc-Ar). 13C NMR (100 
MHz, CDCl3): δ 171.5, 170.9, 169.9, 156.3, 144.1, 141.4, 131.9, 129.4, 127.8, 127.2, 
125.4, 120.8, 120.0, 81.8, 71.7, 70.9, 68.3, 67.9, 67.4, 66.4, 61.0, 51.6, 47.2, 37.9, 
23.7, 6.9, 6.9, 4.6, 4.6, 4.5. HRMS (ESI-TOF) m/z [M + H]+ Calcd for 







glucopyranosyl-Nα-(9-fluorenylmethyloxycarbonyl)-L-asparagine (6a). To a 
solution of 5a (1 g, 1.1 mmol) in DCM (50 mL) were added 
tetrakis(triphenylphosphine)palladium(0) (25.4 mg, 0.02 mmol) and  phenylsilane (238 
mg, 2.2 mmol). The resulting mixture was stirred at RT, under argon, for 45 min. After 
completion of reaction as indicated by TLC, water (2 mL) was added to quench the 
reaction, and the biphasic mixture was vigorously stirred for 30 min. The mixture was 
concentrated to dryness and the residue was purified by flash silica gel column 
chromatography (0-15% MeOH in DCM containing 0.5% acetic acid) and the crude 
product was further purified by size-exclusion chromatography (Sephadex LH-20, 2:1 
CH2Cl2/MeOH) to afford 6a (0.93 g, 94% yield) as a white powder. 
1H NMR (500 
MHz, CDCl3): δ 0.11-0.16 (m, 18H, Si-Me), 0.88-0.96 (m, 27H, Si-tBu), 2.06 (s, 3H, -
NHAc), 2.85-2.98 (m, 2H, Asn-β-CH2), 3.39-3.48 (m, 3H, H-4, H-6), 3.81 (m, 1H, H-
5), 4.06 (m, 1H, H-2), 4.19-4.35 (m, 3H, Fmoc-CH, Fmoc-CH2), 4.49 (t, J = 11.9 Hz, 
1H, H-3), 4.65 (m, 1H, α-CH-Asn), 5.58 (d, J = 6.35 Hz, 1H, H-1), 6.22 (d, J = 6.60 
Hz, 1H, Asn-α-NH), 7.27-7.74 (m, 10H, Fmoc-Ar, -NHAc, 1-NH). 13C NMR (100 
MHz, CDCl3): δ 173.7, 173.1, 172.8, 156.4, 144.1, 144.0, 141.4, 127.8, 127.3, 125.5, 
120.1, 81.3, 71.9, 69.9, 69.3, 67.5, 58.5, 51.0, 47.3, 25.9, 23.5, 18.1, 4.8. HRMS (ESI-
TOF) m/z [M + H]+ Calcd for C45H74N3O10Si3: 900.4682; Found 900.4694. 
 
Nω-(2-Acetamido-3,4,6-tri-O-diethylisopropylsilyl-2-deoxy-β-D-glucopyranosyl-





1.0 mmol) in DCM (50 mL), were added tetrakis(triphenylphosphine)palladium(0) 
(25.4 mg, 0.02 mmol) and  phenylsilane (238 mg, 2.2 mmol).The resulting mixture 
was stirred at RT, under argon, for 45 min. After completion of reaction as indicated 
by TLC, water (2 mL) was added to quench the reaction, and the biphasic mixture 
was vigorously stirred for 30 min. The mixture was concentrated to dryness and the 
residue was purified by flash silica gel chromatography (0-15% MeOH in DCM 
containing 0.5% acetic acid), and the crude product was further purified followed by 
size exclusion chromatography (Sephadex LH-20, 2:1 CH2Cl2/MeOH) to afford 6b 
(0.89 g, 95% yield) as a white powder. 1H NMR (500 MHz, CDCl3): δ  0.59-0.69 (m, 
15H, Si-CH2, Si-CH), 0.94-1.01 (m, 36H, Si-CH3), 2.03 (s, 3H, -NHAc), 2.77-2.88 
(m, 2H, Asn-β-CH2), 3.87-3.96 (m, 5H, H-3, H-4, Fmoc-CH, Fmoc-CH2), 3.98-4.01 
(m, 1H, H-2), 4.17-4.33 (m, 3H, H-5, H-6), 4.59-4.61 (m, 1H, α-CH-Asn), 5.58 (d, J 
= 7.5 Hz, 1H, H-1), 6.09 (d, J = 6.5 Hz, 1H, Asn-α-NH), 7.19 (d, J = 7.0 Hz, 1H, 1-
NH), 7.28 (d, J = 7.0 Hz, 1H, -NHAc), 7.34-7.73 (m, 8H, Fmoc-Ar). 13C NMR (100 
MHz, CDCl3): δ 173.2, 172.7, 171.2, 155.9, 143.9, 141.2, 127.6, 127.1, 125.3, 119.8, 
81.7, 71.7, 71.2, 67.9, 67.2, 61.1, 51.5, 50.5, 47.1, 23.4, 17.3, 12.6, 12.6, 12.5, 6.9. 




fluorenylmethyloxycarbonyl)-L-asparagine (6c). To a solution of 5c (1 g, 1.1 
mmol) in DCM (50 mL) were added tetrakis(triphenylphosphine)palladium(0) (25.4 





stirred at RT, under argon, for 45 min. After completion of reaction by TLC, water (2 
mL) was added to quench the reaction, and the biphasic mixture was vigorously 
stirred for 30 min. The mixture was concentrated to dryness and purified by flash 
silica gel column chromatography size exclusion chromatography (0-15% MeOH in 
DCM containing 0.5% acetic acid), the crude product was further purified by size-
exclusion chromatography (Sephadex LH-20, 2:1 CH2Cl2/MeOH) to afford 6c (0.92 
g, 97% yield) as a white powder (0.92 g, 97% yield).1H NMR (500 MHz, CDCl3): δ  
0.54-0.69 (m, 18H, -Si-CH2-CH3), 0.89-0.99 (m, 27H, -Si-CH2-CH3), 1.95 (s, 3H, -
NHAc), 2.63-2.90 (m, 2H, Asn-β-CH2), 3.57 (m, 1H, H-5), 3.68-3.71 (m, 2H, H-6), 
3.82-3.85 (m, 2H, Fmoc-CH2), 3.95 (m, 1H, H-2), 4.17-4.19 (m, 1H, Fmoc-CH), 
4.25-4.29 (m, 1H, H-4), 4.35-4.48 (m, 1H, H-3), 4.58-4.59 (m, 1H, α-CH-Asn), 5.14 
(d, J = 8.0 Hz, 1H, H-1), 6.24 (d, J = 8.2 Hz, 1H, NH-Asn), 6.58 (d, J = 9.2 Hz, 1H, 1-
NH), 7.19 (d, J = 8.4 Hz, 1H, -NHAc), 7.28-7.29 (d, J = 7.35 Hz, 2H, Fmoc-Ar), 
7.35-7.38 (t, J = 8.7 Hz, 2H, Fmoc-Ar), 7.57-7.61 (t, J = 8.6 Hz, 2H, Fmoc-Ar), 7.73-
7.74 (d, J = 7.6 Hz, 2H, Fmoc-Ar).13C NMR (100 MHz, CDCl3): δ  173.6, 172.0, 
171.2, 162.9, 156.4, 141.2, 132.4, 132.2, 128.6, 128.5, 127.1, 119.9, 79.3, 67.4, 62.6, 
50.5, 47.1, 36.5, 31.5, 23.2, 6.9, 4.4, 4.0. HRMS (ESI-TOF) m/z [M + H]+ Calcd for 
C45H74N3O10Si3: 900.4682; Found 900.4689. 
 
Nω-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-Nα-(9-
fluorenylmethyloxycarbonyl)-L-asparagine tert-butyl ester (7). A solution of 2 (5 
g, 13.4 mmol) and Fmoc-Asp-OtBu (4.96 g, 12.1 mmol) in DCM (10 mL) was cooled 





(31.9 mg, 0.27 mmol) was added, and the reaction mixture was stirred to RT overnight. 
The product (7) precipitated as a white solid.2 The solid was collected and recrystallized 
from warm CH2Cl2 to afford 7 (8.03 g, 81% yield). 
1H NMR (500 MHz, CDCl3): δ  
1.45 (s, 9H, t-Bu), 1.96 (s, 3H, -NHAc), 2.04, 2.05, 2.07 (three s, 9H, 3 × OAc), 2.69-
2.87 (m, 2H, Asn-β-CH2), 3.74-3.76 (m, 1H, H-5), 4.05-4.24 (m, 3H, H-2, 6), 4.28-
4.44 (m, 3H, Fmoc-CH2, Fmoc-CH), 4.52 (m, 1H, Asn-α-CH), 5.06-5.14 (m, 3H, H-1, 
3, 4), 5.98 (d, J = 8.5 Hz, 1H, Asn-α-NH), 6.19 (d, J = 8.0 Hz, 1H, -NHAc), 7.22 (d, J 
= 10 Hz, 1H, 1-NH), 7.30 (t, J = 8.4 Hz, 2H, Fmoc-Ar), 7.39 (t, J = 8.2 Hz, 2H, Fmoc-
Ar), 7.60 (d, J = 7.4 Hz, 2H, Fmoc-Ar), 7.75 (t, J = 7.4 Hz, 2H, Fmoc-Ar).13C NMR 
(100 MHz, CDCl3): δ 172.8, 172.2, 171.5, 171.1, 170.4, 169.7, 156.6, 144.2, 141.7, 
141.6, 128.1, 127.5, 125.6, 120.4, 80.7, 80.5, 73.9, 73.2, 68.1, 67.6, 62.1, 53.8, 51.4, 
47.5, 38.6, 28.3, 23.5, 21.1, 21.00, 13.9, 0.4. MS (ESI) m/z [M + H]+ Calcd for 
C37H45N3O13: 739.30; Found 740.74. The 
1H and 13C NMR data were consistent with 
the reported data 41. 
 
Nω-(2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-Nα-(9-
fluorenylmethyloxycarbonyl)-L-asparagine (8). Compound 7 (1 g, 1.35 mmol) was 
dissolved in neat formic acid. The mixture was stirred at RT until complete removal 
of the tBu group, as indicated by TLC. Formic acid was removed in vacuo to provide 
8 (0.922 g, quant.).1H NMR (400 MHz, (CD3)2SO): δ 1.72 (s, 3H, NHAc), 1.89 (s, 
3H, OAc), 1.96 (s, 3H, OAc), 1.99 (s, 3H, OAc), 2.62-2.67 (m, 2H, Asn-β-CH2), 
3.79-3.95 (m, 3H, H-5, 6), 4.16-4.29 (m, 4H, H-2, Fmoc-CH2, Fmoc-CH), 4.35-4.39 





7.33 (t, J = 8.5 Hz, 2H, Fmoc-Ar), 7.41 (t, J = 8.1 Hz, 2H, Fmoc-Ar), 7.51 (d, J = 8.40 
Hz, 1H, Asn-α-NH), 7.71 (d, J = 7.60 Hz, 2H,  Fmoc-Ar), 7.89 (m, 3H, -NHAc, 
Fmoc-Ar), 8.61 (d, J = 9.2 Hz, 1H, 1-NH). 13C NMR (100 MHz, (CD3)2SO):  δ 173.9, 
170.9, 170.7, 170.4, 170.4, 170.2, 163.2, 156.7, 144.7, 144.7, 141.6, 129.8, 128.5, 
127.9, 126.2, 126.1, 120.9, 78.9, 74.2, 73.1, 69.2, 66.6, 62.7, 52.9, 50.9, 47.5, 37.8, 
36.7, 31.6, 23.5, 21.4, 21.3, 21.2. MS (ESI) m/z [M + H]+ Calcd for C37H45N3O13: 
683.23; Found 683.24. The 1H and 13C NMR data were consistent with the reported 
data 41. 
 
Synthesis of the precursor glycopeptides incorporating the GlcNAc-Asn building 
blocks. All the three precursor glycopeptides were synthesized on a 0.1 mmol scale 
using 5-fold excess of reagents [0.2 M amino acid solution (in DMF)] with 1 M DIC 
(in DMF) and 0.5 M HOBt (in DMF). Low-loading Fmoc-PAL-PEG-PS resin (0.17 
mmol/g, Life Technologies) was used for the synthesis of the peptides. The 
glycosylamino acid building blocks (6a-c and 8) were coupled to the growing peptide 
at 90 °C with a 50 Hz MW power for 10 min, Fmoc-Cys(Trt)-OH and Fmoc-His(Trt)-
OH were coupled at 50°C with a 50 Hz MW power for 2 min. Fmoc-Arg(Pbf)-OH 
was double coupled (RT without MW for 25 min, followed by 90 °C with 50 Hz MW 
power for 2 min). All other amino acids were coupled at 90 °C with 50 Hz MW 
power for 2 min. The deblocking reagent used was 20% piperidine with 0.1 M HOBt 
(deblocking occurred at 50 °C and 50 Hz MW power). The N-terminus was capped 
with a biotin tag by treatment with biotin-LC-N-hydroxysuccinimide (3 mol. 





achieved after washing the resin with DCM (3x) and adding freshly prepared cocktail 
R (TFA/thioanisole/1,2-EDT/anisole, 90/5/3/2) and shaking for 2 h at RT. The resin 
was filtered onto ice-cold ethyl ether for precipitation in a 50 mL centrifuge tube.  
The crude glycopeptides were purified by RP-HPLC and the purity and identity were 
confirmed by analytical HPLC and LC-MS analysis. Glycopeptide (10): Analytical 
RP-HPLC, tR = 26 min. (gradient, 0-90% aq. MeCN containing 0.1% TFA for 30 
min; flow rate = 0.5 mL/min.); ESI-MS: Calcd M = 3856.50; found: 771.53 [M + 
5H]5+, 964.24 [M + 4H]4+, 1285.43 [M + 3H]3+. Deconvolution mass: 3856.03 ± 0.15.  
Glycopeptide (11): Analytical RP-HPLC, tR = 21 min. (gradient, 5-25% aq. MeCN 
containing 0.1% FA for 30 min; flow rate, 1 mL/min.); ESI-MS: Calcd M = 3628.37; 
found: 726.55 [M + 5H]5+, 908.18 [M + 4H]4+, 1210.57 [M + 3H]3+, 1815.35 [M + 
2H]2+. Deconvolution mass: 3628.65 ± 0.28. 
 
Synthesis of glycopeptide (12): Compound 11 (50 mg) was dissolved in DMSO (5 
mL) and then the solution was diluted with water (20 mL) (final concentration of 
DMSO, 20%). The solution was shaken overnight at RT. After cyclization was 
complete (by HPLC analysis), the mixture was lyophilized and the resulting residue 
was purified by preparative HPLC, yielding 12 (43 mg, 85%) as a white powder. 
Analytical RP-HPLC, tR = 33 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA 
for 30 min; flow rate, 0.5 mL/min.); ESI-MS: Calcd M = 3626.21; found: 726.61 [M + 
5H]5+, 908.04 [M + 4H]4+, 1210.08 [M + 3H]3+, 1789.79 [M + 2H]2+. Deconvolution 






Preparation of Man5GlcNAc and Man9GlcNAc oxazolines (13 and 20). 
Man9GlcNAc2Asn was isolated from soy bean flour, using the method previously 
reported 42. For the synthesis of Man5GlcNAc oxazoline (13), a solution of 
Man9GlcNAc2Asn (10 μmol) was dissolved in 50 mM citrate buffer (pH = 5.6) 
containing 5 mM calcium chloride. α1,2-mannosidase from Bacteroides 
thetaiotaomicron was added to a final concentration of 0.02 mg/mL, the enzymatic 
reaction was incubated at 37 °C for 8 h, while monitoring by HPAEC-PAD analysis. 
Once complete conversion was observed, the pH of the solution was adjusted to 7.0, 
and enzyme Endo-A was added to convert Man5GlcNAc2Asn to Man5GlcNAc via 
enzymatic cleavage of the chitobiose core. Man5GlcNAc was purified by gel filtration 
on a Sephadex G-15 (GE Healthcare) column. The carbohydrate positive fractions 
(assessed by phenol-sulfuric acid analysis) were pooled and lyophilized to obtain the 
free glycan Man5GlcNAc (9 mg, 87%). The identity and purity of the Man5GlcNAc 
was confirmed by MALDI-TOF and HPAEC-PAD (data not shown). The sugar 
oxazoline of Man5GlcNAc was prepared by treatment of a solution of Man5GlcNAc 
(9 mg, 87.3 μmol) in water (0.45 mL) with triethylamine (3.9 mmol) and 2-chloro-
1,3-dimethylimidazolinium chloride (DMC) (1.3 mmol). The reaction was incubated 
on ice for 30 min, while monitored by HPAEC-PAD analysis. The glycan oxazoline 
product was purified by SEC (Sephadex G-10) eluting with 0.1% triethylamine. The 
carbohydrate containing fractions were pooled and lyophilized to give 13 (8 mg, 
91%). The sugar oxazoline of Man9GlcNAc (20) was prepared from soy flour in a 






Enzymatic transglycosylation: Synthesis of glycopeptide 14 bearing a 
Man5GlcNAc2 moiety.  A solution of the GlcNAc-containing peptide 12 (1 mg, 0.28 
μmol) and Man5GlcNAc-oxazoline (13) (2.3 mg, 2.24 μmol) in a Tris buffer (40 μL, 
80 mM, pH 7.2) was incubated with EndoM-N175Q (final concentration, 0.2 μg/μL) at 
RT. The reaction was monitored by RP-HPLC. After 30 min, the reaction was 
quenched by addition of 0.1% aq. TFA. The transglycosylation product was purified 
by RP-HPLC to afford 14 (1.1 mg, 85%) as a white powder after lyophilization. 
Analytical RP-HPLC, tR = 31 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA 
for 30 min; flow rate = 0.5 mL/min.); ESI-MS: Calcd M = 4639.56; found: 929.31 [M 
+ 5H]5+, 1161.43 [M + 4H]4+, 1548.71 [M + 3H]3+. Deconvolution mass: 4640.32 ± 
0.84. 
 
Deprotection of glycopeptide 15. Compound 14 (0.95 mg, 0.21 μmol) was dissolved 
in 2.5% aqueous hydrazine (final concentration 2 mg/mL). The mixture was shaken at 
RT for 30 min. When the reaction was complete as indicated by RP-HPLC, the 
solution was neutralized by addition of glacial acetic acid. The product was purified 
by RP-HPLC yielding 15 (0.54 mg, 58%) as a white powder. Analytical RP-HPLC, tR 
= 28 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA for 30 min; flow rate = 
0.5 mL/min.); ESI-MS: Calcd M = 4514.63; found: 904.11 [M + 5H]5+, 1129.53 [M+ 
4H]4+, 1506.03 [M + 3H]3+. Deconvolution mass: 4514.94. 
 
Enzymatic transglycosylation: Synthesis of glycopeptide 17 bearing a 





GlcNAc-containing peptide (15) (1 mg, 0.22 μmol) and 
(NeuGalGlcNAc)2Man3GlcNAc-oxazoline (16) (2 mg, 0.9 μmol) in Tris buffer (40 μL, 
80 mM, pH 7.2) was incubated with EndoM-N175Q (final concentration, 0.2 μg/μL) at 
RT. The reaction was monitored by RP-HPLC. After 30 min, the reaction was 
quenched by addition of 0.1% aq. TFA. The transglycosylation product was purified 
by RP-HPLC yielding 17 (1.32 mg, 92%) as a white powder. Analytical RP-HPLC, tR 
= 22 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA for 30 min; flow rate = 
0.5 mL/min.); ESI-MS: calcd M = 6517.30; found: 1304.66 [M + 5H]5+, 1630.41 [M + 
4H]4+. Deconvolution mass: 6516.21 ± 1.45. 
 
Synthesis of glycopeptide 19. The enzymatic transglycosylation of 15 with glycan 
oxazoline (18) under the catalysis of EndoM-N175Q was carried out in the same 
manner as for the preparation of 17, giving 19 (95% yield based on HPLC estimation).  
Analytical RP-HPLC, tR = 24 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA 
for 30 min; flow rate = 0.5 mL/min.); ESI-MS: Calcd M = 5933.01; found 996.55 [M 
+ 6H]6+, 1188.28 [M + 5H]5+, 1484.88 [M + 4H]4+ , 1978.93 [M + 3H]3+. Deconvolution 
mass: 5934.49 ± 1.67. 
 
Synthesis of glycopeptide 21. The enzymatic transglycosylation of 15 with glycan 
oxazoline (20) under the catalysis of EndoM-N175Q was carried out in the same way 
as for the preparation of 17, giving 21 in 95% yield (based on HPLC estimation). 





for 30 min; flow rate = 0.5 mL/min.); ESI-MS: Calcd M = 6175.37; found: 1236.54 [M 
+ 4H]4+, 1735.28 [M + 3H]3+. Deconvolution mass: 6175.76 ± 0.81.  
 
Synthesis of the linear glycopeptide (S-1). Compound 12 (0.5 mg, 0.14 µmol) was 
incubated with 0.5 mM dithiothreitol (DTT) for 1 h at 37°C. Iodoacetamide was 
added to a final concentration of 180 mM, and the reaction was incubated for 30 min 
at 37°C. The reaction was monitored by HPLC. The reaction was purified by HPLC 
yielding S-1 (0.47 mg, 90%) as a white powder. Analytical RP-HPLC, tR = 30 min. 
(gradient, 15-30% aq. MeCN containing 0.1% TFA for 30 min; flow rate = 0.5 
mL/min.); ESI-MS: calcd M = 3740.71; found: 748.38 [M + 5H]5+, 935.78 [M + 
4H]4+, 1246.93 [M + 3H]3+ , 1870. 61 [M + 2H]2+. Deconvolution mass: 3740.82 ± 
0.92.  
 
Transglycosylation of linear glycopeptide S-1 by the Endo D mutant. Compound 
S-1 (0.5 mg, 0.13 μmol) and Man5GlcNAc-oxazoline (13) (1.1 mg, 1.05 μmol) in Tris 
buffer (20 μL, 80 mM, pH 7.2) was incubated with EndoD-N322Q (final concentration, 
40 ng/μL) at RT. The reaction was monitored by RP-HPLC. After 30 min, the reaction 
was quenched by addition of 0.1% aq. TFA. The transglycosylation product was 
purified by RP-HPLC yielding S-2 (0.57 mg, 92%) as a white powder. Analytical RP-
HPLC, tR = 26 min. (gradient, 15-30% aq. MeCN containing 0.1% TFA for 30 min; 
flow rate = 0.5 mL/min.); ESI-MS: Calcd M = 4736.06; found: 947.94 [M + 5H]5+, 
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Chapter 4: Synthesis and binding studies of an anti-HIV PG9 
neoglycoprotein immunogen mimic of gp120 quaternary 




          The past five years have yielded an enormous amount of information regarding 
the vulnerability of HIV-1 to neutralization by carbohydrate-reactive antibodies. 
Initial attempts at HIV vaccine design resulted in a vast number of designed 
constructs1-3 4 5 6-10 aimed at simulation of Env architecture, none of which have been 
able to raise a sustaining neutralizing humoral immune response. The functional Env 
is a trimer of heterodimers composed of the receptor binding protein gp120, and a 
membrane-spanning fusion protein gp41. These heterodimers, constructed from 
homotrimers (gp41 and gp120), assemble into the non-covalently associated viral 
spike. The trimeric structure is inherently unstable, with a pronounced lability 
resulting in heterogeneous surface display of viral spikes at different levels of 
composition. The major issue in these early designs was the use of gp120 monomer, 
which exposed the trimer-associated face that is normally occluded in functional Env 
protein. The bulk of the immune response was therefore directed against the highly 
antigenic trimer-associated face, while the solvent exposed face was protected by the 
endogenous dense glycosylation (i.e. the “glycan shield”). Therefore, any vaccination 





against non-functional Env protein, distracting the response from the solvent exposed 
face on functional trimeric Env proteins and consequently yielding no vaccine-
induced protection from HIV-1. This “glycan shield,” comprising ~50% of gp120 by 
weight,  once considered one of HIV’s most effective tools for immune evasion is 
now viewed as the most promising target for vaccine design. Indeed, the discovery of 
carbohydrate-reactive broadly neutralizing antibodies (bNAbs) has revolutionized the 
field of HIV vaccine design by providing a number of partially defined and potent 
epitopes on the so-called glycan shield. The first of these epitopes to be discovered 
was that of the bNAb 2G12. 2G12 recognizes an oligomannose cluster within the 
HIV glycan shield, with three epitopes per trimeric Env protein. The epitope of 2G12 
is unique in that it consists solely of carbohydrate, comprised of 2-3 oligomannose 
glycans, with 2G12 binding to the distal α1, 2-linked Man-Man glycans. After the 
initial description of the 2G12 epitope, many mimics of the gp120 oligomannose 
cluster were generated using a wide variety of scaffolds in the hope of eliciting 2G12-
like Abs (see Chapter 2). Despite very impressive antigenicity studies with 2G12 
recognition of synthetic antigens comparable 11-13 to more potent 14 than the affinity 
of 2G12 for its natural substrate, gp120, to date, none of the synthetic antigens have 
been successful as immunogens. Among the multifarious reasons often cited for the 
lack of success in inducing 2G12-like bNAbs,15 most likely the problem is 
exacerbated by the unusual domain-exchanged arrangement of the Ab heavy chains. 
The domain-exchanged combining sites, providing greater surface area for binding to 
carbohydrate antigens, accounting for its unique mode of antigen recognition, is most 





        Until 2009, the only reported anti-HIV-1 carbohydrate-reactive bNAb was 
2G12. Since that time, thanks to aggressive high-throughput screening of B cell 
clones from elite-neutralizer patients, a number of carbohydrate-reactive bNAbs have 
been described. 17-20 These new classes of carbohydrate-reactive bNAbs, isolated 
from several infected donors, all have a typical Y-shaped IgG architecture, in contrast 
to the very unusual domain-exchanged structure of 2G12. 18 17, 21 22-23 24 It was 
initially thought that bNAbs were extremely rare, only arising in a small number of 
infected individuals after an extended period of HIV infection. It is now known that 
approximately 10-30% of HIV-1 infected individuals develop bNAbs within 3 years 
of infection, with some arising after just one year. 25 In particular, two series of 
bNAbs, the PG and PGT-series, are exceptionally potent and have very broad 
neutralizing capacity across multiple HIV clades. The first antibodies to be described 
in this new class were PG9 and the closely related PG16, both of which neutralize 
HIV-1 with extremely high potency and breadth, particularly in comparison to 2G12. 
For example, when tested against a 162-pseudovirus panel, PG9 was shown to 
neutralize 77% of HIV-1 strains with an IC50 of 0.23 μg mL
-1 (compared to 32% and 
2.4 μg mL-1 for 2G12). 17 The PG-series of bNAbs is able to achieve such a high 
potency and neutralization breadth in spite of its conventional Y-shaped architecture. 
The PG-series (as well as the PGT-series) has several unusual features not found on 
more typical IgGs, most notably extended, heavily tyrosine-sulfated CDRH3 loops. 
The extended CDRH3 loops protruding from the Fab forms a “hammer-head” 
conformation, penetrating the glycan shield and contacting the N160 and N156/173 





Specifically, the HCDRH3 hammerhead mediates largely charged interactions with a 
beta-strand (bearing the cationic sequence KQKKD) on the V1V2 region of gp120, 
while the glycans at N160 and N156/173 interact with the surrounding Ab paratope. 
21 Thus the PG-series bNAbs targets an integrated epitope, augmenting the binding 
mode and enhancing the overall potency versus the solely anti-carbohydrate Ab 
2G12. Cryoelectron microscopy studies have suggested that the PG-series of bNAbs 
are trimer-preferring, targeting an epitope at the apex of the gp120 trimer that spans 
across two monomers, as a second N160 glycan on a neighboring protomer was 
involved in PG9 recognition (Figure 4.1A). Such findings suggest that PG9 
immunogen design must be guided within the context of quaternary structure, as the 
quaternary epitope spans two V1V2 loops straddling two gp120 protomers (Figure 
4.1B). 26 
 
Figure 4.1. A) Electron microscopy crystal structure of a PG9 Fab bound to trimeric 
gp120 spanning two protomers. B) Detail of putative PG9 quaternary epitope (images 
reproduced by permission of the publishers). 26, 28  
 
        The breadth and potency of PG9 have made the bNAb an attractive target for 






the bNAbs in complex with gp120.  Mutational analysis indicated the critical role of a 
PNG site at N160 for PG9 binding. 29 Indeed, X-ray crystallographic studies of PG9 
bound to a segment of the V1V2 region of gp120 ectopically grafted onto a scaffold 
protein clearly showed that PG9 makes extensive contacts with a Man5GlcNAc2 
glycan at N160. Lower, but significant contact was also made with PNG sites at the 
spatially-related N156/N173 positions. Unfortunately, the most informative structural 
studies were performed using V1V2 constructs that were produced in cell lines 
deficient of N-acetylglucosaminyltransferase I (GnTI), giving rise to homogeneous 
Man5GlcNAc2 glycoforms, limiting the information obtained regarding the specific 
glycan requirements of PG9. 21 Moreover, from the crystal structure obtained, the 
identity of the glycan at N156/173 was unclear, although the results indicated the 
precise fitting of Man5GlcNAc2 at the N160 site. To clarify the glycan requirement 
for optimized PG9 recognition, a number of studies have been performed by our 
group and others. 30-32 Our group was the first to interrogate the glycan requirement of 
PG9 using a chemoenzymatic method involving “random-glycosylation” to 
synthesize a library of glycopeptides that were tested for PG9 recognition. 30 The 
findings supported the observed requirement from structural studies for an 
oligomannose Man5GlcNAc2 glycan at N160. The study also found that a biantennary 
sialylated complex-type glycan at N156/173 was critical for optimal recognition, 
exhibiting 20-fold stronger binding affinity compared to an analogous peptide bearing 
Man5GlcNAc2 at both positions. The importance of a sialylated glycan at N156/173 
was supported by a STD-NMR study. 27 Independently, Danishefsky’s group 





intended to roughly approximate the quaternary requirements of the bNAbs. 33 31 The 
peptide was glycosylated with either two Man5GlcNAc2 glycans or two 
Man3GlcNAc2 glycans (bearing four glycans total). The mimics yielded the strongest 
antigenicity results for PG9 to date, in spite of the non-optimal glycosylation pattern, 
presumably due to the incorporation of quaternary-like elements to the peptide 
antigens. The study also incorporated full-length PG9 IgGs in the SPR affinity 
studies, which, when compared to the PG9 Fab alone in the study by Wang and co-
workers, artificially enhances the observed recognition. Subsequent analysis by our 
group of the strongest binding cyclic glycopeptide (ZM strain where N160 = Man5 
and N173 = SCT), probed with PG9 whole IgG, revealed similar affinity to that 
reported by Danishefsky and co-workers, minimizing the enhancement due to 
dimerization. However, the very strong recognition of the non-optimal glycosylation 
pattern in Danishefsky’s peptides (i.e. two Man5 glycans rather than Man5/SCT) 
suggests an enhancement in recognition due dimerization, even in the absence of a 
sialylated glycan at N173.  
        A major innovation in the overall understanding of the structure and 
conformation of gp120 has been the recent successes of recombinantly expressed, 
covalently conjugated gp140 trimer (BG505 SOSIP.664) proteins. 34 Despite 
mutational modifications to the gp120/gp41 structure to introduce covalent 
attachments to maintain the trimeric structure, the well-folded BG505 SOSIP.664 
gp140 trimer has proven to be an excellent antigenic 35-37 and structural19, 38 39 mimic 
of the native viral spike. These well-folded SOSIP gp140 trimers have been tested as 





nanoparticle scaffolds.41 42 43 The gp140 trimers alone have proven to be unsuccessful 
as immunogens, 40 however, the VLP-scaffolded gp140 immunogens have shown 
great promise as a potential path toward a successful anti-HIV-1 vaccine. One of the 
major limitations to the design, however, is the presentation of multiple non-natural 
immunodominant epitopes that can direct the host immune response toward epitopes 
that do not exist in a native context. For example, the multifaceted systematic 
immunization strategy recently report by Iyer et al. is extremely encouraging, 
however, a major antigenic determinant in the study was the presence of the 
cytoplasmic tail of gp41, normally occluded in the native context within the interior 
of the virus. 43 Burton and co-workers made the first attempt to address this issue by 
the design of self-assembling nanoparticle proteins that ectopically expressed the 
trimeric V1V2 epitope of PG9 of the ZM HIV-1 strain. 42 In this comprehensive and 
very elegant study, the trimeric V1V2 domain was based on the BG505 SOSIP gp140 
trimer. The sole expression of the V1V2 epitope abrogates the issue of alternative 
immunodominant epitopes on the immunogen. A major limitation of this strategy, 
however, is the lack of control over glycosylation, as the nanoparticles were 
expressed in N-acetylglucosaminyltransferase I-negative (GN TI-/-) HEK 293S cells, 
yielding mostly Man5GlcNAc2 glycans. Although PG9 has remarkable promiscuity, 
accommodating different glycans in the N173 position, PG9 has a specific preference 
for a biantennary sialylated complex-type glycan at the N173 position. The ability to 
define the glycosylation at both sites would be a major advantage in tuning the 





with defined glycosylation in a quaternary context will potentially lead to a more 
directed response solely against the neutralizing epitope. 
             The goal of the present work is to combine successful features from the 
previous studies in a trimer-like context to measure any improvement in antigenicity. 
The study incorporated peptides that were previously demonstrated to be potent 
antigens for PG9 in a monomeric context. The quaternary mimicry is achieved 
through the multi-valent presentation of V1V2 peptide antigens, which, when 
presented to PG9, roughly approximates quaternary structure. The use of peptides 
allows selective control over tuning the pattern of glycosylation, and represents an 
alternative strategy towards a quaternary-like HIV-1 immunogen to the recombinant 
approaches previously reported. 
 
4.2 Results and Discussion 
 
           The crystal structure of PG9 in complex with the ectopically expressed 
monomeric V1V2 region revealed a Greek key motif with the epitope consisting of a 
short segment centered at the N160 position. Two glycans critical for PG9 binding are 
located on two of the strands. Our approach began with the observation, reported by 
our group and others 30-31, 44 that short, properly designed peptide mimics of the V1V2 
loop were potent antigens for PG9. We reasoned that multivalent display of manifold, 
glycan-defined, glycopeptides on an appropriate scaffold could approximate gp120 
quaternary structure. Our choice of the self-assembling virus-like particle (VLP) 
bacteriophage Qβ was informed by recent reports of its superior antigenicity and 





use of a VLP scaffold presents advantages from several angles. First, the particles are 
stable, uniform, and provide a smooth surface for highly repetitive antigen 
presentation with well-defined surface chemistry. 45 Second, the application of a 
viral-based scaffold incorporates a virus-like presentation of the antigens that differs 
from mammalian glycoprotein presentation, which helps to overcome immune 
tolerance mechanisms. Third, the encapsulation of random bacterial RNA during 
expression/self-assembly delivers an internal adjuvant that can stimulate a more 
pronounced and sustained immune response during vaccination. 
          We chose to use a minimal V1V2 peptide sequence that contained the critical 
features of the epitope, including both glycans that are critical for binding, as well as 
the cationic peptide sequence (KQKKD). The sequence chosen has been used by our 





Scheme 4.1 Synthesis of GlcNAc-containing peptides using orthogonally protected 
glycosylaminoacid building blocks. 
 
         The precursor glycopeptides that served as the building blocks for the final 
complex antigens were synthesized using microwave-assisted solid-phase peptide 
synthesis (MW-SPPS) in excellent yields (Scheme 4.1). To introduce a defined N-
glycan at a pre-determined site, selectively protected GlcNAc-moieties were installed 
at pre-determined locations on the peptide, the N160 and N173 (for the doubly 





building blocks for the antigens, one that includes only a single GlcNAc at the N160 
position, and another that includes two glycans, one at N160 and the other at N173. 
During the synthesis of the second glycopeptide containing two GlcNAc acceptor 
sites, two selectively protected building block were incorporated, with an acid-labile 
Fmoc-Asn(DEIPS3GlcNAc)-OH glycosylamino acid installed at the N160 position 
and a base-labile Fmoc-Asn-(Ac3GlcNAc)-OH glycosylamino acid installed at the 
N173 position (5). This method followed the site-selective orthogonal protection 
strategy recently reported by our group. 44 The method provided a path to selectively 
glycosylate the glycopeptide with two distinct N-glycans at pre-determined sites. An 
alkyne tag with a short (3 carbon) linker was introduced at the N-terminus of the 
glycopeptides to facilitate biorthogonal attachment to the protein scaffold. After 
global peptide deprotection and peptide release using cocktail R, the GlcNAc at 
position N160 was selectively unmasked, while the acetylated GlcNAc at N173 
remained protected. Both glycopeptides were cyclized after release from the resin. 
The glycopeptide bearing a single acetylated GlcNAc was cyclized concomitantly 
with deacetylation of the GlcNAc by treatment with 2.5% aqueous hydrazine. The 
double glycosylated glycopeptide was cyclized using a very mild method of 20% 
DMSO in water to maintain the acetyl protecting groups on the N173 position. 49 
After cyclization, the glycopeptides were appropriate substrates for endoglycosidase-
mediated transglycosylation. Given the specific substrate preferences of the 
endoglycosidase mutants, different endoglycosidase mutants were used for each 
substrate. Our group previously reported the high efficiency of the endoglycosidase D 





substrates, 30, 50 we therefore chose to use the glycosynthase EndoD-N332Q to 
catalyze the transfer of Man5GlcNAc (8) to the N160 position of the singly 
glycosylated peptide (4). We have previously shown that a cyclic glycopeptide 
bearing an acetylated GlcNAc is a poor substrate for transglycosylation catalyzed by 
EndoD-N332Q mutant. This result was supported when 6 was tested as a substrate for 
transfer of a Man5GlcNAc glycan from its oxazoline form by EndoD-N332Q to give 
compound 10. Unfortunately, EndoD-N332Q was found to be very inefficient at 
transfer, yielding <5% transglycosylation product. 
Scheme 4.2. A) Transglycosylation (Man5ox) of single GlcNAc acceptor peptide 4 at 
N160. B) Transglycosylation of orthogonally protected peptide 6. 
 
We therefore chose to use the glycosynthase EndoM-N175Q mutant to transfer 
Man5GlcNAc oxazoline to the N160 position of the doubly glycosylated peptide 6 
(Scheme 4.2B), as our previous work indicated that the acetylated GlcNAc was well 





glycopeptide bearing a single GlcNAc, lacking the second unfavorable acetylated 
GlcNAc, EndoD-N332Q was highly efficient at transferring a Man5GlcNAc 
oxazoline glycan, yielding the target glycopeptide building block 9 in excellent yield 
(Scheme 4.2A). Both the purity and identity of the V1V2 glycopeptides was 
confirmed by HPLC and LC/MS analysis (see appendix).  
Synthesis and Characterization of V1V2 Glycopeptide-Qβ Conjugates 
       In order to achieve the multivalent display of the glycopeptides that we believed 
would be required to mimic the quaternary epitope of PG9, an appropriate carrier 
needed to be selected to provide a repetitive clustered pattern that will enhance the 
immunogenicity. An ideal carrier should also contain multiple T helper cell epitopes 
to be able to induce strong IgM and IgG responses, as well as potentiate these Ab 
responses. We again turned to virus-like particles (VLPs) as synthetic PG9-epitope 
delivery platforms. VLPs are composed of subunit proteins that self-assemble into 
highly ordered (usually) icosahedral structures. VLPs offer a promising approach to 
vaccine development, as VLPs, while non-infectious to human or animal hosts, are 
highly immunogenic. The high immunogenicity of VLPs can be attributed to their 
sizes, <100 nm diameter, which promotes trafficking to lymph nodes, as well as 
uptake by antigen presenting cells (APCs), their repetitive subunit display, which 
promotes B cell recognition, and their ability to cross-link B cell receptors, promoting 
a stronger, more sustained immune response. In addition, during recombinant 
bacterial expression, VLPs package bacterial RNA within the capsid, which acts as an 
internal adjuvant for activating Toll-like receptors during immunization. In addition, 





hemocyanin (KLH), tetanus toxoid (TT), etc.) cannot achieve the highly organized 
antigen geometry that is intrinsic to VLP scaffolds. The VLP bacteriophage Qβ was 
used by Huang, X. and co-workers in a number of studies with great success as a 
carrier protein for the multivalent display of short peptide-based tumor associated 
carbohydrate antigens (TACAs). 46-48 Qβ has also been used in a number of anti-HIV 
vaccine candidates associated with reconstitution of the 2G12 epitope. 51 45 The Qβ 
particle is a self-assembling protein composed of 180-identical protein subunits (~14 
kD each). The subunits organize into an icosahedral structure that is 28 nm in 
diameter, and has excellent stability toward chemical modifications to its surface. We 
therefore chose to use the Qβ particle as scaffold for multivalent clustered display of 
the V1V2 glycopeptides.  
 






        The ligation of the alkyne-tagged glycopeptides to the Qβ capsid was achieved 
via the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction using 
biorthogonal reaction conditions similar to those described in Chapter 2. The CuAAC 
reaction is highly efficient and allowed high density loading of bulky glycopeptides 
onto a relatively small area. The decision to incorporate a highly stable covalent bond 
(i.e. the triazole linkage) between the glycopeptide and the Qβ surface was informed 
by recent reports that the covalent linkage ensures that the antigen is processed with 
Qβ and both are presented together to B cells. 52-53 Such a manner of presentation will 
ensure potent B cell stimulation by matching activated T helper cells. The Qβ particle 
14 was derivitized with azido groups following the method described in Chapter 2. 
The alkyne-modified V1V2 glycopeptides were added to the azide-bearing Qβ 16 in 
the presence of the copper catalyst, using THPTA (17) as the ligand (Scheme 4.3). In 
order to ensure high loading of the glycopeptides onto Qβ (i.e. 2-3 
glycopeptides/subunit), a large excess of alkyne-tagged glycopeptides was found to 
be necessary. When 10 equivalents of alkyne-glycopeptide was added per subunit 
(2.5 equivalents per reactive azide) the loading was excellent for compounds 18-20 
with an average of 2-3 glycopeptides per subunit. Conditions were tested with less 
alkyne-glycopeptide (5 equivalents, or 1.25 eq. per reactive azide) and loading was 
correspondingly diminished to an average of 1-2 glycopeptides per subunit. The 
excess unreacted glycopeptides could be recovered from the reaction mixture by 
HPLC. The doubly glycosylated alkyne peptide 13 proved difficult to load fully onto 





of excess alkyne-linked glycopeptides. The obstinacy toward high loading is likely a 
result of the high steric hindrance of these bulky glycopeptides bearing two large 
conformationally dynamic glycans. The reactive amines on the surface of Qβ are 
well-dispersed in a repetitive pattern, thus the glycopeptide display is expected to be 
uniformly dispersed as repetitive clusters, potentially mimicking the display of the 
trimeric PG9 epitope. The glycopeptide-Qβ conjugates were analyzed by MALDI-
TOF analysis and SDS-PAGE to assess loading. For compounds 21 and 22 with 
significant quantities of unmodified subunits, MALDI-TOF underestimated the 
glycopeptide loading. The MALDI-TOF profiles of 21 and 22 indicate the presence 
of mostly unmodified subunits, while SDS-PAGE analysis indicates significant (i.e. 
1-2 glycopeptides/subunit) loading (Figure 4.2). This apparent discrepancy is most 
likely attributable to the use of C4 ZipTips for protein purification prior to MALDI 
sample preparation. The hydrophobic (C4) stationary phase of the ZipTip most likely 
preferentially bound free subunits without glycosylation, as the large hydrophilic 
glycans have a low affinity for the hydrophobic C4 resin, thus artificially inflating the 
presence of free subunits by enrichment during purification. For glycopeptide-Qβ 
conjugates with no significant portion of unmodified subunits, only subunits with 
glycosylation were present, yielding a profile that is much more consistent with the 















         In order to assess the ability of PG9 to interact with the glycopeptide-conjugates 
as well as estimate the enhancement in binding affinity due to multivalent display, a 
conventional ELISA format was used. As a control, monomeric gp120 from clade M, 
strain M.CON-S (gp120M.CON-S) was used. PG9 can only bind to monomeric gp120 
from a select number of strains, as the binding affinity is frequently too low outside of 
the quaternary context. The glycopeptide conjugate antigens were immobilized on the 
plate and probed by a serial dilution of PG9. As a comparison, the monovalent 







Figure 4.3. Conventional ELISA binding of V1V2 antigens to apex-directed PG9 
bNAb. LL = low-loading (1-2 peptides/subunit); HL = high-loading (2-3 
peptides/subunit). 
 
       The antigenicity of the conjugates was found to be highly dependent upon 
glycosylation, as protein conjugates bearing GlcNAc (either one or two) peptides 
alone yielded no recognition by PG9 (see Figure 4.3), whereas the addition of a single 
Man5GlcNAc2 glycan substantially increased the binding affinity. The results suggest 
that the peptide component of the epitope alone, containing the cationic KQKKD 
sequence, is insufficient for significant binding affinity by PG9, even in a multivalent 
context. The finding is in agreement with the lack of affinity observed between PG9 
and monovalent peptides containing GlcNAc alone previously reported by our group 
and others. 30-31, 44 Clearly the epitope requires two or more components (i.e. cationic 
peptide sequence and one or more critical glycans), and even the presentation of 
multiple cationic peptide sequences in close proximity is not sufficient to produce 
high avidity binding in the absence of a glycan component. The addition of a single 
Man5GlcNAc2 glycan (construct 20) was sufficient to significantly increase the 
binding affinity. Of note, the binding affinity of compound 20 for PG9 was 
significantly higher than for monomeric gp120M.CON-S monomer, suggesting that the 
multivalent display provides enhanced binding, even in the absence of a second 
glycan at N173, when compared to monomeric gp120. In contrast, the monovalent 
glycopeptide 9, bearing a single Man5GlcNAc2 glycan displayed significantly lower 





display produced a ~18-fold enhancement compared to the monovalent peptide. 
Likewise, compound 21, bearing two N-glycans, exhibited a similar enhancement in 
binding affinity, due to multivalent display, for the glycopeptide conjugate, versus the 
monovalent doubly glycosylated glycopeptide 13 producing a ~4-fold enhancement 
due to multivalency. As expected, the double glycosylated monovalent peptide (13) 
displayed higher binding affinity for PG9 than the corresponding singly glycosylated 
monovalent peptide (9). The lower affinity binding of 21 compared to 20 (~3-fold 
lower) with PG9 is striking as it is anticipated that the addition of a sialylated glycan 
at the N173 position should enhance binding. The lower binding affinity suggests that 
proper reconstitution of the quaternary PG9 epitope requires dense peptide loading 
onto the VLP surface. The loading of compound 21 (1-2 glycopeptides/subunit) is 
low compared to high-loading compound 20 (2-3 glycopeptides/subunit), and in spite 
of the sub-optimal glycosylation pattern, the higher glycopeptide loading is enough to 
significantly enhance recognition by PG9. In order to confirm that high-loading was 
critical for optimal PG9 binding, a low-loading glycopeptide-Qβ conjugate bearing 
the V1V2 peptide with a single Man5GlcNAc2 glycan at N160 was prepared. Low 
glycopeptide loading was achieved by reducing the quantity of alkyne-tagged V1V2 
glycopeptide added to the CuAAC reaction to 5 equivalents. The low-loading 
glycopeptide-Qβ conjugate 22 exhibited ~4-fold reduced binding affinity for PG9 
compared to the high-loading analog (20). Notably, the low-loading conjugate 22 also 
bound PG9 with reduced affinity compared to the double-glycosylated-Qβ conjugate 





the superior binding affinity of compound 21 can be attributed to the presence of a 




         Recent innovations in the knowledge of trimeric gp120 epitope presentation 
have propelled the field of HIV-1 vaccine design forward and have emphasized the 
significance of quaternary structure in the proper orientation of bNAb epitopes on 
gp120. The recent report of low-level induction of neutralizing Abs by native-like 
envelope trimers 40 suggests that soluble trimers alone are not sufficient as 
immunogens and other factors, including proper multivalent display of bNAb 
epitopes, may be required to stimulate the type of response needed for an effective 
immunogen. Similarly, the multivalent display of stabilized gp120-like trimers on a 
nanoparticle scaffold was insufficient as both an antigen and immunogen to target the 
type of responses necessary for an effective vaccine. One promising approach is the 
multivalent display of specific bNAb epitopes. The display of the epitopes alone, 
outside of the context of gp120, can potentially direct the response toward induction 
of bNAbs, and prevent the dilution of the humoral response by the presentation of 
multiple antigenic regions, as on gp140. In this study, we sought to determine the 
effect of multivalent display on a VLP scaffold on recognition by PG9 to determine 
the ability to reconstitute the trimeric quaternary PG9 epitope using strategically 
designed glycopeptides. The use of glycopeptides gave us control over the specific 





antigenicity. Our results clearly indicate the ability of multivalent glycopeptide 
clustering to mimic the quaternary context of the V1V2 loops on gp120; indicating 
that the level of glycopeptide loading was directly connected to reconstitution of the 
PG9 epitope. In summary, the rational design and antigenic profiling of these V1V2 
trimer-like glycopeptide clusters on a VLP scaffold clearly indicate the importance of 
multivalent display, and merit a detailed investigation into the immunogenic 
properties of these conjugates as potential vaccine candidates. 
4.4 Experimental  
 
General Procedures. Analytical reverse-phase HPLC was performed on a Waters 
Alliance® e2695 HPLC system equipped with a dual absorbance 2489 UV/Vis 
detector. Separations were performed using a C18 column (either Waters XBridge® 
Shield, 4.6 X 250 mm, 3.5 μm; or Thermo Scientific Hypersil Gold®, 4.6 X 250 mm, 
3 μm) at a flow rate of 0.5 mL/min. The column was eluted using a linear gradient of 
either 5-25% MeCN (Waters) in 30 min or 5-50% MeCN in 30 min (Thermo) with 
both solvents containing 0.1% TFA. ESI-MS spectra were obtained using either a 
Waters SQ Detector 2 single quadrupole mass spectrometer, or a ThermoFisher Q 
Exactive LC/MS orbitrap mass spectrometer. MALDI-TOF analysis was performed 
using a Bruker UltrafleXtreme (UTX) mass spectrometer with TOF/TOF detection. 
Preparative RP-HPLC was performed on a Waters 600 HPLC system equipped with a 
dual absorbance UV detector using a C18 column (Waters XBridge, Prep Shield, 10 
X 250 mm, 5 μm) at a flow-rate of 4 mL/min. The column was eluted using a linear 
gradient of 15-25% MeCN containing 0.1% TFA over 30 min. Expression and 





oxazolines (8 and 12) were obtained using the method described previously by our 
group. 30, 54 PG9 and monomeric gp120MCON.S were both obtained from the National 
Institutes of Health (NIH) through the AIDS Reagent Program. 
General CuAAC Reaction Conditions 
        Synthesis of glycopeptide-Qβ conjugates (18-21) was achieved using the 
CuAAC click reaction, with conditions similar to those reported by M.G. Finn and 
co-workers. 46 All solvents were degassed before use. In general, the following 
reagents were combined in the following order, 14 μL 500 mM phosphate buffer, pH 
7.0 (final 80 mM), 50 μg 16 (from 7 mg/mL stock), alkyne-tagged glycopeptides (6-
7, 9, 13) [10 eq./subunit, approximately 2.5 eq./reactive azide]. Pre-mixed Cu-
THPTA solution (CuSO4, 50 mM in water [3.4 eq.] + THPTA ligand (17) 50 mM in 
water, 5-fold excess compared to Cu), aminoguanidine (100 mM in water, 100 eq. 
compared to 16), and sodium ascorbate (100 mM in water, 100 eq. compared to 16). 
After the addition of sodium ascorbate, the reaction tube was flushed with argon and 
sealed. The mixture was shaken at 37°C overnight. Compound 22 was synthesized by 
a similar method, however, 5 eq./subunit (1.25 eq./reactive azide) of 9 was added to 
achieve low-loading. The reaction was quenched by the addition of 500 mM EDTA 
(10 mM final). Purification of the glycopeptide-Qβ conjugates was performed by 
centrifugal filtration against PBS.  
Peptide Synthesis. Peptide synthesis was performed under microwave-enhanced 
conditions using a CEM Liberty Blue microwave-assisted peptide synthesizer. 
Peptide synthesis was based on Fmoc chemistry, using Fmoc-PAL-PEG-PS resin (18 





of both Fmoc-protected amino acids and TBTU, and a 12-fold excess of DIPEA (in 
NMP). The couplings were performed at 45°C for 20 min. The selectively protected 
glycosylamino acid building blocks ((DEIPS3GlcNAc)-Asn-OH and (Ac3GlcNAc)-
Asn-OH) were introduced at pre-determined sites. The selectively protected 
glycosylamino acid building blocks were synthesized following methods recently 
reported by our group. 44 Fmoc deblocking was performed in 20% piperidine in DMF 
containing 0.1 M HOBt. After synthesis, the resin was washed with DMF (3x) and 
DCM (3x), dried, and then coupled with 5-alkynoic acid (3 eq.) in DMF using TBTU 
(3 eq.) and DIPEA (6 eq.) at RT. The resin was again washed with DMF/DCM and 
global peptide cleavage was performed using cocktail R 
(TFA/Thioanisole/Ethanedithiol/Anisole [90/5/3/2]) for 2 h. The peptide was 
separated from the resin by filtration and the peptide precipitated onto cold (-20°C) 
diethyl ether. The crude peptide was dried and dissolved in glacial acetic acid, 
followed by lyophilization. The doubly, differentially glycosylated peptide (5) was 
cyclized in 20% DMSO (aq.) at RT. The singly glycosylated peptide (6) was 
simultaneously cyclized and de-O-acetylated at the GlcNAc by treatment with a 2.5% 
hydrazine (aq.) solution at RT. All crude peptides were purified on preparative RP-
HPLC to afford the purified glycopeptides. 
Synthesis of cyclic peptide 6, bearing a single GlcNAc at Asn160. The precursor 
resin (0.1 mmol) was cleaved using cocktail R (supra vide). The crude, acyclic, 
released peptide was treated with an aqueous solution of 2.5% hydrazine (final 
peptide concentration = 2 mg/mL) at RT for 2h. After complete de-O-acetylation and 





glacial acetic acid. The crude material was purified by preparative RP-HPLC, 
yielding the target peptide 6 as a white powder (147.31 mg, 48% overall yield). ESI-
MS: Calcd. M = 3039.22; found (m/z): 608.92 [M + 5 H]5+, 760.84 [M + 4 H]4+, 
1014.44 [M + 3 H]3+, 1520.57 [M + 2 H]2+ Deconvolution mass: 3037.4. RP-HPLC 
retention time, tR = 18.06 min. 
Synthesis of cyclic peptide 5, bearing a GlcNAc at Asn160 and an acetyl-
protected GlcNAc at Asn173. The precursor resin (0.1 mmol) was cleaved using 
cocktail R (supra vide). The crude, acyclic released peptide was cyclized using 20% 
DMSO (aq.) (2 mg/mL final peptide concentration) at RT overnight with shaking. 
The crude reaction mixture was lyophilized and purified by preparative RP-HPLC 
yielding glycopeptide 5 as a white powder (129.23 mg, 38% overall yield). ESI-MS: 
Calcd. M = 3369.35; found (m/z): 674.72 [M + 5 H]5+, 843.18 [M + 4 H]4+, 1123.87 
[M + 3 H]3+, 1685.30 [M + 2 H]2+. Deconvolution mass: 3369.4. RP-HPLC retention 
time, tR = 29.58 min. 
Synthesis of glycopeptide 7, bearing a GlcNAc at Asn160 and a GlcNAc at 
Asn173. Glycopeptide 5 (50 mg, 14.8 μmol) was treated with an aqueous mixture of 
2.5% hydrazine (final peptide concentration = 2 mg/mL) at RT for 1 h. The reaction 
was quenched by the addition of glacial acetic acid, and the crude mixture was 
purified by preparative RP-HPLC yielding glycopeptide 7 as a white powder (27.41 
mg, 57%). ESI-MS: Calcd. M = 3242.32; found (m/z): 649.29 [M + 5 H]5+, 811.36 
[M + 4 H]4+, 1081.50 [M + 3 H]3+, 1621.73 [M + 2 H]2+. Deconvolution mass: 
3241.0. RP-HPLC retention time, tR = 16.96 min. 






Synthesis of glycopeptide 9, bearing a single Man5GlcNAc2 glycan at Asn160. 
Glycopeptide 6 (4 mg, 1.32 μmol) was incubated with excess Man5-oxazoline (8.02 
mg, 7.92 μmol) at RT in the presence of EndoD-N332Q (40 ng/μL final) in phosphate 
buffer (80 mM, pH 7.2, 200 μL). After completion of the enzymatic reaction after 1 h, 
as indicated by RP-HPLC analysis, the reaction was quenched by addition of 0.1% 
TFA (aq.). The product was purified by preparative RP-HPLC to give glycopeptide 9 
as a white powder (4.82 mg, 90%). ESI-MS: Calcd. M = 4052.56; found (m/z): 
811.37 [M + 5 H]5+, 1014.13 [M + 4 H]4+, 1351.71 [M + 3 H]3+ Deconvolution mass: 
4051.8. RP-HPLC retention time, tR = 13.53 min.  
Synthesis of glycopeptide 10, bearing a Man5GlcNAc2 glycan at Asn160 and an 
acetylated GlcNAc at Asn173. Glycopeptide 5 (5 mg, 1.48 µmol) and Man5-
oxazoline (12.03 mg, 11.87 μmol) were incubated at RT with EndoM-N375Q (0.2 
µg/μL) in phosphate buffer (80 mM, pH 7.2, 200 μL). After completion of the 
transglycosylation reaction in 30 min (RP-HPLC monitoring), the reaction was 
quenched by the addition of 0.1% TFA (aq.). The product was purified by preparative 
RP-HPLC yielding glycopeptide 10 as a white powder (5.52 mg, 84%). ESI-MS: 
Calcd. M = 4380.69; found (m/z): 877.17 [M + 5 H]5+, 1096.44 [M + 4 H]4+, 1461.58 
[M + 3 H]3+. Deconvolution mass: 4380.8. RP-HPLC retention time, tR = 29.58 min. 
Synthesis of glycopeptide 11 bearing a Man5GlcNAc2 glycan at Asn160 and a 
GlcNAc at Asn173. Glycopeptide 10 (5.5 mg, 1.26 μmol) was treated with aqueous 
2.5% hydrazine to remove the O-acetyl protecting groups (final concentration = 2 
mg/mL) at RT. The reaction mixture was neutralized by the addition of glacial acetic 





glycopeptide 11 as a white powder (3 mg, 56%). ESI-MS: Calcd. M = 4254.66; found 
(m/z): 851.96 [M + 5 H]5+, 1064.96 [M + 4 H]4+, 1419.92 [M + 3 H]3+. Deconvolution 
mass: 4254.7. RP-HPLC retention time, tR = 28.32 min. 
Synthesis of glycopeptide 13 bearing a Man5GlcNAc2 glycan at Asn160 and a 
sialylated complex-type glycan (SCT) at Asn173. Glycopeptide 11 was dissolved in 
phosphate buffer (80 mM, pH 7.2, 150 μL) with SCT-oxazoline (8.5 mg, 4.23 μmol) 
in the presence of EndoM-N375Q (0.2 μg/μL) at RT. After completion of the reaction 
as determined by RP-HPLC, the enzymatic reaction was quenched by the addition of 
0.1% TFA (aq.). The product was purified by preparative RP-HPLC, yielding the 
target glycopeptide 13 as a white powder (3.1 mg, 70%). ESI-MS: Calcd. M = 
6256.35; found (m/z): 1252.29 [M + 5 H]5+, 1565.41 [M + 4 H]4+. Deconvolution 
mass: 6257.0. RP-HPLC retention time tR = 24.68 min. 
Enzyme-linked immunosorbant assay (ELISA) 
Each well of a high binding Ultra Cruz 96-well assay plate (Santa Cruz Biotech.) was 
first coated with 100 μL PBS containing the V1V2 antigens (5 μg/mL). The plates 
were incubated overnight at 4°C. The plate was then washed three times with 
PBS/0.05% Tween-20 (PBS-T), followed by the addition of 100 μL 3% (w/v%) BSA 
in PBS to each well. The plate was incubated at RT for 1 h. The plate was again 
washed with PBS-T (3x). Next, PG9 was diluted in blocking buffer (PBS/0.05% 
Tween-20/1% (w/v %) BSA [PBS-BT]) to a maximum concentration of 2 mg/mL, 
followed by a 2-fold dilution series. For each PG9 antibody dilution, a total of 100 μL 
was added to the appropriate wells. The plate was incubated with PG9 for 2 h at RT 





(AP)-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch 
Laboratory) was made in PBS-BT, with 100 μL of this diluted secondary antibody 
added to each well. The plates were incubated with the secondary antibody for 1 h at 
RT then washed with PBS-T (3x). Finally, the wells were developed with 50 μL p-
nitrophenyl phosphate liquid substrate system (Sigma) for 5 min at RT before 
quenching the reaction with 30 μL of 3 M NaOH. The optical density was then 
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Chapter 5:  Chemoenzymatic synthesis of diverse high-mannose 
N-glycan library and related neoglycoproteins through top-






           Among the three major classes of asparagine-linked (N-linked) glycans, high-
mannose (oligomannose) glycans contribute to the glycome in remarkably diverse 
and important roles, being implicated in such disparate functions as mannose binding 
protein interactions, HIV-related immunogenicity (via DC-SIGN, 2G12, etc.), 
neuronal cellular outgrowth, serum clearance rates of human IgG, etc. In particular, 
the well-known enrichment of oligomannose glycans on gp120 presents an interesting 
opportunity for vaccine design. Dense oligomannose glycan clusters are not common 
in mammalian systems 1 and their extensive presence on gp120 represents a significa-
nt aberration in the glycosylation pattern when compared to host glycoproteins. The 
incorporation of predominantly oligomannose glycans within the glycan shield is a 
result of the enormous level of glycosylation that characterizes gp120. The dense 
glycosylation prevents access by host glycosylation machinery, stalling the glycan 
processing pathway, and resulting in significant levels of underprocessed glycans. 2-3 





protomer interface), higher levels of oligomannose glycans are observed. 4-5 The 
preponderance of oligomannose glycans are critical both for gp120 structure and 
function. There are both long-range and short-range glycan stabilization effects that 
have been observed, and any perturbation results in a redistribution of 
Man9GlcNAc2/Man8GlcNAc2 glycans within the glycan shield. 
3 In addition, 
perturbations in the infectivity of the virus have been observed upon loss of 
glycosylation sites at N262, N386, and N392. 6 7-8 Although HIV uses deletion of 
potential N-glycosylation sites (PNGS) as a means of escape from immunological 
recognition, the virus usually compensates for the loss of glycans by the addition of 
glycans at other sites, thereby maintaining a relatively constant glycosylation pattern 
within the glycan shield. 9 Many bNAbs have been shown to bind promiscuously with 
gp120 and are able to accommodate the shifting PNGSs, as the glycans are usually 
spatially conserved. 10 Many of the most promising bNAbs described to-date 
incorporate oligomannose glycans as a key component of their neutralizing epitope. 11  
Finally, the interaction between HIV virions and dendritic cells homozygous for 
SIGN expression (i.e. DC-SIGN) is mediated by oligomannose glycans on gp120. 12 
The mannose-binding proteins on DC-SIGN bind to the virions at the infection site 
and shuttle the active virus to the CD4+ T cell-rich lymphatic tissue, facilitating HIV 
infection. 13 The reliance of HIV on N-glycans for both immune evasion and 
infectivity creates a weak point in the HIV armor that can be exploited by vaccine 
design that incorporates glycan epitopes. Targeting proteins (NAbs and others) that 
bind to oligomannose glycans on gp120 could provide a template for vaccine design. 





        Despite the significance of oligomannose glycans in mediating HIV infection 
there is a conspicuous lack of access to the intermediate oligomannose isoforms, 
creating a major limitation in probing the exact glycan preferences of the 
immunological participants. Facile access to defined individual oligomannose 
isoforms (i.e. an oligomannose N-glycan library) would represent a major 
advancement in facilitating our understanding of the specific functions of these 
glycans in the corresponding biological processes. There have been a number of 
previous studies toward the development of a oligomannose N-glycan library, 
primarily utilizing a purely synthetic approach. An elegant solution to this problem 
was the development of a top-down chemoenzymatic strategy for the synthesis of a 
complete oligomannose N-glycan library including all possible regioisomers, recently 
reported by Ito et al. 17 18 A limitation of this method is the scale, as well as the 
inaccessibility and time required for the synthesis of each component. The primary 
purpose of this work is the development of a chemoenzymatic method that allows 
facile access to a complete oligomannose library derived from natural sources 
consisting of Man9GlcNAc2-Asn down to the smallest constituent member 
Man1GlcNAc2-Asn and including all intermediate glycans from Man8GlcNAc2-Asn 
to Man2GlcNAc2-Asn. Such a library of defined oligomannose glycans could be used 
to reconstitute bNAb epitopes and selectively incorporate the specific oligomannose 
glycan that is optimal for the gp120-NAb interaction, together with many other 
applications that will facilitate our understanding of HIV-host interactions. In 
addition, the conjugation of defined oligomannose glycans to a carrier protein will 





mannose-reactive proteins, with specific mannose-preferences, that could be used as a 
template for vaccine design. We here report the top-down chemoenzymatic synthesis 
of a complete oligomannose library, as well as the synthesis of oligomannose-protein 
conjugates. The associated binding studies demonstrate the utility of the reported 
method.   
 
5.2 Results and Discussion 
 
       In the construction of the oligomannose library, speed and efficiency were of 
paramount importance. Given the rigor and time consuming nature of synthetic 
carbohydrate chemistry, we opted to obtain all necessary precursors from natural 
sources; chemoenzymatically modifying the precursors as needed. For the 
construction of the complete library, two precursors are critical starting materials, 
including Man9GlcNAc2-Asn (M9), for the construction of glycans Man9-4GlcNAc2-
Asn, and sialylated complex-type glycan (SCT), for glycans Man3-1GlcNAc2-Asn. 
Two natural sources were identified for isolation of the precursors. The plant lectin 
soybean agglutinin (SBA) is well-characterized as a source for Man9GlcNAc2-Asn 
and has been used extensively by our group and others. 19-21 Hen egg yolk is known to 
contain a myriad of useful glycoproteins and glycopeptides, in particular here, we 
isolated SCT-Asn from sialylated glycopeptide (SGP) obtained from hen egg yolk.  
       Each of the precursors, M9 and SCT-Asn, were released from the associated 
protein via exhaustive proteolytic digestion. SBA was first digested to peptidic 
fragments using proteolytic digestion with pepsin from procine gut mucosa that 





peptides were more easily digested with pronase down to the corresponding 
glycosylamino acid than starting with the parent protein. After release, the precursor 
glycan was purified by size exclusion chromatography and the oligosaccharide-Asn 
rich fractions were tagged with a 9-fluorenylmethyl (Fmoc) chemical handle to 
facilitate further purification as well as downstream isomer separation following a 
strategy similar to that reported by Kajihara et al. 22 Fmoc was selected due to its ease 
of attachment/removal, its excellent UV-activity, and high degree of hydrophobicity, 
which affords better differentiation of individual glycans in the context of high-








Scheme 5.1 Top-down chemoenzymatic synthesis starting from Man9GlcNAc2Asn 
yields oligomannose glycans Man4-9GlcNAc2Asn-Fmoc. 
 





         In order to facilitate the chemoenzymatic construction of a functional 
oligomannose library, a variety of specific exoglycosidase enzymes were required. A 
major challenge in the synthesis of the Man5-9GlcNAc2Asn-Fmoc (2-6) isoforms is 
the presence of four α1, 2-Man-Man linkages. These linkages are chemically 
indistinguishable by the bacterial human gut symbiont enzyme α1, 2-mannosidase 
(Bacteroides Thetaiotaomicron) reported by Davies et al., 23  although the enzyme 
appears to have specific preferences based on substrate accessibility as dictated by the 
steric demands. Analysis of the mannosidase digestion by high-performance anion 
exchange chromatography with pulsed amperometric detection (HPAEC-PAD) 
revealed the presence of two regioisomers each for Man6, Man7, and 
Man8GlcNAc2Asn-Fmoc (Figure 5.1) despite the possibility of three regioisomers 
each for Man8 and Man6, and four isomers possible for Man7 (Scheme 5.1). The 
results of the HPAEC-PAD analysis demonstrate a clear preference by the enzyme for 
particular arms of each oligomannose glycan. In an uncontrolled reaction, all four α1, 
2-Man linkages will be hydrolyzed, yielding Man5GlcNAc2 as the sole product. We 
sought to capture the intermediate oligomannose glycans by controlling the enzyme 
concentration and carefully monitoring the progress of reaction. We discovered that at 
very low enzyme concentrations (i.e. 2 ng/mL), the intermediate HM-glycans Man8-
6GlcNAc2 could be captured yielding a mixture of glycans particularly enriched with 
the intermediate glycans Man6-8 (Figure 5.1).  Man4GlcNAc2Asn-Fmoc (7) was 
selectively obtained from Man5GlcNAc2Asn-Fmoc (6) by exploiting the preference of 





linear α1, 3-mannose, while removal of the branched α1, 6-mannose proceeded 











Figure 5.1 A) Separation of oligomannose glycans 2-6 was well resolved via 2D-
HPLC. B) HPAEC-PAD analysis of Man5-9GlcNAc2Asn reveals the formation of two 
regioisomers each for Man6, Man7, and Man8GlcNAc2Asn. 
 
        The construction of the pauci-mannose glycan library required the use of more 
diverse exoglycosidase enzymes including α2-4,6,8-neuraminidase, β1,4-
galactosidase, β-N-acetyl-glucosaminidase, α1,2,3-mannosidase, and α1,6-
mannosidase (Scheme 5.2). Digestion of the SCT glycan, up to the Man3 core could 
be conveniently performed as a one-pot reaction following a modified procedure from 
that reported by Huang et al. 25  The pauci-mannose glycans Man2GlcNAc2Asn-Fmoc 
(10) and Man1GlcNAc2Asn-Fmoc (11) were synthesized from Man3GlcNAc2Asn-
Fmoc (9) using α1-2, 3-mannosidase and α1, 6-mannosidase respectively. It should be 
noted that it was necessary for the Man2 species to contain an α1, 6-linked mannose, 
given the linear substrate requirement of α1,6-mannosidase. 24 Therefore, enzymatic 













Scheme 5.2 Digestion of sialylated complex-type glycan yields pauci-mannose 
glycans Man1-3GlcNAc2Asn-Fmoc. 
 
Oligomannose glycan separation  
     Careful 2D-HPLC was necessary for separation of both the Man5-9 glycans. The 
Fmoc-tagged glycans were first purified using reverse-phase (RP)-HPLC, followed 
by normal-phase (NP)-HPLC using an amide-bonded column. The oligomannose 
glycans were well resolved and collected as individual glycans (Figure 5.1). The 
individual oligomannose glycans were characterized by NP-HPLC and MALDI-TOF 





While analysis by NP-HPLC and MALDI established the purity and homogeneity of 
each individual glycan, HPAEC-PAD analysis revealed the presence of isomers for 
Man6-8 that could not be resolved on conventional NP-HPLC (Figure 5.1B). 
 
 
Figure 5.2 HILIC-HPLC separation of Man5-9GlcNAc2Asn-Fmoc and the associated 
regioisomers.  
       While the Man6-8 regioisomers were impossible to separate using conventional 
NP-HPLC, the regioisomers were resolved using careful hydrophilic liquid 
interaction chromatography (HILIC)-HPLC. Figure 5.2 reveals near baseline 
separation between isomers, and the isomer pattern is in agreement with the HPAEC-
PAD data. The ability to separate the isomers using HILIC-HPLC is highly 
significant as it provides access to functional quantities of very precious 
oligomannose isomers previously accessible only by chemical synthesis.  





Subsequent to the separation of the oligomannose glycans, the Fmoc tag was removed 
during a deblocking step using 20% piperidine in DMF/water. The unmasked primary 
amine was tagged using a heterobifunctional linker bearing both N-
hydroxysuccinimide and maleimide functionalities (Scheme 5.3). The maleimide 
functionalized oligomannose glycans were purified by RP-HPLC yielding defined, 
conjugatable oligomannose glycans that facilitate downstream binding studies with a 
compatibly derivitized carrier protein.  
Scheme 5.3 Deblocking the Asn amino-terminus to exchange tags with maleimide. 
  
Synthesis of oligomannose-BSA conjugates. 
        Bovine serum albumin (BSA) was chosen as the carrier protein for serum 
screening studies. BSA is an optimal carrier for this context given its well-understood 
surface chemistry and resolved antigenicity. BSA was derivitized using Traut’s 





5.4). Incubation of sulfhydryl-derivitized BSA with maleimide-tagged oligomannose 
ligands, yielded oligomannose glycan-BSA conjugates, with an average loading of 10 
oligomannose glycans per BSA carrier (Scheme 5.4). The strategy employed was 
reported previously by our group. 26-27 The oligomannose glycan loading was 
quantified using the phenol-sulfuric acid test against a monosaccharide standard 
curve. The oligomannose-BSA conjugates were purified by size-exclusion 







Scheme 5.4 Sulfhydryl functionalization of native BSA and subsequent formation of 






Glycan Microarray Serum Screening Studies 
          In order to verify the compositions of the structures as well as illustrate the 
utility of the described method, the oligomannose-BSA conjugates were tested 
against various oligomannose binding proteins in an ELISA format. The 
oligomannose-BSA conjugates were directly printed onto the microarray plate, and 
the oligomannose-binding proteins were incubated with each conjugate. The 
oligomannose-binding proteins chosen included two lectins, Narcissus 
pseudonarcissus lectin (NPA) and Galanthus nivalis lectin (GNA), as well as the 
broadly-neutralizing antibody (bNAb) 2G12, which targets the high-mannose patch 
on the envelop glycoprotein gp120 of HIV. The two lectins, NPA and GNA, are 
specific for terminal Manα1→6 moieties and Manα1,3Man/Manα1,6Man linkages 
respectively. 2G12 recognizes the terminal Manα1,2 linkages on the three arms of 
Man9. Positive controls included native gp140, which is heavily glycosylated with 
oligomannose glycans, and a tetravalent galactose scaffold bearing four Man9 glycans 
conjugated to a Keyhole lymphocyte hemocyanin (KLH) carrier [(M9)4-TH] reported 







Figure 5.3 Binding of mannose-reactive proteins 2G12, GNA, and NPA to 
oligomannose-BSA conjugates 
 
        The binding data was in agreement with the expected preferences of the 
oligomannose-binding proteins. The intensity of the 2G12 recognition of the 
oligomannose-BSA conjugates roughly corresponded to the number of Manα1,2 
linkages present. The affinity of 2G12 for the oligomannose-BSA conjugates 
decreased for conjugates bearing fewer Manα1, 2 linkages. As expected, the gp120 





conjugates, compounds 31 and 30 (M9 and M8-BSA) showed the best recognition 
(Figure 5.3). The far lower binding of the BSA conjugates as compared to the 
controls can be attributed to the mode of oligomannose glycan presentation. The 
high-mannose patch of gp120 and the tetravalent (M9)4-TH conjugate present the 
oligomannose glycans in a dense, clustered arrangement optimal for 2G12 binding. In 
the BSA conjugates, the glycan is dispersed across the face of the protein resulting in 
a lower density non-clustered presentation and decreased 2G12 recognition. The 
oligomannose-BSA conjugates with higher access to the α1, 6-linked mannose 
generally bound more strongly to NPA, with compound 27 displaying the highest 
affinity (Figure 5.3). Recognition of the BSA conjugates by GNA appeared to be 
dependent upon the accessibility of the target Manα1, 3-Man linkages. GNA had little 
affinity for compound 31 (M9-BSA), however, recognition improved as access to the 
core Manα1, 3-Man linkages became more available. It follows that the two smallest 
pauci-mannose constituents (M1 and M2) had no affinity for GNA as they both lack 
Manα1, 3-Man linkages (Figure 5.3).  
5.3 Conclusions 
 
         The method described entails a novel approach giving unprecedented access to 
preparative quantities of critical oligomannose glycan intermediates that can be used 
for functional and analytical studies. The utility of this method is emphasized by the 
epitope mapping studies, highlighting the different characteristics between the 
oligomannose glycans. This facile method introduces a powerful tool for probing the 





the library also allows the specific contribution of each individual glycan type to be 
measured, optimizing the specific oligomannose glycan chosen for functional studies. 
The ability of the mannose-binding proteins used in this study to discriminate 
between the oligomannose glycans conjugated to BSA adumbrates the use of these 
glycan-protein conjugates for identifying novel mannose-binding proteins that may be 
present in the serum of HIV infected individuals via serum screening studies. The 
identification of new mannose-binding proteins could define new epitopes on gp120, 
yielding new templates for vaccine design and expanding the options for HIV 
eradication. 
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5.5 Experimental  
 
         Untoasted soy flour was obtained from Archer-Daniel-Midlands (ADM) 
(Chicago, IL). α1-2-mannosidase was isolated from bacteroides thetaiotaomicron as 
reported. 23 Neuraminidase, α1-2,3-mannosidase, α1-6-mannosidase, and β-N-acetyl-
glucosaminidase were purchased from New England Biolabs. β1-4-galactosidase was 
purchased from Sigma. Reverse phase analytical high performance liquid 
chromatography was performed using a Waters Alliance e2956 HPLC system using a 
Waters XBridge C18 column (4.6 x 250 mm, 3.5 µm). Solvent A was water 





0.1% TFA. Normal phase HPLC was performed with a YMC Amide-bonding NH2 
column (4.6 x 250 mm, 3.5 µm). Preparative HPLC was performed using a Waters 
(600e) HPLC system. The RP preparative column used was a Waters XBridge Shield 
C18 column. HILIC-HPLC was performed using a Waters BEH Glycan column (4.6 
x 250 mm, 3 µm), with 100 mM ammonium formate (pH 4.6) [solvent A] and 
acetonitrile (solvent B). A linear gradient was used for HILIC-HPLC from 
22→44%A in 80 min. Electrospray ionization mass spectrometry was performed 
using a Thermo Q Exactive LC/MS. Matrix-assisted laser desorption ionization with 
time-of-flight detection was performed using a Bruker UltrafleXtreme MALDI 
TOF/TOF Mass Spectrometer with a dihydroxybenzoic acid/dimethylamide 
(DHB/DMA) matrix. High-performance anion-exchange chromatography with 
pulsed-amperometric detection (HPAEC-PAD) was performed using a Dionex 9000 
system equipped with a Carbopac PA200 anion-exchange column (Thermo). Fast 
Protein Liquid Chromatography (FPLC) was performed using a General Electric (GE) 
Akta Explorer equipped with a GE Sephadex G-25 column. 
 
Isolation of SBA from Untoasted Soy Flour and Subsequent Man9GlcNAc2Asn 
Release and Fmoc Labelling.  
Man9GlcNAc2Asn was prepared by enzymatic digestion of soybean agglutinin (SBA) 
and subsequent size-exclusion chromatographic purification. Crude SBA was 
obtained from untoasted soy flour following a modified method from that reported by 
our group and others. 19 16 Briefly, 0.8 kg untoasted soy flour was suspended in 4 L 





adjusted to 4.6 using 2 M hydrogen chloride, and vigorously stirred at 4°C for 2 hrs. 
The suspension was centrifuged at 8,000 RPM for 20 min, and to the supernatant was 
added 30% (NH4)2SO3 and the solution was stirred for 2 hrs at 4°C. Again the 
solution was centrifuged (8,000 RPM for 20 min), and ammonium sulfate was added 
to the supernatant to a final concentration of 60%. The solution was stirred vigorously 
overnight (RT) and centrifuged at 8,500 RPM for 30 min. The pellet was dissolved in 
400 mL water, and the crude SBA was dialyzed against 0.2% saline with 3 changes of 
dialysis solution (2 hr for each). The SBA was dialyzed against running water 
overnight. The dialyzed protein was centrifuged (8,000 RPM/20 min) and the pH of 
the supernatant was adjusted to 2. Pepsin from porcine gut mucosa was added (1:20 
protein to enzyme as assessed by Nanodrop estimation) and the solution was shaken 
at 37°C overnight. After determination of the complete protein digestion (Bradford 
Assay), the pH of the solution was adjusted to pH 8 with 2 M NaOH. The solvent was 
reduced in vacuo to 60 mL, and CaCl2 and NaN3 was added to final concentrations of 
5 mM and 0.02% respectively. Pronase was added (1:50 protein to enzyme ratio) and 
the solution was incubated overnight at 55°C. The release of Man9GlcNAc2Asn was 
monitored by high-performance anion exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD). The enzyme digestion was lyophilized and 
purified by size-exclusion chromatography (Sephadex G50) with monitoring by the 
phenol-sulfuric acid test (for carbohydrates). The carbohydrate positive fractions were 
pooled and lyophilized to yield semi-pure Man9GlcNAc2Asn. Semi-pure 
Man9GlcNAc2Asn was further purified by C18 solid phase extraction (SPE) eluted by 





7.4) was added Fmoc-OSu (20 mg, 59.29 μmol) dissolved in dimethylformamide 
(200 μL).  The solution was shaken at RT for 4 hrs, and the target was precipitated by 
the addition of a 10-fold excess of cold (-20°C) acetone. The crude product 2 was 
dissolved in water and purified by RP-HPLC (0-90% B in 30 min, tR = 16 min), 
yielding the target compound 2 (19.6 mg, 88% yield). MALDI-TOF: m/z: [M + H] = 
2221.17 (Calculated = 2220.14).  
 
Isolation of sialylated glycopeptide (SGP) from hen egg yolk, and subsequent 
sialylated complex-type (SCT) glycan release and Fmoc labelling (8). 
SGP was isolated from hen egg yolk using a method previously reported by our 
group. 28 The purified SGP was dissolved in 80 mM Tris buffer (pH 8.0) containing 5 
mM CaCl2 and pronase was added (final concentration 0.1 mg/mL), and the digestion 
was incubated at 55°C overnight. The released SCT-Asn glycan was purified by G50 
SEC, monitored by the phenol-sulfuric acid test. The carbohydrate positive fractions 
were pooled and lyophilized. Semi-pure SCT-Asn was further purified by C18 solid 
phase extraction (SPE) eluted by water. To a solution of SCT-Asn (30 mg, 12.8 
μmol) in PBS (300 μL, pH 7.4) (pH adjusted to 7.5 with 0.5 M NaOH) was added 
Fmoc-OSu (30 mg, 88.93 μmol) dissolved in dimethylformamide (300 μL).  The 
solution was shaken at RT for 4 hrs, and the target was precipitated by the addition of 
a 10-fold excess of cold (-20°C) acetone. The crude product 8 was dissolved in water 
and purified by RP-HPLC (0-90% B in 30 min, tR = 15 min), yielding the target 
compound 8 (29.1 mg, 89% yield). ESI-Orbitrap: m/z: [M + 3H] =  [M + 2H] = [M + 





Synthesis of high-mannose glycans (3-6) from Man9GlcNAc2 (2) precursor 
To a 2 mM solution of 2 (27 mg, 12.2 μmol) in sodium citrate buffer (50 mM, pH 
5.6) containing CaCl2 (10 mM) was added α1, 2-mannosidase (final concentration = 2 
ng/µL). The solution was incubated at RT for 30 min, while monitoring by HPAEC-
PAD. The deblocked HPAEC-PAD samples were prepared by incubating 1 μL of the 
enzymatic digestion with 1 μL 0.5 NaOH at 60 °C for 5 min. After achieving optimal 
digestion, the reaction was quenched by the addition of excess 0.1% TFA. The 
mixture of oligomannose glycans was purified by RP-HPLC and the individual 
oligomannose glycans were separated by NP-HPLC, using a gradient of 22-41%B in 
40 min. The individual isomers were desalted using RP-HPLC, yielding each isomer 
in milligram quantities (2, 3 mg, 1.40 μmol, 16%; 3, 4 mg, 1.95 μmol, 21%; 4, 5 mg, 
2.64 μmol, 26%; 5, 4 mg, 2.31 μmol, 21%; 6, 3 mg, 1.91 μmol, 16%; 19 mg total 
recovered, 82% estimated yield [based on Man7]).  
Compound 3 (Man8GlcNAc2Asn-Fmoc) 
NP-HPLC: tR = 20.7 min. MALDI-TOF: m/z: [M + H] = 2057.13 (Calculated = 
2057.71). HPAEC-PAD: tR = 35.67 min. 
Compound 4 (Man7GlcNAc2Asn-Fmoc) 
NP-HPLC: tR = 19.9 min. MALDI-TOF: m/z: [M + H] = 1894.96 (Calculated = 
1895.66). HPAEC-PAD: tR = 29.4 min. 
Compound 5 (Man6GlcNAc2Asn-Fmoc) 
NP-HPLC: tR = 18.5 min. RN-MALDI-TOF: m/z: [M - H] = 1732.83 (Calculated = 
1732.59). HPAEC-PAD: tR = 22.7 min. 





NP-HPLC: tR = 17.8 min. RN-MALDI-TOF: m/z: [M - H] = 1570.80 (Calculated = 
1570.45). HPAEC-PAD: tR = 15.9 min. 
Synthesis of Man4GlcNAc2Asn-Fmoc (7) from Glycan Precursor Man5Asn-Fmoc 
(6)  
To a solution of 6 (10 mg, 6.37 μmol) in sodium citrate buffer (50 mM, pH 6.0) 
containing CaCl2 (10 mM) was added α1-2,3-mannosidase (final concentration = 1 
µg/µL). The enzymatic reaction mixture was incubated at 37°C overnight. The 
complete conversion of Man5 to Man4 was monitored by HPAEC-PAD and ESI-MS. 
The product was purified by RP-HPLC (0-90%B, tR = 16 min), yielding the target 
compound 7 (8.1 mg, 90% yield). MALDI-TOF: m/z: [M +H] = 1409.67 (Calcd. = 
1409.54). 
Synthesis of pauci-mannose library (11-13) 
The starting material 8 (20 mg, 7.8 μmol) was digested to the largest common 
precursor 11, following a modified version of the one-pot enzymatic procedure 
reported by Huang et al. 25 Briefly, 8 (20 mg, 7.8 μmol) was dissolved in 50 mM 
sodium acetate buffer (50 mM, pH 5.5, pH adjusted with 0.5 M NaOH). 
Neuraminidase was added (60 U), after complete removal of sialic acid (determined 
by HPAEC-PAD/ESI-MS), the pH was adjusted to 4.5 with 1 M HCl and β-
galactosidase was added (32 U), the solution was incubated at 37°C overnight. After 
removal of terminal galactose, the pH was adjusted to 5.5 and β-N-Acetyl-
glucosaminidase was added (0.2 U) and the solution was again incubated overnight at 





pauci-mannose precursor 11 (9.1 mg, 89%). MALDI-TOF: m/z: [M +H] = 1247.92 
(Calcd. = 1247.17). 
Synthesis of Man2GlcNAc2-Asn-Fmoc (12) from compound 11. 
To a solution of 11 (7 mg, 5.6 μmol) in sodium citrate buffer (50 mM, pH 6.0) α1-
2,3-mannosidase was added (960 U) and the solution was incubated overnight at 
37°C. The target compound was purified by RP-HPLC yielding the target compound 
12 (6 mg, 94% yield). MALDI-TOF: m/z: [M +H] = 1085.79 (Calcd. = 1085.03). 
Synthesis of Man1GlcNAc2-Asn-Fmoc (13) from compound 12. 
To a solution of 12 (3 mg, 2.7 μmol) in sodium citrate buffer (50 mM, pH 6.0) was 
added α1-6-mannosidase (1200 U) and the solution was incubated overnight at 37°C. 
The target was purified by RP-HPLC yielding the target compound 13 (2.3 mg, 92% 
yield). ESI-MS: m/z: [M +H] = 923.10 (Calcd. = 922.89). 
 
General Procedure for Deblocking N-Terminus of Asparagine on Oligomannose 
Library 
Fmoc-tagged compounds 2-10 were dissolved in a small amount of water. Piperidine 
in DMF was added to give a final concentration of 20% in 1:9 water/DMF. The 
reaction mixture was shaken at RT for 30 minutes while monitoring by HPLC. The 
reaction mixture was neutralized with glacial acetic acid and lyophilized. The product 
was precipitated using cold 80% acetone. The white precipitate was collected, dried 
and used in the next step without further purification. 





General conditions: The individual deblocked oligomannose glycan was dissolved in 
1X PBS (final concentration = 25 mg/mL), 8 equivalents of the heterobifunctional 
linker N-ε-malemidocaproyl-oxysuccinimide ester (EMCS) dissolved in acetonitrile 
was added, giving a final acetonitrile concentration of 20%. The solution was shaken 
at RT for 2 hrs, while monitoring with RP-HPLC (0-50%B, 214/302 nm, tR = 15 
min). Once the reaction was complete, the solution was diluted with solvent A and 
purified by RP-HPLC, giving the target compound as a white powder. 
Compound 14 (Man1GlcNAc2Asn-Maleimide) 
From 13 (3 mg, 4.2 µmol), recovered yield (14): 3.2 mg, 84%. RP-HPLC: tR = 14.8 
min. MALDI-TOF: m/z: [M + H] = 894.14 (Calculated = 894.86).  
Compound 15 (Man2GlcNAc2Asn-Maleimide) 
From 12 (3 mg, 3.4 µmol), recovered yield (15): 3.0 mg, 83%. RP-HPLC: tR = 14.9 
min. MALDI-TOF: m/z: [M + H] = 1057.64 (Calculated = 1057.00).  
Compound 16 (Man3GlcNAc2Asn-Maleimide) 
From 11 (3 mg, 2.9 µmol), recovered yield (16): 3.0 mg, 86%. RP-HPLC: tR = 14.9 
min. MALDI-TOF: m/z: [M + H] = 1219.47 (Calculated = 1219.14).  
Compound 17 (Man4GlcNAc2Asn-Maleimide) 
From 7 (3 mg, 2.5 µmol), recovered yield (17): 3.1 mg, 89%. RP-HPLC: tR = 15.0 
min. MALDI-TOF: m/z: [M + Na] = 1402.12 (Calculated = 1402.26).  
Compound 18 (Man5GlcNAc2Asn-Maleimide) 
From 6 (3 mg, 2.2 µmol), recovered yield (18): 3.0 mg, 88%. RP-HPLC: tR = 15.0 
min. MALDI-TOF: m/z: [M + Na] = 1564.23 (Calculated = 1564.40).  





From 5 (3 mg, 1.9 µmol), recovered yield (19): 2.7 mg, 84%. RP-HPLC: tR = 15.1 
min. MALDI-TOF: m/z: [M + Na] = 1726.88 (Calculated = 1726.54).  
Compound 20 (Man7GlcNAc2Asn-Maleimide) 
From 4 (3 mg, 1.7 µmol), recovered yield (20): 2.9 mg, 90%. RP-HPLC: tR = 15.1 
min. MALDI-TOF: m/z: [M + Na] = 1888.79 (Calculated = 1888.68).  
Compound 21 (Man8GlcNAc2Asn-Maleimide) 
From 3 (3 mg, 1.6 µmol), recovered yield (21): 2.8 mg, 84%. RP-HPLC: tR = 15.2 
min. MALDI-TOF: m/z: [M + Na] = 2050.12 (Calculated = 2050.82).  
Compound 22 (Man9GlcNAc2Asn-Maleimide) 
From 2 (3 mg, 1.5 µmol), recovered yield (22): 2.9 mg, 88%. RP-HPLC: tR = 15.2 
min. MALDI-TOF: m/z: [M + Na] = 2212.78 (Calculated = 2212.96).  
Sulfhydryl Derivitization of Bovine Serum Albumin  
Sulfhydryl groups were installed on the surface of BSA following a procedure 
previously reported by our group.26-27 In brief, 20 mg of BSA was dissolved in 1X 
PBS containing 5 mM EDTA. 20 equivalents (5 mg) of Traut’s reagent was added, 
and the mixture was shaken at RT for 2 hrs. The derivitized protein was purified by 
FPLC (G25). The protein positive fractions (Bradford assay) were pooled and 
concentrated by a protein concentrator. The quantity of recovered protein (18 mg) 
was estimated by Nanodrop analysis. Free sulfhydryl groups loaded on the surface of 
BSA was quantified by Ellman’s reagent (9 μmol free sulfhydryl groups), against an 
L-cysteine standard curve. The sulfhydryl-containing BSA was used within hours to 





Conjugation of Maleimide-Tagged Oligomannose Glycans with Sulfhydryl-
Derivitized BSA 
Sulfhydryl-derivitized BSA (21) (4 mg, 2 μmol sulfhydryl groups) was diluted in 
phosphate buffer (20 mM, pH 7.2) containing EDTA (5 mM). Maleimide-tagged 
glycan (1 µmol) was added and the solution was shaken at RT for 3 hrs and purified 
by FPLC (G-25) using 10 mM phosphate buffer (pH 6.6). Protein positive fractions 
were pooled, and carbohydrate-loading was estimated by phenol-sulfuric acid assay, 
quantified against a mannose monosaccharide standard curve, yielding an average 
loading of 12% carbohydrate by weight (see appendix Table A 5.1).  
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Chapter 6: Expanding the N-glycan library: Chemoenzymatic 
Synthesis of a Highly-Branched Bisected Gal and GlcNAc 




         Since its discovery over thirty years ago, the human immunodeficiency virus 
(HIV) has proven to be one of the most intractable virological targets encountered. 
Multifarious aspects of HIV account for the challenge of vaccine design, including 
the high rate of mutation, owing to an error-prone reverse-transcriptase, the ability of 
the virus to remain latent for extended periods as a pro-virus, the profound rate of 
viral-tropism, allowing HIV adapt to the evolving immune system avoiding 
recognition. Also, the variability in the HIV isolates themselves, manifested as 
different clades and subtypes, has obfuscated efforts to make a universal HIV 
vaccine. 1 Moreover, the viral spike of HIV is one of the most heavily glycosylated 
proteins ever described. The extensive glycan shield is dynamic, allowing changes in 
both the type and occupancy of the potential N-glycosylation sites (PNGSs). 2 The 
formation of escape variants, together with the other evasive tactics, have been so 
successful that HIV has, to-date, largely eschewed extensive vaccine efforts. The 
surface of the HIV capsid consists of bare phospholipid, with the exception of the 
presence of the viral spike composed of the non-covalently associated homotrimers 
gp120/gp41, and several host-derived (non-antigenic) membrane-bound proteins. 3 As 





3 Each monomer of gp120 consists of two faces, the heavily-glycosylated solvent-
exposed, so-called silent face, and the trimer associated face. As the glycosylated 
solvent-exposed face is the primary feature of HIV that is a presented to the host 
immune system, nearly all efforts to target gp120 have incorporated glycans as a 
point of focus. As viruses are produced by host-cellular machinery, the HIV glycan 
shield is derived from “self-glycans” that effectively mask HIV from host-immune 
recognition. 4 The reliance of HIV on glycosylation for immune evasion creates a 
tenuous predicament for vaccine design. Targeting host-derived glycans by 
overcoming immunological tolerance mechanisms to host glycan structures has the 
potential of inducing auto-reactive Abs, creating a serious immunological challenge. 5 
The incorporation of “self-glycans” on HIV has forced efforts to be directed against 
deviations from host-glycosylation patterns. As such, many efforts have focused on 
specific features of the humoral immune system raised against specific glycan-based 
gp120 epitopes, representing aberrations in host-glycosylation patterns. Examples 
include the high-density of mainly oligomannose glycans (i.e. 2G12) and integrated 
glycan-peptide epitopes (i.e. PG and PGT-series bNAbs). An alternative strategy is to 
target unusual cryptic N-glycans that are either unique to gp120 or at least under-
represented in host-glycosylation. The presence of aberrant cryptic N-glycans on 
gp120 with a non-native presentation would presumably produce a humoral immune 
response in the form of monoclonal antibodies (mAbs). Unusual N-glycan structures 
rarely seen in host glycoproteins provide a natural point of deviation to target as a 





mAbs raised against a cryptic HIV N-glycans would be a valuable addition to the 
repertoire of anti-HIV Abs.             
         HIV gp120 glycosylation is well known to contain a paucity of highly branched 
galactose and GlcNAc terminating tri-/tetra-/penta-antennary glycans with and 
without core fucose/terminal sialylation. 6-8 As these glycans are present to a limited 
extent in host glycosylation, there is a major question regarding host tolerance 
mechanisms to these glycans in a viral context. Targeting such glycans requires a 
delicate balance between host tolerance and auto-reactivity. The use of cryptic N-
glycans as immunological targets has a virological precedent as such glycans were 
found to be humoral immune targets in severe acute respiratory syndrome corona 
virus (SARS-CoV). 9-10 Further support for the notion of targeting highly branched 
Gal terminal glycans as potential N-glycan epitopes on HIV is drawn from the report 
by Wang and co-workers that a leucoagglutinin lectin from phaseolus vulgaris (red 
kidney bean) (PHA-L), specific for terminal N-acetylgalactosamine and galactose 
glycans, was moderately cross-reactive with native HIV. 10 Indeed, previous studies 
incorporating tetra-antennary complex-type glycans have indicated a moderate degree 
of HIV-1 antigenicity, as indicated by recognition by carbohydrate specific bNAbs in 
a glycan microarray format. 11  
        The majority of N-glycosylation on gp120 is known to be oligomannose, with 
the average 25 potential N-linked glycosylation sites (PNGSs) largely occupied by 
oligomannose glycans present as a mosaic cluster. 8, 12 The overwhelming presence of 
under-processed oligomannose-type glycans is thought to be a result of the dense 





Both glycan and protein congestion contribute to limiting access by host-
glycosylation machinery, restricting the extent of glycan processing at sterically 
hindered sites. 15 The result of the limited glycan processing at highly hindered sites 
is the presence of oligomannose clusters near the protomer interface, within the 
intrinsic mannose patch (IMP), and other regions that are highly congested. 16 
Glycan/protein congestion at specific locations suggests that processed complex-type 
glycans are limited to regions that are minimally congested, resulting in an 
enrichment of complex-type glycans in defined locations. Confining complex-type 
glycans to low-congestion regions could potentially give rise to a clustered 
arrangement of complex-type glycans that are immunologically distinct from host 
glycosylation. Given that highly-branched (i.e. tetra-antennary) galactose-terminal 
glycans constitute a non-trivial component of gp120 glycosylation (~10%), these 
heavily processed glycans are likely present at only the least congested regions and 
potentially present as clusters. 8 
      The availability of defined N-glycan libraries through synthetic and 
chemoenzymatic approaches have provided essential standards and probes for MS 
analysis and glycan microarray studies of various carbohydrate binding proteins. 17-19 
20 The goal of this work was to develop an N-glycan library of highly-branched 
bisected GlcNAc-/Gal-terminal glycans on a protein scaffold for N-glycan microarray 
analysis. The strategy employed in this work was the synthesis of glycan-protein 
conjugates that incorporate various defined cryptic highly branched N-glycans that 
can be used to screen serum derived from HIV+ patients (compared to the serum of 





anti-cryptic N-glycan mAbs and provide a basis of support for targeting such glycans 
in vaccine design. The cryptic N-glycans were obtained from ovalbumin after a series 
of intensive enrichments and careful NP-HPLC isolation. The highly-branched N-
glycans were remodeled by treatment with either an exoglycosidase or 
glycosyltransferase yielding two libraries of GlcNAc or Gal-terminal N-glycans.  
6.2 Results and Discussion 
 
          A number of studies have reported synthetic routes toward the chemical 
synthesis of highly congested N-glycans. For example, Danishefsky and co-workers 
reported the synthesis of a sialylated triantennary complex-type glycan. 21 22 Wong 
and co-workers recently reported a modular synthetic strategy to produce bi-, tri-, and 
tetra-antennary complex-type glycans. 11 Similarly, Paulson’s group reported the 
synthesis of multi-sialylated glycans. 23 Boons and co-workers reported a very elegant 
synthetic strategy to chemoenzymatically construct a library of asymmetric 
multiantennary N-glycans. 24 The synthesis of a bisected pentaantennary glycan has 
also been reported in a landmark study by Unverzagt and co-workers. 25 The previous 
efforts toward the design of highly-branched complex-type glycan libraries have all 
relied on extremely difficult synthetic routes, usually performed on an analytical 
scale. In our approach to a complex-type library, we envisioned a chemoenzymatic 
strategy relying on precursor glycans obtained from a natural source; the precursor N-
glycans could then be chemoenzymatically remodeled yielding the target glycans on a 
preparative (i.e. milligram) scale. In the design of the N-glycan library, it was 





of highly branched N-glycans. The N-glycosylation pattern of hen ovalbumin (Gallus 
gallus) has been extensively studied, 26-28 and is well-known to contain bisected tri-
/tetra-/and penta-antennary glycans with and without terminal galactose at the sole N-
glycosylation site (N292). We therefore chose ovalbumin as the source for highly-
branched N-glycans. The impact of the presence of a bisected GlcNAc on biological 
recognition will presumably be negligible, as the dense presentation of terminal Gal 
and GlcNAc will likely be largely unaffected. Ovalbumin has been shown to 
incorporate a very diverse variety of N-glycans, including pauci-mannose and 
oligomannose glycans, as well as bisected complex-type glycans with two to five 
branches. In addition, there are significant amounts of hybrid-type glycans containing 
the Man4/Man5 core with the addition of a bisected GlcNAc and terminal 
GlcNAc/Gal branching (see Figure 6.1). 
 






         A major limitation of ovalbumin as a natural source for specific N-glycans is the 
extensive glycan heterogeneity. The construction of a library of highly-branched N-
glycans required the selective enrichment of target glycans by removal of non-target 
glycans.  
 
Scheme 6.1 Chemoenzymatic synthesis of a library of bisected highly-branched N-
glycans from ovalbumin. 
 
       The total N-glycans on ovalbumin were released via a two-step proteolytic 
digestion using thermolysin first, followed by pronase. The use of thermolysin (from 
geobacillus stearothermophilus) eschewed the need to denature the protein prior to 
digestion by incubating at 90°C, which unfolded the protein sufficiently to digest into 





from the glycopeptides by exhaustive pronase (from streptomyces griseus) digestion 
(Scheme 6.1). The N-glycans were purified by size-exclusion chromatography and 
solid-phase C18 extraction. The N-terminus of the asparagine of the purified glycans 
was tagged with 9-Fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu), to 
facilitate further purification as well as down-stream separation, and purified by RP-
HPLC yielding compound 1. Initial attempts to separate the N-glycans via normal-
phase HPLC were complicated by the presence of a free carboxylic acid group at the 
C-terminus of asparagine, resulting in longer retention times and the inability to 
resolve individual glycans. The C-terminus was therefore protected by N-acylation 
with methylamine forming an amide bond, after activation of the carboxylic acid by 
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) 
yielding 2. The protection of the C-terminus yielded enhanced resolution of the N-
glycans by NP-HPLC (Figure 6.2).  
Figure 6.2 Hydrophilic interaction chromatography (HILIC)-HPLC profile of 





The released N-glycan were characterized by hydrophilic interaction chromatography 
(HILIC)-HPLC and MALDI-TOF analysis, revealing a diverse number of asparagine-
linked glycans (see Figures 6.2 and 6.3).  
Figure 6.3 MALDI-TOF analysis of total released ovalbumin glycans indicates the 
predominance of oligomannose and hybrid-type glycans. 
 
A major component of the released N-glycans was comprised of oligomannose 





Figure 6.4 HILIC-HPLC analysis of endoglycosidase-cocktail enriched OVA glycans 
3. 
 
        In order to remove the dominant oligomannose glycans and enrich the lower 
quantity, highly-branched glycans, the modified N-glycan mixture was treated with 
an endoglycosidase cocktail containing EndoA (WT) and EndoD (WT). EndoA (WT) 
is selective for high-mannose glycans, and was used to cleave the prevalent Man5 and 
Man6 species. EndoD (WT) is selective for pauci-mannose glycans, and removed 
Man1-3 glycans. Endoglycosidase treatment hydrolyzed the chitobiose core, leaving 
behind GlcNAc-Asn(N-Fmoc)(C-ONMe), which was easily removed from the Fmoc 
tagged glycans by RP-HPLC. The released GlcNAc-Asn(N-Fmoc)(C-ONMe) was 
retained longer on RP-HPLC (tR = 26 min) compared to the Fmoc tagged glycans (tR 





treatment yielded enhanced access to the lower abundance glycans 3, in particular the 
highly-branched bisected glycans (Figure 6.4).  
 
Figure 6.5 HILIC-HPLC analysis of GlcNAc-terminal glycans 4. 
 
        The target bisected tri-/tetra-/penta-antennary glycans were isolated from 
bisected bi-antennary complex-type glycans, as well as bisected hybrid-type glycans 
by NP-HPLC (Figure 6.4). The target highly-branched glycans with and without low-
level galactosylation were thus isolated and used as the precursor building blocks for 
chemoenzymatic remodeling. One portion of the mixture of tri-/tetra-/penta-antennary 
glycans (3) was treated with β-galactosidase (from aspergillus oryzae) an 
exoglycosidase specific for β1,4-Gal linkages, yielding a mix of GlcNAc-terminating 
bisected tri-/tetra-/penta-antennary glycans 4 (Figure 6.5). The second portion of 





β1,4-galactosyltransferase (B4GALT) (from Neisseria meningitides) in the presence 
of uridine-diphosphate (UDP)-Gal. B4GALT is known to efficiently transfer UDP-
Gal to an appropriate acceptor. 29 The B4GALT treatment yielded a mix of Gal-
terminating bisected tri-/tetra-/penta-antennary glycans (5). The use of excess UDP-
Gal yielded nearly complete galactosylation of the branched GlcNAc, and even a 
small quantity of galactose added to the bisected GlcNAc (Figure 6.6). 
Figure 6.6 HILIC-HPLC analysis of Gal-terminal OVA glycans 5. 
 
 
Synthesis of highly-branched bisected N-glycan neoglycoproteins 
       The functional purpose of the highly-branched complex-type N-glycan library is 
to screen human serum to identify carbohydrate binding proteins that recognize 
highly-branched GlcNAc and Gal terminal glycans. Such an identification could 
potentially yield new viral epitopes that can be targeted as templates through 
antibody-based vaccine design. Proper multivalent presentation of the glycans in an 
ELISA or microarray format is critical for optimal protein-carbohydrate binding 





protein scaffold have yielded interesting and impressive screening results. 30 10, 31-32 
We therefore chose to adopt a similar strategy, beginning with the identification of an 
appropriate carrier protein. Bovine serum albumin (BSA) was chosen as the protein 
scaffold, as it is a commonly used scaffold for the multivalent presentation of ligands, 
including oligosaccharides. 33-34 BSA contains numerous chemically accessible Lys 











Scheme 6.2. Synthesis of neoglycoproteins based on highly-branched bisected 
GlcNAc/Gal-terminal N-glycans. 
 
           In order to introduce a chemically complimentary group onto BSA that would 
facilitate conjugation of the maleimide-linked sugars, BSA (8) was treated with 
Traut’s reagent, which reacted with the exposed surface lysine groups, installing free 
sulfhydryl groups, yielding compound 9. The addition of maleimide-linked N-glycans 
(6 or 7) resulted in two neoglycoproteins bearing 15% and 14% glycosylation (an 
average of ~10 glycans per BSA molecule) respectively. The presentation of the 
glycan portion of these neoglycoproteins is currently being evaluated by our 
collaborators (Dr. Denong Wang, Stanford University) by binding to a series of 
carbohydrate binding proteins. Subsequent to the evaluation, the neoglycoproteins 
will be incorporated into serum screening studies. 
6.3 Conclusion 
          The sophisticated ability of HIV to evade immune recognition necessitates the 
use of multifaceted immunological approaches to develop an effective vaccine. 
Targeting unusual glycans that may be enriched regionally on HIV Env protein 
represents a potentially lucrative approach by exploiting aberrations from host-
glycosylation. Capturing carbohydrate-reactive proteins in the serum of infected 
individuals that may be elicited by these cryptic N-glycan epitopes could yield 
valuable templates for vaccine design. The work presented here demonstrates the 
development of a successful top-down chemoenzymatic strategy towards the efficient 





combination of enzymatic modifications (both glycan extension and glycan trimming) 
with extensive 2D-HPLC separation provided access to these unusual highly-
branched glycans on a multi-milligram scale. The entire method was predicated on 
the use of robust glycosyltranferase/exoglycosidase enzymes. Conjugation of these 
highly-branched glycans to a BSA protein carrier yielded two unique antigens bearing 
GlcNAc or Gal-terminal glycans that can be used for serum screening capture of 
serum proteins that recognize these cryptic N-glycans. In summary, the top-down 
chemoenzymatic method described here provides a practical approach for the rapid 
production of highly-branched, bisected glycans with defined, non-reducing termini. 
The method described has the potential to become a general approach to introduce 
access to other unusual glycans. 
6.4 Experimental 
 
General Procedures. All chemical reagents, unless otherwise noted were purchased 
from Sigma-Aldrich. Analytical reverse-phase HPLC was performed on a Waters 
Alliance® e2695 HPLC system equipped with a dual absorbance 2489 UV/Vis 
detector. Separations were performed using a C18 column (Waters XBridge® Shield, 
4.6 X 250 mm, 3.5 μm). The column was eluted using a linear gradient of 5-25% 
MeCN containing 0.1% TFA in 30 min. Analytical normal-phase HPLC was 
performed using an amide-bonded column (YMC America, Pack-NH2, 4.6 X 250 
mm, 5 μm), using a linear gradient of 15-50%A with a flow rate of 1 mL/min, where 
solvent A = 100 mM ammonium formate (pH 4.5) and solvent B = 100% acetonitrile. 





(YMC America, Pack-NH2, 20 X 250 mm, 5 μm), using a linear gradient of 15-
50%A with a flow-rate of 12 mL/min. Analytical hydrophilic interaction 
chromatography-HPLC was performed using a HILIC analytical column (Waters, 
XBridge® BEH Glycan, 4.6 X 250 mm, 3.5 μm), using a linear gradient of 22-44%A 
with a flow rate of 1 mL/min. All HILIC-HPLC samples were prepared in 80% 
acetonitrile (solvent B) and 20% solvent A. ESI-MS spectra were obtained using a 
ThermoFisher Q Exactive LC/MS orbitrap mass spectrometer. MALDI-TOF analysis 
was performed using a Bruker UltrafleXtreme (UTX) mass spectrometer with 
TOF/TOF detection. Preparative RP-HPLC was performed on a Waters 600 HPLC 
system equipped with a dual absorbance UV detector using a C18 column (Waters 
XBridge, Prep Shield, 10 X 250 mm, 5 μm) at a flow-rate of 4 mL/min. The column 
was eluted using a linear gradient of 15-25% MeCN containing 0.1% TFA over 30 
min. Ovalbumin was obtained from Sigma-Aldrich as a crystallized powder (grade 
III). Thermolysin (geobacillus stearothermophilus) was obtained as a lyophilized 
powder from Sigma-Aldrich. Pronase (Streptomyces griseus) was obtained through 
Roche. β1,4-galactosidase (aspergillus oryzae) was obtained as a lyophilized powder 
from Sigma-Aldrich. β1,4-galactosyltransferase (B4GALT) (neisseria meningitides) 
was expressed from E. coli by Dr. Joseph Lomino. UDP-Gal was purchased through 
CalBioChem. 
Proteolytic release of N-glycans from ovalbumin 
Ovalbumin (grade III) (5 g) was dissolved in 50 mM Tris-HCl buffer (pH = 8.0), 
CaCl2 was added to a final concentration of 5 mM. Thermolysin (20 mg, 1:0.004 





overnight with periodic shaking. After complete digestion of the protein into peptides 
(as assessed by Bradford assay), the reaction was cooled to 37°C and pronase (40 mg, 
1:0.008 protein:enzyme ratio) was added. The reaction was incubated at 55°C while 
monitoring with high-performance anion-exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD). When the peaks corresponding to released 
Asn-linked glycans were highest (usu. 1-2 days), the mixture was lyophilized and 
applied to a Sephadex G-25 size-exclusion column, eluting with 0.1 M acetic acid. 
The carbohydrate positive fractions (as determined by phenol-sulfuric acid 
monitoring) were pooled and applied to a C18 solid-phase extraction column (column 
was previously washed with one-column volume MeCN, one column volume MeOH, 
and equilibrated with three column volumes of water). The carbohydrate positive 
fractions were pooled and lyophilized. The released OVA N-glycans were obtained as 
a white powder (117 mg, 78% recovery, based on 3% OVA glycosylation weight).  
Derivitization of Asn N-terminus with a lipophilic Fmoc tag (1) 
The released Asn-linked OVA N-glycans (100 mg) were dissolved in 1 mL 0.3 M 
NaHCO3 (pH 8.0). Fmoc-OSu (100 mg) dissolved in 1 mL DMF was added at once 
to the solution, and the mixture was vigorously mixed at RT overnight. The glycans 
were precipitated by the addition of 10-fold excess cold (-20°C) acetone, which 
simultaneously removed excess Fmoc-OSu. The acetone layer was discarded and the 
white pellet dissolved in water and purified by RP-HPLC yielding the Fmoc-tagged 
glycans 1 as a white powder (80 mg).   





Fmoc-tagged glycans 1 (70 mg) were dissolved in dry DMSO (3 mL). Methylamine-
HCl (20 eq.) was added to the solution, followed by diisopropylethylamine (DIPEA) 
(3.5 eq.) and HBTU (3.5 eq.). The reaction was shaken at RT for 1 h, while 
monitoring with analytical HPLC. After the reaction was complete, the mixture was 
purified by RP-HPLC yielding the product 2 as a white powder (62 mg).  
Enrichment of low-abundance bisected N-glycans via endoglycosidase digestion 
(3) 
The modified N-glycans 2 (60 mg) were dissolved in phosphate buffer (50 mM, pH 
7.0). EndoA (WT) (10 μg) and EndoD (WT) (5 μg) were added and the reaction was 
shaken at 37°C overnight. The reaction was monitored by RP-HPLC. After the 
reaction was complete, the Fmoc-tagged glycans were purified by RP-HPLC yielding 
the enriched low-abundant hybrid-/complex-type Fmoc-tagged glycans as a white 
powder (33 mg). The highly-branched bisected glycans were further enriched by NP-
HPLC purification. The fractions containing tri-/tetra-/penta-antennary bisected 
glycans were separated from the hybrid-type glycans, pooled and lyophilized. The 
resulting mix of glycans was desalted by RP-HPLC yielding the target glycans as a 
fluffy white powder (3) (15 mg). 
Enzymatic synthesis of bisected highly-branched terminal GlcNAc glycans (4) 
The partially galactosylated highly-branched glycans (4) (5 mg) were dissolved in 
sodium acetate (50 mM, pH 4.5) and β1,4-galactosidase (20:1 glycan:enzyme ratio) 
was added. The reaction was shaken overnight at 37°C. After complete removal of 
Gal (as determined by NP-HPLC and LC/MS), the mixture was purified by RP-





Enzymatic synthesis of bisected highly-branched terminal Gal glycans (5) 
The partially galactosylated highly-branched glycans (4) (5 mg) were dissolved in 
Tris-HCl buffer (50 mM, pH = 8.0). MnCl2 was added to a final concentration of 20 
mM, along with UDP-Gal (20 eq.). β1,4-Galactosyltransferase was added to a final 
concentration of 1.5 mg/mL and the enzymatic reaction was shaken at 37°C 
overnight. After nearly complete addition of terminal Gal (as determined by NP-
HPLC and LC/MS), the mixture was purified by RP-HPLC, yielding the Gal-terminal 
glycans (5) as a white powder (4.1 mg).  
General Procedure for Deblocking N-Terminus of Asparagine on highly-
branched bisected complex-type N-glycans  
Fmoc-tagged compounds 4 and 5 were dissolved in a small amount of water. 
Piperidine in DMF was added to give a final concentration of 20% in 1:9 water/DMF. 
The reaction mixture was shaken at RT for 30 min while monitoring by HPLC. The 
reaction mixture was neutralized with glacial acetic acid and lyophilized. The product 
was precipitated using cold 80% acetone. The white precipitate was collected, dried 
and used in the next step without further purification. 
Maleimide Conjugation of highly-branched bisected complex-type N-glycans (6 
and 7) 
General conditions: The deblocked highly-branched bisected N-glycans were 
dissolved in 1X PBS (final concentration = 25 mg/mL), 8 equivalents of the 
heterobifunctional linker N-ε-malemidocaproyl-oxysuccinimide ester (EMCS) 
dissolved in acetonitrile was added, giving a final acetonitrile concentration of 20%. 





214/302 nm, tR = 15 min). Once the reaction was complete, the solution was diluted 
with solvent A and purified by RP-HPLC, giving the target compounds 6 and 7 as 
white powders. 
Compound 6 (GlcNAc-terminal-Maleimide) 
From 4 (3 mg), RP-HPLC: tR = 15.1 min. Product (6) obtained as a white powder (2.5 
mg). 
 
Compound 7 (Gal-terminal-Maleimide) 
From 5 (3 mg), RP-HPLC: tR = 14.9 min. Product (7) obtained as a white powder (2.7 
mg). 
 
Sulfhydryl Derivitization of Bovine Serum Albumin (9) 
Sulfhydryl groups were installed on the surface of BSA following a procedure 
previously reported by our group. In brief, 20 mg of BSA (8) was dissolved in 1X 
PBS containing 5 mM EDTA. 20 equivalents (5 mg) of Traut’s reagent was added, 
and the mixture was shaken at RT for 2 h. The derivitized protein was purified by 
FPLC (G25). The protein positive fractions (Bradford assay) were pooled and 
concentrated by a protein concentrator. The quantity of recovered protein (18 mg) 
was estimated by Nanodrop analysis. Free sulfhydryl groups loaded on the surface of 
BSA was quantified by Ellman’s reagent (9 μmol free sulfhydryl groups), against an 
L-cysteine standard curve. The sulfhydryl-containing BSA (9) was used within hours 
to prevent disulfide formation and protein aggregation. 
Conjugation of Maleimide-Tagged Highly-Branched Bisected Glycans with 
Sulfhydryl-Derivitized BSA (10 and 11) 
Sulfhydryl-derivitized BSA (9) (4 mg, 2 μmol sulfhydryl groups) was diluted in 
phosphate buffer (20 mM, pH 7.2) containing EDTA (5 mM). Maleimide-tagged 





3 h and purified by FPLC (G-25) using 10 mM phosphate buffer (pH 6.6), yielding 
compounds 10 and 11. Protein positive fractions were pooled, and carbohydrate-
loading was estimated by phenol-sulfuric acid assay, quantified against a mannose 
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            A successful HIV vaccine must either completely prevent viral transmission, 
or prevent the establishment of a latent pool of HIV infected cells by destroying the 
initial round of infected CD4+ T cells. Such a vaccine cannot rely on memory 
immune responses as the virus will establish the infection before an immune 
challenge, and will instead require high levels of protective immunity at the time of 
contact with the virus. The de novo synthesis of an optimized HIV-1 antigen leading 
to an effective vaccine is challenging and will likely require a multifaceted approach 
involving a number of antigens combinations on different carriers. The work that I 
have presented here represents a small but significant step forward in our 
understanding of rational HIV-1 antigen design.  
        Epitope-based immunogen design targets induction of bNAb B cell lineages via 
Env epitope immunogens that mimic the native Env epitopes on HIV virions, while 
minimizing (or removing) non-/restricted-NAb epitopes. 1-2 Such a strategy 
concentrates the immune focus on the conserved neutralizing epitope. The epitope-
based immunogen design strategy was utilized in the construction of the immunogens 
in Chapters 2 and 4. In Chapter 2, the oligomannose-VLP conjugates were designed 
to mimic the 2G12 epitope. The diverse forms of oligomannose glycan that were 





epitope. The characterization of the conjugates, as well as the antigenicity results 
were very promising, and the ongoing vaccination study will be extremely 
informative regarding the contribution of the chitobiose core in proper orientation of 
the oligomannose 2G12 epitope. Similarly, the immunization results of the mixed-
display Man5-9 conjugate, which demonstrated the highest affinity for 2G12, will 
potentially indicate the preference of 2G12 for heterogeneous oligomannose display, 
in contrast to homogeneous Man9 only.  
             The dramatic preference of PG9 for multivalent peptide display in contrast to 
monovalent, as described in chapter 4, is an exciting finding. The preference suggests 
the ability to mimic gp120 quaternary structure via multivalent peptide display. Such 
an ability could be harnessed to design a PG9 immunogen that displays the 
neutralizing epitope with higher fidelity than monovalent glycopeptide alone. The 
prospect is extremely exciting; if the multivalent display truly mimics trimeric gp120, 
then a “native-like” neutralizing epitope can be presented to the immune system 
without the complications of the presence of non-neutralizing epitopes. It will be 
necessary to perform vaccination studies to determine the extent to which these 
glycopeptide-VLP conjugates are able to mimic the actual trimeric PG9 epitope.  
          The orthogonal protection strategy, developed in Chapter 3, used to synthesize 
the differentially glycosylated glycopeptides in Chapter 4, is broadly applicable to 
any glycopeptide containing two or more unique glycans. The method is highly 
valuable for determining specific glycan preferences in a variety of biological 
interactions, and can be used to probe the specific glycan preference at a given site. 





group to synthesize differentially glycosylated glycopeptides that mimic the 
neutralizing epitopes of various V3-directed bNAbs. 
         The design of N-glycan libraries containing unusual glycans that are otherwise 
difficult to obtain, provides unprecedented access to the glycan preferences of 
carbohydrate reactive proteins, beyond the canonical N-glycans (i.e. Man9GlcNAc2, 
Man5GlcNAc2, biantennary complex-type, etc.) that are more readily available. 
Moreover, the unusual glycans can be used to screen for novel carbohydrate-reactive 
proteins that target atypical glycans that can be used as a basis of discrimination in 
host-pathogen interactions. Such unusual glycans are potentially enriched in a 
pathological state, adumbrating a path to novel vaccine design. The top-down 
chemoenzymatic synthesis of an oligomannose (Man5-9GlcNAc2) library is not new, 
3 
4 however, the use of naturally derived Man9GlcNAc2 from soybean agglutinin, as 
described in Chapter 5, grants access to the full suite of oligomannose glycans with 
unprecedented speed and scale. The top-down chemoenzymatic method provided a 
means to synthesize oligomannose-BSA conjugates on a multi-milligram scale for 
serum-screening studies. The results of preliminary binding studies with 
oligomannose-reactive proteins (i.e. lectins and IgG Abs) indicated binding 
preferences corresponding with the known glycan targets of the proteins. Vaccination 
studies are underway to raise anti-oligomannose Abs against these glycan-protein 
conjugate antigens. The long-term goal of these conjugates will be the identification 
of novel oligomannose-reactive proteins from the serum of HIV+/viral infected 
individuals. A preference for a specific intermediate oligomannose glycan could 






Scheme 7.1. Construction of oligomannose-BSA conjugates bearing regioisomers 
will complete the oligomannose N-glycan library. 
 
          Another long-term goal is the isolation of intermediate (Man6-8GlcNAc2) 
oligomannose glycan regioisomers and the associated BSA-conjugates to complete 
the oligomannose library including all possible regioisomers (Scheme 7.1). Such a 
project would likely require multiple mannosidase enzymes from a variety of sources 
to accommodate the specific branching preferences of the exoglycosidases.  
        The chemoenzymatic construction of a naturally-derived library of highly-
branched complex-type N-glycans, affords access to unusual, inaccessible glycans 
that may have a significant role in viral pathology. Due to the enormous complexity 





these interesting oligosaccharides, and the work that has been reported is limited to 
very small scale. 5-8 The method reported in Chapter 6, regarding the synthesis of an 
N-glycan library of highly-branched complex-type glycans represents the first study 
of its kind on a preparative scale. The identification of ovalbumin as a source for 
highly-branched N-glycans was critical, as was the enzymatic enrichment process to 
remove the dominant N-glycans. The use of 2D-HPLC to separate the enriched 
glycans on a multi-milligram scale was invaluable for facilitating the study design. 
Scheme 7.2. Expanding the highly-branched complex-type N-glycan library. 
 
        Future work should be directed toward expanding the library of these highly-
branched N-glycans. Glycan analysis of trimeric gp120 has indicated the presence of 
highly-branched complex-type glycans on HIV, particularly at the gp120-gp41 
interface, 9 10-11 as well as the four PNGSs on gp41. 12-13 The results have shown both 
sialylated and non-sialylated glycans, as well as the presence and absence of a core 
fucose. 9 Expanding the library described in Chapter 6 to include terminal sialylation 





branched glycans found on HIV virions (Scheme 7.2). In addition, the existing 
highly-branched, GlcNAc/Gal-terminal glycan-BSA conjugates should be applied to 
serum screening studies to search for novel carbohydrate reactive proteins that may 
recognize previously unknown cryptic N-glycan HIV-1 epitopes. The discovery of 
serum proteins that recognize enriched highly-branched glycans on BSA could 
suggest novel non-self epitopes on gp120 that could be exploited for vaccine design. 
       Given the current status of HIV-1 vaccine design, it seems evident that an 
effective vaccine will require a sequential vaccination strategy to “walk” the immune 
system toward production of bNAbs. The immunogens described in this work 
concentrate the immune focus on neutralizing epitopes and could therefore become 
useful vaccine candidates. To be successful, these immunogens (i.e. 
oligomannose/V1V2-glycopeptide-Qβ conjugates) will likely need to incorporate 
antigenic elements that allow binding to germline precursors, as well as the 
intermediate Ab precursors to the mature bNAb of interest. One method that has 
proven successful for recombinant immunogens is the glycan deletion method, in 
which deletion of certain glycans from gp120 allow recognition by germline bNAbs. 
14 15 The initial step will require testing the existing immunogens for binding to 
germline bNAbs. In order to achieve a useful breadth of protection, it will likely be 
necessary to design multivalent immunogens that target multiple bNAbs. A final 
future direction for this research is the design of multivalent immunogens that bear 
multiple putative, minimal epitopes for a variety of bNAbs to stimulate a broad 





         The development of an effective vaccine against HIV-1 continues to present a 
formidable challenge. A combination of epitope masking and the rapid formation of 
escape variants have helped HIV evade all previous vaccine strategies. The discovery 
of bNAbs together with the recent advances that indicate that it is possible to elicit 
such highly modified IgG Abs by proper vaccination strategies has given renewed 
hope to the field. Synthetic HIV-1 antigens such as those presented in this work will 
be key to the development of an effective HIV-1 vaccine.  
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A.2.1 Chapter 2: Supplementary Information 
 
    







Figure A 2.2 Size-exclusion analysis of oligomannose-Qβ conjugates using a 



































































































































Figure A 2.17  1H-13C HSQC NMR (D2O, 600 MHz) (bottom: anomeric region) 
compound 6. 
 











Figure A 2.19 1H-13C HSQC NMR (D2O, 600 MHz) (bottom: anomeric region) 
compound 7. 
 
Figure A 2.20 1H-1H COSY NMR (D2O, 600 MHz) compound 7. 
 
 
A.3.1 Chapter 3: Supplementary Information 
 
Scheme A 3.1. Synthesis and evaluation of a linear version of GlcNAc-peptide (11) 
























aHPLC runs were performed on a C18 column with a linear gradient of 15-30% 
































aHPLC runs were performed on a C18 column with a linear gradient of 15-30% 











aCompound 10 purified on a Thermo Acclaim C18 column (4.6 × 150 mm, 3.5 μm), 



























aCompound 11 purified on a XBridge® Shield BEH C18 column (Waters, 3.5 μm, i.d. 






































aHPLC runs were performed on a C18 column with a linear gradient of 15-30% 
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aHPLC runs were performed on a C18 column with a linear gradient of 15-30% 
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aHPLC runs were performed on a C18 column with a linear gradient of 15-30% 












1H NMR (CDCl3, 500 MHz) 2 
 


















































13C NMR (CDCl3, 125 MHz) 4b 
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aHPLC runs were performed on a C18 column with a linear gradient of 5-50% MeCN 
in 30 min.  
 











aHPLC runs were performed on a C18 column with a linear gradient of 5-25% MeCN 
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aHPLC runs were performed on a C18 column with a linear gradient of 5-50% MeCN 
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Figure A 5.1 MALDI-TOF analysis of compound 8. 
 
Figure A 5.2 MALDI-TOF analysis of compound 9. 
[M + 2H] 
[M + 3H] 


















Figure A 5.4 MALDI-TOF analysis of compound 11. 
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Figure A 5.6 MALDI-TOF analysis of compound 13. 
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Figure A 5.7 MALDI-TOF analysis of compound 14. 
 
 
Figure A 5.8 MALDI-TOF analysis of compound 15. 
 
[M + Na+] 






Figure A 5.9 MALDI-TOF analysis of compound 16. 
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Figure A 5.13 MALDI-TOF analysis of compound 20. 
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Figure A 5.15 MALDI-TOF analysis of compound 22. 
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Figure A 6.2 ESI-MS (Orbitrap) Profile of Fmoc-tagged GlcNAc-terminal highly-
branched ovalbumin glycans. 
 
 
Figure A 6.3 ESI-MS (Orbitrap) Profile of Fmoc-tagged Gal-terminal highly-




Figure A 6.4 ESI-MS (Orbitrap) Profile of Maleimide-tagged GlcNAc-terminal 







Figure A 6.5 MALDI-TOF Profile of Maleimide-tagged Gal-terminal highly-
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